Lipids and dementia:  
An investigation of their relationship

Luke A McGuinness

**Background**  
In the UK, an estimated 800000 people are currently living with dementia and this number is expected to double by 2040. Despite the number of dementia cases and decades of research, there remains much unknown about the pathogenesis and progression of the disease, and, at present, no effective treatment exists to arrest or reverse the cognitive decline associated with the condition. In this context, identification of causal relationships between modifiable targets and dementia risk is central to the development of evidence-based prevention strategies and will be critically important in maintaining the long-term health of the ageing public. Blood lipid levels have been implicated in the aetiology of dementia by genetic linkage and functional cell biology studies, but current epidemiological evidence has yet to reach a consensus on their role in dementia risk.

Table of Contents

# Covering material


Word count: 33796

Table words: 3092

Days: 311

Words behind: -1951

Words today: 1630



# Introduction

## Additional ideas

### General

* Explore difference/similarities between the published and unpublished literature, potentially formally, using funnel plots and also by following up preprints to see if they are eventually published. Limit to the date we ran the original search and see if any study included in the study had not been published by the time the review was finished.
* Compare and contrast the codes used to find the AzD cases in the previous study and in this study, potentially with a view to contrasting misclassification between the two.

### Background

### medrxivr

# Background, Theoretical framework, Aims & Objectives

## Lay summary

[Note: see Section 2.7.2 for details on the layout of each chapter.]

Around 850,000 people in the UK live with dementia, and by 2040, nearly twice as many will have the condition. Despite many promising candidates, no cure for dementia currently exists, meaning the focus is on finding ways to prevent the condition. The best way to do this is to find risk factors (characteristics that influence a person’s chance of developing a disease) for dementia that we can easily change. Avoiding a risk factor does not guarantee that a person will not develop dementia but makes it less likely. A key risk factor for dementia may be the levels of lipids (fatty substances such as cholesterol) in a person’s blood, though not all existing research agrees. The aim of this thesis is to use all available evidence to assess whether blood lipids levels are in fact a risk factor for dementia.

This introductory chapter provides background information on both dementia and blood lipids, and on the potential link between them. It introduces the theory used to frame the research presented here, and then maps the formal aims and objectives of the research project to the relevant chapters of this thesis. Finally, it summarises the outputs (journal articles, presentations and software) that were created as part of this thesis.

## Introduction

This chapter provides an overview of the broad context of this thesis, introducing the core concepts used throughout and providing some background on each. It briefly discusses the underlying pathologies and diagnosis of dementia, its public health importance, and the current state of treatment and prevention research. It then provides background on blood lipids and lipid-modifying treatments, and summarises the types of evidence used to examine the effect of these exposures on dementia outcomes.

The chapter introduces evidence synthesis as the key framework used to guide the research presented in the remaining chapters. Finally, it outlines the aims, objectives and structure of this thesis, and briefly summarises the contributions to the scientific literature that arose from this research.

## Dementia

### Definition and underlying pathologies

Defined by the Diagnostic and Statistical Manual of Mental Disorders as a “major neurocognitive disorder”, dementia is a progressive disease which impairs cognitive functions including speech, memory and executive reasoning.[**edition2013diagnostic?**](#ref-edition2013diagnostic) At advanced stage, the condition causes severe behavioral and personality changes,[1](#ref-cerejeira2012) cumulating in reduced motor control that affects patients ability to swallow or breathe.[2](#ref-kumar2013) The condition has several distinct underlying causes, including Alzheimer’s disease and vascular dementia.[3](#ref-burns2009)

Alzheimer’s disease is the most common cause of dementia, accounting for approximately 60-80% of cases. Characterised by substantial cognitive impairment and difficulty with high level executive function to the extent that it interferes with, it is an insidious disease, within initial onset thought to occur up to 15 years prior to symptomatic presentation.[4](#ref-robinson2015) Much remains unknown about Alzheimer’s pathogenesis, despite research implicating the “amyloid hypothesis”,[4](#ref-robinson2015) as a potential mechanism of disease. Under this hypothesis, the build-up of amlyoid plaques (composed mainly of amlyoid- peptide) and neurofibrillary tangles (composed mainly of tau protein) triggers a range of physiological changes, including inflammation and cell death, that result in cognitive impairment.[4](#ref-robinson2015)

Vascular dementia (VaD) is the second largest underlying pathology of dementia, accounting for ~10% of cases. Vascular dementia is caused by a range of cerebrovascular disorders, and as a result, presentation of symptoms can vary widely.[5](#ref-iadecola2013) Similarly, due to the varied underlying pathophysiology, vascular dementia can onset either quite rapidly following a cerebrovascular event such as a stroke or over a long time-frame due to a series of small infarcts.[6](#ref-venkat2015) Vascular dementia regularly co-occurs in patients with Alzheimer’s disease.[5](#ref-iadecola2013) This presentation is described as “mixed” dementia,[7](#ref-custodio2017) and occurs in approximately 25% of cases.[3](#ref-burns2009)

The remaining 10-30% of cases are caused by other dementia subtypes (e.g. Lewy body dementia, frontotemporal dementia) or by progression of other neurological diseases (e.g. Parkinson’s disease).[3](#ref-burns2009)

### Diagnostic criteria

Dementia is difficult to diagnose, primarily due to its slow onset, in addition to the confusion of initial symptoms with normal ageing.[4](#ref-robinson2015) Dementia is diagnosed on the basis of behavioral and cognitive changes as assessed by an experienced clinician, using one of several diagnostic criteria.

Table 1: Overview of the DSM-5 criteria for dementia and vascular dementia.[@edition2013diagnostic]

| **Criterion** | **Major neurocognitive event (previously dementia)** |
| --- | --- |
| **A** | Evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains:\* - Learning and memory - Language - Executive function - Complex attention - Perceptual-motor - Social cognition |
| **B** | The cognitive deficits interfere with independence in everyday activities. At a minimum, assistance should be required with complex instrumental activities of daily living, such as paying bills or managing medications. |
| **C** | The cognitive deficits do not occur exclusively in the context of a delirium. |
| **D** | The cognitive deficits are not better explained by another mental disorder (eg, major depressive disorder, schizophrenia). |

One of the most commonly used criteria are those found in the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria (Table 1).[**edition2013diagnostic?**](#ref-edition2013diagnostic) These criteria are outlined in Table 1, and form the broad definition of a dementia diagnoses, supported by a detailed patient history, evidence from carers and family members, and objective assessments of cognitive ability using neurocognitive tests.

Many cognitive assessment tools exist for the purpose of informing a diagnoses of dementia,[8](#ref-sheehan2012) with two of the best known of these being the Mini Mental State Exam (MMSE) and Montreal Cognitive Assessment (MoCA) scale. The distinction between these memory scales and diagnostic criteria presented above should be noted. For example, the MMSE is used to provide evidence for part A of the criteria presented in 1. Taken alone, it does not indicate the absence or presence of dementia, instead merely indicating cognitive impairment which could be due to another cause (for example, temporary delirium as a result of an infection or surgery).

Differentiating between the underlying causes of a dementia diagnosis is challenging but necessary, as whether the patient has Alzheimer’s disease or vascular dementia will affect expected progression and potential treatment options available (see Section 2.3.4). Cause-specific criteria exist for the diagnosis of dementia sub-types. For example, the NINCDS-ADRDA criteria are commonly used to assess patients for Alzheimer’s disease,[9](#ref-dubois2007) while vascular dementia is diagnosed using the NINCDS-AIREN criteria.[**roman1993vascular?**](#ref-roman1993vascular)

### Public health importance

Dementia is quickly becoming a critically important public health issue. Despite the age-specific incidence and prevalence of dementia remaining relatively constant over time,[10](#ref-prince2016) an ageing population is set to create a dementia epidemic, particularly in Westernised countries.[11](#ref-flier2005) While approximately 525,000 patients have received a dementia diagnosis, the true number of people currently living with dementia in the UK is thought to be closer to 850,000, with this figure expected to double by 2040.[12](#ref-baker2019) Globally, the prevalence of dementia is expected to reach 75 million by 2030.[10](#ref-prince2016) Dementia is the leading cause of death in the UK, and the only one without a proven cure.

Dementia also has a substantial economic impact. In 2015, the estimated total cost of dementia in England was £24.2 billion. Health care costs alone were £3.8 billion,[13](#ref-wittenberg2019) Globally, the cost of dementia care is expected to rise to $1tr by 2030.[**prince2014dementia?**](#ref-prince2014dementia)

As such, the urgent need to reduce the burden of dementia, both at the personal and system level, is clear.

### Treatments

Developing treatments for dementia is regularly deemed to be one of the hardest markets in the pharmaceutical world, with trials of seemingly promising therapeutics being regularly abandoned due to futility.[14](#ref-cummings2020). At present, there are no known curative treatments for dementia, regardless of the underlying cause, though several available therapeutics can help alleviate the symptoms of Alzheimer’s disease.

The most common of these are acetylcholinesterase (ACE) inhibitors, which inhibit the degradation of the neurotransmitter acetylcholine by competitively binding the ACE enzyme. Acetylcholine plays a key role in controlling the cholingeric synapses, which are highly concentrated in regions of the brain (such as the neocortex) that control higher level brain functions such as memory and attention.[15](#ref-hampel2018) Commonly prescribed ACE inhibitors include donepezil and galantamine.[16](#ref-pariente2008) ACE inhibitors increase the availability of the neurotransmitter, and has shown clinical effect is easing the behavioural and memory-related symptoms of Alzheimer’s disease.[17](#ref-marucci2020) ACE inhibitors represent only a stop-gap treatment, treating the symptoms rather than the underlying pathology which may continue to progress.[18](#ref-francis2010)

### Risk factors

Given the substantial burden that dementia represents and the absence of any curative therapies, as detailed in the above sections, the assessment of easily modifiable targets for their utility in the prevention of dementia should be prioritized.[**winblad2016a?**](#ref-winblad2016a) To date, a substantial amount of research has been produced examining putative risk factors for dementia.[19](#ref-feingold2000)–[21](#ref-anstey2019)

The benefits of a prevention-based approach based on addressing these risk factors are well-studied. Reducing the prevalence of the seven most important risk factors for dementia (obesity, hypertension,[**hughes2020association?**](#ref-hughes2020association) diabetes, smoking, physical inactivity, and low educational attainment) by 10-20% per decade is estimated to result in a reduction in dementia prevalence of 8-15% by 2050.[22](#ref-norton2014potential)

In this context, lipid levels represent a promising target for preventative treatment, due to the ready availability of lipid-modifying treatments which could be repurposed.[**pushpakom2019a?**](#ref-pushpakom2019a) Determining whether variations in lipid levels are causative for dementia may prove critical in reducing the future burden of the condition.

This thesis will focus on blood lipids as the primary risk factor of interest. The next section provides an overview of blood lipid fractions and therapeutic interventions that modify them, while Section 2.5 provides an overview of the existing evidence for an association between lipids and dementia outcomes.

## Serum lipids

### Lipid fractions

The blood lipid profile contains a range of component parts, or fractions. However, this thesis will only consider the two most important fractions, trigylcerides (TG) and cholesterol, which are either absorbed from food (exogenous lipids) or produced internally (endogenous lipids).[19](#ref-feingold2000)

Triglycerides are the simplest and most common type of lipids found across the body. They are used to store unused calories from food, and to move energy around the body.[23](#ref-laufs2020) In contrast, cholesterol is primarily used to create cell walls and certain sex hormones.[24](#ref-zampelas2019) As lipids are not water soluble, within the blood stream, cholesterol is transported in lipoprotein structures of varying densities. Low-density-lipoprotein cholesterol (LDL-c), commonly know as the “bad” cholesterol, transports fat to cells, acting as an energy conveyor. In contrast, High density-lipoprotein cholesterol (HDL-c), transports cholesterol to the liver to be broken down and excreted.[19](#ref-feingold2000)

In addition to the individual fractions, total serum cholesterol (TC) is a commonly-used summary measure to estimate the total amount of lipid present in the blood. The measure is derived from measurements of the individual HDL-c, LDL-c and TG levels using the Friedwald formula:[25](#ref-friedewald1972)

where is 0.20 if measurements are in milligrams per decilitre (*mg/dl*) and 0.45 if measured in millimole per litre (*mmol/l*).

Widely-used ranges for the acceptable levels of different types of lipids are based on the National Cholesterol Education Program (NCEP)[26](#ref-national2002third), and are outlined in Table 2.

Table 2: Classification of blood lipid levels according to the National Cholesterol Education Program guidelines.[26](#ref-national2002third)

|  |  |  |
| --- | --- | --- |
| Fraction | Measure (mg/dL) | Classification |
| LDL cholesterol | <100 | Optimal |
| LDL cholesterol | 100-129 | Near/above optimal |
| LDL cholesterol | 130-159 | Borderline high |
| LDL cholesterol | 160-189 | High |
| LDL cholesterol | >190 | Very high |
| HDL cholesterol | <40 | Low |
| HDL cholesterol | >60 | High |
| Triglycerides | <150 | Normal |
| Triglycerides | 150-199 | Borderline high |
| Triglycerides | 200-499 | High |
| Triglycerides | >500 | Very high |
| Total cholesterol | <200 | Desirable |
| Total cholesterol | 200-239 | Borderline high |
| Total cholesterol | >240 | High |

Elevated LDL-c in the bloodstream, a condition also known as hypercholesterolaemia or hyperlipidaemia,[27](#ref-nelson2013) can lead to atherosclerosis,[28](#ref-libby2019) the build-up of fatty deposits in the blood vessels. These deposits constrict blood flow and can lead to vascular complications. Alternatively, part of the deposit can detach from the artery walls, forming a clot that can lead to a heart attach or stroke.[28](#ref-libby2019) Globally, the prevalence of elevated cholesterol was estimated by the World Health Organization to be approximately 40%.

### Statins

Statins are a commonly prescribed method of lipid regulation.[29](#ref-collins2016) Statins inhibit the conversion of 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) into mevalonate, by competitively binding with HMG-CoA reductase (HMG-CoA-R). This conversion is a key rate-limiting step in the cholesterol biosynthesis pathway (see Figure ??), enabling statins to reduce effectively the production of LDL cholesterol.

(ref:statin-mechanisam-cap) Overivew of statins mechanism of action, inhibiting HMG-CoA reductase which controls the conversion of HMG-CoA to mevalonate, the rate-limiting step in cholesterol biosynthesis.




Figure 1: (ref:statin-mechanisam-cap)

Several statin treatments have been widely available for some time (see Table 3). Depending on the statin and dosage prescribed, the average reduction in LDL-c concentrations ranges from 15% with low-intensity regimen (e.g. ravastatin 5 mg/day) up to 60% with a high-intensity regimen (e.g. rosuvastatin 80 mg/day).[30](#ref-collins2016a),[31](#ref-law2003) Statins also vary with regard to their lipophilicity (the extent to which they are lipid soluble), affecting their localisation within the body, with hydophilic statins being concentrated in the liver and lipophilic statins circualting more widely.[32](#ref-schachter2005) This may create a divide in the pleiotropic affects of statins with differing lipophilicity, particularly given the ability of lipophilic statins to permeate the blood brain barrier.[33](#ref-sierra2011)

Table 3: Overview of commonly-prescribed statins, summarising their approval date (US), properties and lipid-lowering effect.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Name | Brand name | Year approved | Properties | Lipid-lowering effect |
| Atorvastatin | Lipitor | 1996 | Lipophilic | +++ |
| Pravastatin | Lipostat | 1989 | Hydrophilic | + |
| Rosuvastatin | Crestor | 2003 | Hydrophilic | ++++ |
| Simvastatin | Zocor | 1992 | Lipophilic | ++ |

### Other lipid regulating agents (LRA)

There are several other interventions that can be used to modify a persons lipid profile, which each acting in slightly different ways (Table ??). However, in general, these treatments are either used as adjunct (additional) treatments with statins therapy or are used in situations where statins are contra-indicated or not tolerated.

The most commonly used non-statin therapeutic is ezetimibe,[34](#ref-kosoglou2005) which prevents intestinal absorption of cholesterol. However, when used alone, it has a limited LDL-c lowering effect, leading to the creation of combined statin/ezetimibe therapies (both compounds contained in a single pill, as opposed to complimentary treatments).[35](#ref-genest2006)

Fibrates provide a second example of non-statin therapy. They are used to treat hypertriglyceridaemia by reducing production of triglyceride carrying compounds in the liver. They are commonly used in patients with mixed hyperlipidaemia if treatment with statins has failed to sufficiently control cholesterol levels.

Finally, PCSK9 inhibitors (or PCSK9i) are a relatively new treatment with strong lipid lowering effects, lauded as a potential alternative to statins.[36](#ref-chaudhary2017) Their mechanism of action is to bind to and inhibit PCSK9, which breaks down LDL-c receptors on the surface of the liver, thus allowing more LDL-c to be internalised and broken down.

Other therapies targeting triglycerides exist, including nicotinic acids[37](#ref-mckenney2004new) and omega-3-fatty acids,[38](#ref-skulas-rayannc.2019) but they far less effective in LDL-c lowering than the therapies described above.

Table 4: Summary of available treatments for hyperlipidaemia.

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment | Effect | Mechanism of action | Examples |
| HMG CoA reductase inhibitors (statins) | Lowers LDL-c & TG Raises HDL-c | Inhibits cholesterol biosynthesis pathway in the liver | Atorvastatin, Simvastatin, Pravastatin |
| Ezetimibe | Lowers LDL-c | Prevents absorption of cholesterol from diet |  |
| Bile acide sequestrants | Lowers LDL-c | Prevent bile acid reabsorption in the gastro-intestinal tract, increasing conversion of cholesterol to bile acids | Colestipol |
| Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors | Lowers LDL-c | Bind to PSCK9 protein, preventing it from breaking down LDL receptors on heptatic cells, increasing cholesterol uptake | Evolocumab, Alirocumab |

## Evidence for the association between blood lipids and dementia

This section provides an overview of the varying sources of evidence on the relationship between blood lipid levels and dementia risk.

### Basic science

A role for lipids in the aetiology of the dementia is supported by both genetic linkage studies and functional cell biology studies. The generation of the amyloid plaques found in the brains of Alzheimer’s patients is cholesterol dependent,,[39](#ref-burns2003),[40](#ref-mizuno1999) while the most established genetic risk factor for late-onset dementia, apolipoprotein E (ApoE), is involved in cerebral cholesterol transport. Several other genes involved in cholesterol transport have also been found to be associated with increased AD susceptibility.[41](#ref-beecham2014)–[43](#ref-meng2007)

Despite these results, evidence from the diverse range of epidemiological studies on this topic has been inconclusive.

### Observational studies

By far the largest source of evidence on the relationship between comes from observational designs. Several studies have examined the relationships between concentrations of serum lipids (total cholesterol (TC), low density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol (HDL-c) and triglycerides) and both Alzheimer’s disease and vascular dementia and reported extremely varied results. In some studies, a high serum cholesterol concentration has been found to be associated with an increase in susceptibility to AD,[44](#ref-kivipelto2002)–[48](#ref-whitmer2005) however others have shown no association,[49](#ref-li2005a)–[52](#ref-tan2003a) or a reduced susceptibility.[53](#ref-mielke2005),[54](#ref-reitz2004a) With regards vascular dementia, decreased levels of HDL-c appear to be associated with increased risk,[54](#ref-reitz2004a) while for LDL-c, studies have reported both positive and negative associations.[54](#ref-reitz2004a),[55](#ref-moroney1999)

Several previous systematic review of observational studies examining the effect of lipids[56](#ref-anstey2015) and lipid-regulating agents[57](#ref-chu2018),[**poly2020c?**](#ref-poly2020c) on dementia outcomes have been performed. However, these reviews have several limitations. Many did not consider grey literature sources (see Section 2.6.1). Additionally, many of the reviews of observational studies did not perform any risk-of-bias assessment[**chu2018b?**](#ref-chu2018b) or used an outdated assessment tool.[56](#ref-anstey2015),[**poly2020c?**](#ref-poly2020c)

### Randomised controlled trials

In terms of the central research of this thesis, RCTs of statin therapy can be used to provide indirect evidence for the effect of reducing blood LDL-c levels on dementia risk.

However, RCTs may be infeasible if the outcome of interest is one with a long prodomal period, such as dementia (see Section 2.3.1), as they would require extremely long and costly follow-up.[58](#ref-ritchie2015) It is no surprise then that the two previous trials providing evidence on the effect of statins on dementia risk, identified by a recent Cochrane review,[**mcguinness2016a?**](#ref-mcguinness2016a) are in fact trials of statins for the prevention of coronary related outcomes.

While being widely cited, these studies have major limitations that reduce their utility as a source of evidence on the effect of statin treatment on in assessing the impact of lipid-lowering treatment on dementia risk. Firstly, there was no clinical cognitive evaluation of patients to determine a dementia outcome. One of the trials, the Prospective Study of Pravastatin in the Elderly (PROSPER) trial,[59](#ref-trompet2010) reported not on dementia outcomes but on the change in cognitive scores over a mean of 3.2 years. As highlighted in Section 2.3.2, a “change in score” alone is insufficient to diagnose a dementia outcome. The second trial, the Medical Research Council/British Health Foundation Protection Study,[**2002?**](#ref-2002) found no effect of simvastatin on dementia (OR: 1.00, 95%CI: 0.61-1.65), but did not report how the outcome was assessed/recorded within the trial.

Additionally, the two trials did not make any effort to assign an underlying pathology to each case, instead reporting an all-cause dementia outcome. As discussed in Section 2.3.1, the different underlying pathology of dementia have different mechanisms of action, and so it is not gauranteed that the effect of statins would be consistent across them.

Both trials were also limited by the relatively short follow-up period examined, expected when the primary outcome of the trials were coronary related conditions rather than dementia.[59](#ref-trompet2010),[**2002?**](#ref-2002) The PROSPER trial had a mean follow-up of 3.2 years, while the MRC/BHF Protection Study estimated risk at 5 years of follow-up. Given the long lag time between non-symptomatic onset of dementia and clinical presentation, it is likely that these durations are insufficient to fully capture the onset of dementia. Finally, as they included only patients at high vascular risk, their generalisability to other settings is limited.[**mcguinness2016b?**](#ref-mcguinness2016b)

### Mendelian randomisation

Newer methodological approaches, such as Mendelian randomisation (MR),[60](#ref-daveysmith2014) have also been used to examine the effect of varying lipid levels on dementia risk in an effort to combat the risk of reverse causation and residual confounding inherent to observational studies.[61](#ref-greenland2000) In brief, MR uses genetic variants that are both strongly associated with the exposure of interest and are independent from potential confounders to strengthen causal inference.[60](#ref-daveysmith2014) The analytic method relies on several assumptions about the instrumental variable (IV),[62](#ref-davies2018) namely that:

1. the IV is associated with the exposure of interest (the relevance assumption);
2. the IV and outcome do not share a common cause (the independence assumption); and
3. the IV does not affect the outcome other than via the exposure (the exclusion restriction assumption).

Recent MR studies indicated that genetically determined low levels of LDL-c may cause a reduction in AD risk.[63](#ref-larsson2017c),[64](#ref-ostergaard2015) However, the effect was attenuated in sensitivity analysis that exclude the region surrounding the ApoE gene, the strongest known risk factor for Alzheimer’s disease.[65](#ref-kim2009) Inclusion of ApoE4 variants invalidates the exclusion restriction criteria (Assumption 3, above), as the risk reduction observed may be driven by variants in this region via a pathway independent of lipid levels. This was supported by further MR studies where *ApoE4* variants were intentionally excluded.[66](#ref-benn2017)

Despite the increasing number of MR studies examining this topic, no systematic review of this study design as a source of evidence has been performed.

In summary, multiple sources of evidence exist on the relationship between statins and dementia. In the next section, I introduce the synthesis of diverse sources of evidence as the theoretical framework used in this thesis.

## Theoretical framework: Evidence synthesis

Evidence synthesis is the process of finding and integrating information from several sources to examine a research question.[67](#ref-donnelly2018a) A common tyoe of evidence synthesis is a systematic review, either with or without a meta-analysis.[68](#ref-chandler2019chapter)

The results of an evidence synthesis exercise can be used to provide a more definitive answer to that question or, failing that, to highlight gaps in the existing evidence base. The ability to identify these gaps is particularly useful in guiding future research to address questions that have yet to be answered.

This thesis seeks to use an evidence synthesis framework to assess the effect of lipids, and treatments that influence lipid levels, on dementia outcomes. Specifically, this thesis considers three concepts within the umbrella term of evidence synthesis:

* Inclusion of preprints
* Triangulation across evidence sources
* Individual patient data meta-analysis

These three elements are expanded on below and are used to frame the research presented in the subsequent Chapters.

### Inclusion of preprints

The importance of including grey (or gray) literature in systematic reviews is widely acknowledged. Meta-research studies have demonstrated that systematic reviews excluding grey literature sources overestimate the effect of interventions.[69](#ref-conn2003)–[71](#ref-hopewell2007) Common, well-accepted forms of grey literature include conference abstracts and theses.[72](#ref-lefebvre2019searching)

A important developing source of grey literature are preprints. Defined by the Committee on Publication Ethics (COPE) as ‘scholarly manuscript[s] posted by the author(s) in an openly accessible platform, usually before or in parallel with the peer review process’[73](#ref-committeeonpublicationethicscope2018), preprints serve several purposes. They are used to establish primacy when submitting to a journal where the peer-review process may take several months,[74](#ref-vale2016) to rapidly disseminate research findings, as occurred during the COVID-19 pandemic,[**fraser2020a?**](#ref-fraser2020a) and to make available publications that may not have been accepted elsewhere in an attempt to combat publication bias or the “file-drawer” effect.[75](#ref-rosenthal1979)

One of the major criticisms of using preprints as an evidence source is that they have not yet undergone formal peer review.[76](#ref-maslove2018),[77](#ref-schalkwyk2020) However, this approach assigns substantial weight to peer-review as a indicator of “quality”, and is at odds with the acceptance of non-reviewed conference proceedings as an evidence source.[72](#ref-lefebvre2019searching),[78](#ref-mahood2014) The argument for including preprints as an evidence source is further strengthened by results that demonstrate preprinted studies seldom change following peer review. Meta-studies of the concordance between preprinted and published studies showed that results were broadly comparable between the two, indicating that while the numerical results may change, the overall interpretation of the results were consistent in the majority of cases.[79](#ref-klein2019),[80](#ref-nicholson2021),[**shi2021a?**](#ref-shi2021a) This indicates that preprints should be considered a reliable reflection of a given study.

In this thesis, preprints are considered an important source of evidence, in contrast to previous reviews on this topic. However, as with many sources of grey literature,[78](#ref-mahood2014) there are several logistical issues with carrying out systematic searches in preprint repositories. As such, to enable the inclusion of preprints in the systematic review described in Chapter 4, a new tool addressing these issues is presented in Chapter ??.

### Triangulating across study designs

As illustrated in Section 2.5, several diverse epidemiological methods have been used to examine the effect of varying blood lipid levels on dementia risk. However, each method is limited by its own biases. Aetiological triangulation is a developing evidence synthesis method that seeks to exploit these inherent differences in study design, and as a result, in biases.[**lawlor2016a?**](#ref-lawlor2016a) If several sources of evidence are available and point towards identical conclusions about an exposure-outcome relationship, and these sources are at risk of unrelated biases, this strengthens our confidence in the result. The ideal scenario is where predicted sources of bias are likely to be in competing directions, strengthen the effect of the exposure and the other to attenuate it.[**lawlor2016a?**](#ref-lawlor2016a) As such, triangulating these results can provides us a middle-ground between the competing directions of bias. A triangulation approach can also prove useful in a prospective manner, helping to design new studies that are at risk of different sources of bias to that already available from the published literature.[81](#ref-munafo2018)

This thesis seeks to apply a triangulation approach to provide the best available evidence on the effect of lipids, and lipid regulating agents, on dementia outcomes.

All existing evidence, regardless of study design, is first identified by the by the systematic review presented in Chapter 4. Risk-of-bias assessment using a domain-based tool is already a recommended part of the systematic review process, but is particularly important to a triangulation exercise.[82](#ref-page2021),[83](#ref-mcguinness2018),[**sterne2019a?**](#ref-sterne2019a) As such, a core component of the review is a comprehensive domain-based risk-of-bias assessment for all included studies.

Finally all evidence, both pre-existing and produced as part of this thesis (Chapter 5 and ??), are triangulated in Chapter ??.

### Individual patient data meta-analysis

Individual patient data meta-analyses are commonly held to represent the gold standard in evidence synthesis methodology.[84](#ref-riley2010),[85](#ref-stewart1993) IPD methods seek to obtain the raw data from each study identified in a systematic review, rather than basing the meta-analysis on summary results extracted from the literature.[84](#ref-riley2010)

In the context of this thesis, if lipids are found to have a causal role in development of dementia, evidence-based preventative strategies would be best informed by identifying the types of individuals who are most likely to receive benefit from treatment with lipid-modifying agents.[86](#ref-arain2009)–[88](#ref-mccartney2016) However, if primary studies do not present results stratified by covariates of interest, meta-analyses of summary-level data on this topic often have limited ability to examine research questions related to exposure-covariate interactions.[84](#ref-riley2010) In terms of this thesis, patient sex is considered to be of particular interest.[86](#ref-arain2009),[89](#ref-letenneur1999)

An IPD meta-analysis of lipid levels on dementia outcomes would overcome this limitation of summary-level data, as access to the raw data allows for an analysis that investigates these interactions.[90](#ref-riley2020) This approach has the added benefit of allowing a common set of inclusion criteria and statistical model to be applied across all datasets, potentially eliminating some important sources of heterogeneity.[91](#ref-stewart2002)

Despite their advantages, IPD meta-analysis are rarely performed.[92](#ref-tugwell2010) Factors limiting their uptake include the increased time and effort they require when compared to a summary-level analysis, and the low success rate associated with obtaining the raw data.[93](#ref-nevitt2017a),[94](#ref-ventresca2020) The data underlying primary studies are frequently not publicly available,[95](#ref-alsheikh-ali2011),[**federer2018a?**](#ref-federer2018a) and the availability of data “available on request from authors” declines rapidly over time.[96](#ref-vines2014) Several systematic barriers to open data sharing have been identified[**vanpanhuis2014a?**](#ref-vanpanhuis2014a). Of particular concern for biomedical IPD analyses are legal issues surrounding the sharing of medical data, motivated by concerns around patient privacy.[97](#ref-wartenberg2010)

In response to these limitations, new collaborative initiatives have developed to enable rapid access to relevant data in a secure supported workshop. The most import in relation to this thesis is the Dementia Platform UK (DPUK),[98](#ref-bauermeister2020) which aims to provide access to several dementia-related datasets via a single simplified application process.

I will will attempt to obtain the raw data from relevant primary studies identified by the systematic review in Chapter 4. Any data obtained will be combined with that available from the DPUK portal as part of an individual participant data meta-analysis in Chapter ??, enabling the assessment of the effect of lipids on dementia stratified by key variables such as sex.

## Thesis overview

### Aims and objectives

The over-arching aim of this thesis is to explore the relationship between blood lipid levels, and by extension treatments that modify blood lipid levels such as statins, and the subsequent risk of dementia and related outcomes

The specific research objectives that this thesis seeks to address are:

* To create a tool that allows for the inclusion of health related preprints in evidence syntheses in a systematic and reproducible manner
* To review all available evidence across multiple diverse study designs to assess the effect of lipids and lipid regulating agents on dementia risk
* To examine whether there is evidence for an effect of lipid-regulating agents on dementia and related outcomes in a large scale population-based cohort, the Clinical Practice Research Datalink (CPRD)
* To meta-analyse raw dementia-related datasets as part of a individual participant data (IPD meta-analysis) to produce evidence on exposure-covariate interactions

### Structure

Chapters are self-contained, presenting the methods and results of that specific research project. They are bookended by introductory and discussion sections which place the methods and results in context. Each chapter is prefaced by a “Lay” or plain English summary, developed with input from the Patient and Public Advisory Group (see Section 8.9 for a discussion of the group’s involvement and Appendix 10.1.2 for more detail on the group).

* **Chapter 2:** Background information on dementia and blood lipid levels. This chapter provides an introduction to the topics covered in this thesis to non-subject area experts, and discusses the motivation for the remainder of the thesis.
* **Chapter 3:** This Chapter introduces a new tool, medrxivr, which was used to developed to allow for systematic searches of the health-related preprint repositories.
* **Chapter 4:** This Chapter describes a comprehensive systematic review and meta-analysis of all available evidence on the effect of blood lipids, and interventions that modified blood lipids, on dementia outcomes.
* **Chapter 5:** This Chapter examines the relationship between lipid-regulating agent use and dementia outcomes in the Clinical Practice Research Datalink, a large primary care electronic health record database.
* **Chapter 6:** This Chapter describes an individual patient data analysis of several longitudinal cohort studies to describe the relationship between blood serum lipids and dementia outcomes, stratified by important covariates such as sex.
* **Chapter 8**: This Chapter integrates the diverse evidence identified by, and produced as part of, this thesis. The overall strengths and weaknesses of this project are discussed in detail, and further avenues of research are suggested.

An overview of how all research studies in this thesis can be found in Table 5

Table 5: Summary of studies included in this thesis, and used as evidence sources in the triangulation exercise performed in Chapter 8. Note, Chapter 3 is intentionally not included in this table, as it describes a tool rather than a research study.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Chapter | Research Question | Exposure/ Intervention | Outcome | Contibution to evidence synthesis framework |
| Chapter 3 | Based on the available evidence; (i) are lipid fractions associated with subsequent dementia risk, stratified by subtype? (ii) Are lipid regulating agents associated with subsequent dementia risk, stratified by subtype? | Lipids (HDL-c, LDL-c, TC, TG), Lipid regulating agents (statins, ezetimibe, fibrates, etc.) | Dementia, stratified by subtype | Provides overview of existing evidence |
| Chapter 4 | Are lipid regulating agents associated with dementia risk in a large scale electonic health record database? | Seven classes of lipid regulating agents | Dementia, stratified by subtype | Provides additional observational data on vascular dementia (under-represented in the literature) Provides a source of observational evidence created using a method with distinct sources of bias to those identified by the systematic review |
| Chapter 5 | Are lipid levels associated with dementia risk in an individual participant data meta-analysis? | Lipids (HDL-c, LDL-c, TC, TG) | Dementia, stratified by subtype | Provides additional evidence from unanalysed datasets Allows for stratification of effect by variables of interest (e.g. sex) |

## Outputs from this thesis

The outputs of this thesis are detailed below, and include peer-reviewed papers, presentations, and open-source evidence synthesis tools.

### Contributions to the scientific literature

During the course of this thesis, I have made several contributions to the scientific literature. Those arising from or directly related to the contents of this submission are presented below.

***McGuinness, L. A.****, and L Schmidt. (2020) medrxivr: Accessing and searching medRxiv and bioRxiv preprint data in R. Journal of Open Source Software 5.54 2651. DOI:* [*10.21105/joss.02651*](https://doi.org/10.21105/joss.02651)

A paper introducing the open-source preprint search tool described in Chapter 3. As is common for journal articles describing software, the paper is intentionally short providing only a broad overview of the tool while extensive documentation is available from the project website (see Section 3.2 for more details).

*Hennessy, E. A., Acabchuk, R., Arnold, P. A., Dunn, A. G., Foo, Y. Z., Johnson, B. T., Geange, S. R., Haddaway, N. R., Nakagawa, S., Mapanga, W., Mengersen, K., Page, M., Sánchez-Tójar, A. Welch, V.,* ***McGuinness L. A.*** *(2021). Ensuring Prevention Science Research is Synthesis-Ready for Immediate and Lasting Scientific Impact. Prevention Science . DOI:* [*10.1007/s11121-021-01279-8*](https://doi.org/10.1007/s11121-021-01279-8)

The experience of extracting data for the systematic review in Chapter 4 inspired a practical guide for researchers. This piece was co-written with Dr. Emily Hennessy (see Author Declarations in the front materials).

***McGuinness, L. A.****, and Higgins J. P. T. (2020) “Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessments.” Research Synthesis Method). DOI:* [*10.1002/jrsm.1411*](https://doi.org/10.1002/jrsm.1411)

The tool used to visualise the risk-of-bias assessments in Chapter 4 has been published in Research Synthesis Methods. See Appendix 11.2 for more details on this tool.

***McGuinness, L. A.****, and Sheppard A. L. 2020. “A Descriptive Analysis of the Data Availability Statements Accompanying Medrxiv Preprints and a Comparison with Their Published Counterparts.” PLOS ONE 16(5): e0250887. DOI:* [*10.1371/journal.pone.0250887*](https://doi.org/10.1371/journal.pone.0250887)

Using the tool described in Chapter ??, I lead a “research-on-research” study to assess the concordance between the openness of data availability statements accompanying a sample of medRxiv preprints and their published counterparts.

For information on additional contributions to the scientific literature not directly related to this thesis, see Appendix 10.1.1.

### Presentations/Talks

*“Identifying and triangulating all available evidence on the effect of blood lipids and statins on dementia outcomes”*: Poster presentation, Alzheimer’s Association International Conference 2021.

*“medrxivr: A new tool for searching for and retrieving records and PDFs from the medRxiv preprint repository”*: Accepted oral presentation abstract, Cochrane Colloquium 2020 (note: event was cancelled due to the COVID-19 pandemic)

*“On the shoulders of giants”: advantages and challenges to building on established evidence synthesis packages, using the {robvis} package as a case study"*: Oral presentation, Evidence Synthesis and Meta-Analysis in R Conference (ESMARConf) 2021.

*“RoB 2.0: A revised tool to assess risk of bias in randomized trials”*: Webinar, co-presented with Dr. Theresa Moore as part of the Evidence Synthesis Ireland Methods Series.

### Software

**medrxvir**

An R package that allows users to easily search and retrieve bibliographic data from the medRxiv[99](#ref-rawlinson2019) and bioRxiv[100](#ref-sever2019) preprint repositories. See Chapter 3 for more details. Install a stable version of the package from the Comprehensive R Archive Network (CRAN), or alternatively install the development version from GitHub, using:

# CRAN version  
install.packages("medrxivr")  
  
# Development version  
devtools::install\_github("ropensci/medrxivr")

**robvis**

An R package and associated shiny web application that allows users to easily visualize the results of the risk-of-bias assessments performed as part of a systematic review. See Appendix 11.2 for more details. Install a stable version of the package from CRAN, or alternatively install the development version from GitHub, using:

# CRAN version  
install.packages("robvis")  
  
# Development version  
devtools::install\_github("mcguinlu/robvis")

## Summary

This Chapter has provided background information on the core elements of the central research question, framed the research presented in this thesis in the context of an evidence synthesis framework, and described the contributions of this thesis to the scientific literature.

## References

# medrxivr: an R package for systematically searching biomedical preprints

## Lay summary

Preprints are copies of academic manuscripts that are posted online in advance of being formally published by an academic journal. They represent an important source of scientific literature. A new software program called medrxivr was created to allow researchers to find preprints related to their research in a transparent and reproducible way. Development of this tool was an essential part of this thesis, as preprints represent a key source of information needed for the research reported in future chapters.

## Introduction

Preprints represent an increasingly important source of scientific information (see Section 2.6.1). As a result, repositories of preprinted articles should be considered a distinct but complementary information source when reviewing the evidence base as part of a systematic review. The two key repositories in the health science are bioRxiv, established in 2013,[100](#ref-sever2019) and medRxiv, which launched in 2019 and was designed to replace the “Epidemiology” and “Clinical Trial” categories of bioRxiv.[99](#ref-rawlinson2019)

Searching these preprints as part of the systematic review described in Chapter 4 was a necessity, as many of the existing reviews on the topic of lipids and dementia have not considered this important source of evidence. At the time of writing, however, the bioRxiv and medRxiv websites allow only simple search queries as opposed to the often complex Boolean logic (AND/OR/NOT) that information specialists use to query other major databases.[101](#ref-bramer2018a),[102](#ref-gusenbauer2020) Additionally, the best available extraction mechanism for obtaining references for all records returned by a search were to go through each record, one-by-one, downloading individual citations. As the scale of these preprint databases increase, particularly in light of the massive expansion of the medRxiv repository as a result of COVID, this already time-consuming and error-prone method is no longer feasible.

This chapter outlines the development and key functionality of medrxivr (version 0.0.5), a tool I created to facilitate the systematic searching of medRxiv and bioRxiv preprints. The factors that necessitated the development of this tool in the context of this thesis are outlined, and the use of medrxivr in my own projects and by other researchers is discussed. As the majority of work on this aspect of my thesis is represented by lines of code or online documentation (available at <https://github.com/ropensci/medrxivr> and <https://docs.ropensci.org/medrxivr/> respectively), this chapter is an intentionally short, high-level summary of my work on this project. The GitHub repository for the medrxivr contains a complete record of the development of this tool, including discussion with other members of the systematic review community.[103](#ref-zotero-15029)



Figure 2: **Role of medrxivr in a systematic review workflow** - medrxivr allows for systematic searching of biomedical preprints as part of the initial literature searching. Following title and abstract screening, reviewers can then programmatically retrieve a copy of the PDF of included records to facilitate the full-text screening stage (similar to Endnote’s “Find Full Text” feature).

## Development

### Success criteria

I developed the tool to meet three success criteria,[104](#ref-wateridge1995) influenced both by the functionality required to perform systematic searches as part of the review in Chapter 4, discussion with information specialist colleagues, and an informal survey of the evidence synthesis and health librarian communities on Twitter. The criteria were as follows:

1. reliable, reproducible and transparent search functionality, allowing for Boolean (AND/OR/NOT) operator logic;
2. support for bulk export of references returned by the search to a file type that can be readily imported into a reference manager (e.g., *.bib* or *.ris*); and
3. automated retrieval of the full-text PDFs of relevant records, similar to the Find Full Text feature offered by EndNote.

### Alternative medRxiv/bioRxiv interfaces

Prior to development of this tool, I conducted an audit of existing tools for accessing medRxiv and bioRxiv metadata. While none address the success criteria described above, two of these tools are useful to consider to highlight the additional functionality that medrxivr contributes.

The first, a platform called Rxivist[105](#ref-abdill2019), allows users to search preprints using keywords. However, the core functionality of the Rxivist platform is focused around exploring the number of times a preprint has been downloaded and/or shared on Twitter, to allow researchers to find the most popular papers related to their topic. The search interface[106](#ref-zotero-15027) does not allow for complex search strategies using Boolean operators and there is no option to batch-export the results of a search.

The second tool, search.bioPreprint, allows users to search for terms across a range of preprint servers, including medRxiv and bioRxiv, but also journals which use a post-publication peer-review process such as F1000Research.[107](#ref-iwema2016) However, similar to the Rxivist platform, this tool is designed for researchers aiming to keep up to date with recent developments in their fields rather than systematically assess the entirety of the available literature. As such, the platform only returns the most recent 1,000 records by publication date.

Finally, neither tool provides an easy way to programmatically download a copy of the PDF of relevant preprints as part of the preparation for the full-text screening stage of a systematic review.

### Early versions

Work on the medrxivr tool began in Summer 2019, and initially consisted of a development of set of R scripts to allow for searching medRxiv and bioRxiv as part of the systematic search outlined in Chapter 4. Following interest from other researchers in using the *ad-hoc* web-scraping scripts, additional development work took place in 2019/2020, allowing for improved searching and exporting functionality and I released the initial version of the medrxivr R package in February 2020.

Early versions of the tool had a reliance on scraping data directly from the repository website. Web-scraping is a fragile mechanism for extracting data, as it is entirely dependent on consistent website design and underlying code structure remaining unchanged.[108](#ref-shaw2002),[109](#ref-laprie1992). In the case of medrxivr, as the medRxiv/bioRxiv websites are regularly updated, ensuring the web-scraping performed as expected required me to regularly update or fix the script.

However, an Application Programming Interface (API) for the medRxiv and bioRxiv repositories was made public in early 2020 by the institution responsible for managing these preprint repositories, the Cold Springs Harbor Laboratory. This allowed for newer versions of the medrxivr package to engage in active “fault prevention” and provide a more robust interface to the data by removing the reliance of web-scraping.[109](#ref-laprie1992)

### Package infrastructure

I wrote the medrxvir package in R using RStudio,[110](#ref-rcoreteam2019) and followed development best-practice, including development of detailed documentation, a robust unit testing framework (99% of all code lines within the package are formally tested across multiple platforms including Windows, MacOS, and Linux), and in-depth code review by two experienced, independent reviewers.

## Usage

The medrxivr R package is split into two component parts:

* an interface to the Cold Springs Harbor Laboratory API, which imports medRxiv and bioRxiv metadata into R; and
* a collection of functions for working with the imported metadata, with an explicit focus on searching this data as part of a systematic review or evidence synthesis project.

The standard workflow is to download a copy of all metadata contained in the repository, and then to perform searches on this local copy. This is a workaround as the Cold Springs Harbor Laboratory API does not provide any functionality to search the database.

While the package allows users to interact with and search both medRxiv and bioRxiv metadata, as the process is identical for both, searching the medRxiv database is used as an illustrative example throughout this chapter.

### Installation

medrxivr has been released to the Comprehensive R Archive Network (CRAN), and can be installed with the following code:

install.packages("medrxivr")

Alternatively, the development version of the package can be installed from GitHub:

# install.packages("devtools")   
devtools::install\_github("ropensci/medrxivr")

### Importing preprint metadata

Prior to searching the metadata, it must first be imported in R. In medrixvr, I have provided two separate but related methods for users to import the data (Figure 3). The first of these methods, accessed via the mx\_api\_content() function, creates a local copy of all data available from the medRxiv API at the time the function is run.

# Get a copy of the database from the live medRxiv API endpoint  
mx\_data <- mx\_api\_content()

This provides an up-to-the-minute reflection of the medRxiv preprint repository. However, this approach has two limitations. Firstly, as the API returns results as a series of pages limited to 100 records per page, downloading the entire database requires a time-intensive process of cycling through multiple pages. Secondly, the API can become unavailable, either during peak usage times or planned maintainence windows.

To address these limitations, I provide a second method of accessing medRxiv data, called via the mx\_snapshot() function, which allows users to access a maintained static snapshot of the database.

# Import a copy of the medRxiv data from the snapshot  
mx\_data <- mx\_snapshot()

This snapshot is created each morning at 6am using a process known as “git-scraping”,[111](#ref-zotero-15031) whereby the entire database is downloaded using the mx\_api\_content() function and saved as a comma separated value (CSV) file to an online server (Figure 3). Calling mx\_snapshot() imports this CSV into R, and has the advantage of both faster loading of the data into R (as it is imported as a single file and does not require cycling through the output of the API) and an absence of any reliance on the API.

The one limitation of this approach is that the snapshot (by its nature) will not contain details of records added to the database since it was taken. However, given that the number of records added each day is relatively low, this should pose minor issues.



Figure 3: **Overview of medrxivr data sources** - Users can either access the API directly via mx\_api\_content(), or can import a maintained snapshot of the database, taken each morning at 6am, via the mx\_snapshot() function. Note: due to the size of bioRxiv, only a maintained snapshot of the medRxiv repository is available via mx\_snapshot().

### Performing a search

Once a local copy of the metadata is created, the first step in searching it is to create a search strategy. Search terms to be combined with the OR operator are contained in vectors (c(...)), while topics to be combined with the AND operator are contained in lists (list(...)).

# Create the search query  
topic1 <- c("dementia","alzheimer's") # Combined with OR  
topic2 <- c("lipids","statins") # Combined with OR  
  
myquery <- list(topic1, topic2) # Combined with AND

For example, when written in standard syntax, the search contained in the myquery object above would be: “((dementia **OR** alzheimer’s) **AND** (lipids **OR** statins))”. There is no limit to the number of search terms that can be included in each topic, nor in the number of topics that can be search for. Search terms can also contain common syntax used by systematic reviewers and health librarians, including the use of NEAR statements which allows for identification of co-localised terms, and wild-cards, which allow for alternate spellings, e.g. “randomi*s*ation” vs “randomi*z*ation”.

Once a strategy has been defined, it is passed along with the local copy of the database to the mx\_search() function.

# Run the search  
results <- mx\_search(mx\_data,  
 myquery)

### Refining a search

An important argument of the mx\_search() is report, which outputs a structured table with each search strategy presented on an individual line and the number of records associated with this strategy.[112](#ref-rethlefsen2021prisma)

results <- mx\_search(mx\_data,  
 myquery,  
 report = TRUE)

## Found 1 record(s) matching your search.  
##   
## Total topic 1 records: 224  
## dementia: 224  
## alzheimer's: 0  
##   
## Total topic 2 records: 119  
## lipids: 90  
## statins: 33

This allows users to discover which terms in their search are contributing most to the total number of results returned. This is important as part of developing a search strategy,[113](#ref-bramer2018) as it allows for the key terms related to each topic to be discovered. It also aids in identifying misspelled or case-sensitive search terms, which will frequently return no results. As an example, in the search presented above, the term “alzheimer’s” returns no records. This is expected, as “Alzheimer” is a proper noun and so should be capitalised, but serves to illustrate the usefulness of the reporting function.

### Exporting to a bibliography file

In line with my second success criteria (Section 3.3.1), one of the key features of the medrxivr is the ability for users to easily export the results of their systematic search to a reference manager. While it is a seemingly simple request, this is is one of the key ways in which medrxivr is set apart for other preprint search tools, including the native medRxiv/bioRxiv website search functionality.

For example, the results of our simple search above can be exported to the "medrxiv\_export.bib" file using the following code:

mx\_export(results,   
 file = "medrxiv\_export.bib",  
 report = TRUE)

### Downloading the PDFs of relevant records

medrxivr alos allows users to download the full text papers for records that are deemed eligible for full-text screening (see Figure 2). mx\_download() takes the list of included records and saves the PDF for each to a folder specified by the user. This functionality is similar to the “Find Full Text” feature offered by EndNote.

mx\_download(results, # Search results, less excluded records  
 "pdf/") # Directory to save PDFs to

## Discussion

### Reception and future plans

The tool has been well received by the community (as of December 2021, medrxivr has been downloaded more than 5000 times), and several use cases have been reported. It has been used to investigate the role of preprints in the response to the 2019 coronavirus outbreak,[114](#ref-kodvanj2020) perform searches of preprints as part of a systematic review,[115](#ref-noone2020),[116](#ref-grassly2020) and examine how data-sharing behaviour is affected by journal policies (see 2.8).[**mcguinness2020c?**](#ref-mcguinness2020c)

The package has been accepted into the rOpenSci suite of packages, a collection of “carefully vetted, staff- and community-contributed R software tools that lower barriers to working with scientific data sources on the web”.[117](#ref-boettiger2015) As part of this process, following rigorous peer-review, an associated article introducing the tool was published by the Journal of Open Source Software.[**mcguinness2020a?**](#ref-mcguinness2020a) The entire review discussion is publicly available and can be viewed online.[118](#ref-zotero-15016) The tool has also been well received by the open-source community, demonstrated by the engagement of other developers in contributing to important new functionality and suggesting bug-fixes.

Lobbying of the Cold Springs Harbor Laboratory to develop the API to allow for direct searching of the database has been ongoing. This would negate the current need to download a local copy of the relevant preprint database before searching it, which is currently the rate limiting step for performing searches. For example, as of January 2021, downloading a copy of the bioRxiv database takes approximately an hour.

### Use case

In addition to being used to search systematically search health-related preprint servers, as illustrated in the systematic review presented in Chapter 4, medrxivr has other uses. For example, I led a descriptive analysis of the change in data availability statements between preprinted and published versions of the same manuscript, stratified by journal data sharing policy access, underpinned by preprint meta-data provided by medrixvr.

By comparing the preprinted and published versions of the data availability statement, I could examine the same manuscript (same content, authors and funders) under two differnt publication policies, and examine whether stricter policies which require data sharing as a condition of publication actually result in increased data availability. We found some evidence that data availability statements more frequently described open data on publication when the journal mandated data sharing compared to when the journal did not mandate data sharing. This study has since been published in PLOS One, and a copy is included in Appendix 11.4. Author contributions are discussed in the

In short, this use case illustrates that easy access to medRxiv/bioRxiv metadata has applications beyond systematic searching of preprints as a part of evidence synthesis exercises.

### Limitations of medrxivr

While searching of the medRxiv and bioRxiv databases was crucial for the systematic review element of my thesis presented in Chapter 4, there are some important limitations to note here. A key example is that the tool only searches the available metadata of preprint records (the title, abstract and keywords), rather than the full text of preprints, meaning some relevant records might be missed. However, this approach echoes that used by other search platforms such as OvidSP, and while some relevant records may be missed (reduced sensitivity), limiting the search to the metadata fields prevents non-relevant records from being returned (high specificity). A key example of the reduced specificity when searching the full text, identified during development of medrxivr, is that a search for “dementia” would return a record where the only occurrence of this term is in the title of one of the references.[119](#ref-bong2019)

There is also the potential that the cross-section of literature posted on medrxiv/bioRxiv is substantially different those suffering from publication bias (studies or analyses that are not published for a range of reasons including results that are not deemed “novel” or are not statistically significant).[120](#ref-song2010) This is because simply lowering the barriers to publication may well encourage authors to published “null” results, but due to the effort involved in writing up a distributable manuscript, it is unlikely to completely address the “file drawer” effect.[75](#ref-rosenthal1979)

Using medrxivr an analysis of the publication rate for medRxiv preprints was performed (see Appendix 10.2). Eighty-seven (67.4%) of the 129 records posted on medRxiv in July 2019 were published by 30th July 2021 (i.e. allowing for a two-year lag between preprint posting and publication). This finding agrees with previous work demonstrating that two-thirds of bioRxiv preprints are published in a peer-reviewed journal within two years of posting,[121](#ref-abdill2019b) indicating that a non-insignificant number of preprints are never formally published but remain accessible as preprints.

It is likely too early (and likely too methodologically difficult) to tell whether the increased popularity and acceptance of preprint repositories will have any effect of the availability of research that was not considered “publishable” at other venues.

### Role of open source tools in evidence synthesis

Part of the motivation for creating the medrxivr tool was a belief that the development and distribution of open source scripts and tools should be a fundamental part of evidence synthesis research.[**goldacre2019b?**](#ref-goldacre2019b),[**mckiernan2016c?**](#ref-mckiernan2016c) In the case of medrxivr, it is likely that several other evidence synthesists had written personal scripts that have a similar, or related, functionality - in fact, following development of the tool, I identified one other researcher that has done so (Nicholas Fraser, author of the rbiorxiv package, which allows for importing medRxiv metadata into R but does not provide search functionality).[**rbiorxiv?**](#ref-rbiorxiv) If these scripts continue to be developed in private and are never shared or publicised, this will inevitably hamper the efforts of evidence synthesis community, not only in terms of duplication of time and effort but also due to lost opportunities for collaboration.[**mckiernan2016c?**](#ref-mckiernan2016c) Creating and sharing well-documented packages, the recognised standard for sharing code in R, represents one way to reduce this inefficiency.[122](#ref-vuorre2020)

## Summary

* In this Chapter, I have introduced a new tool, medrxivr, for performing complex systematic searches of the medRxiv and bioRxiv preprint repositories.
* I have outlined the motivation for developing this tool in relation to this thesis - more specifically, that it was used to perform systematic and reproducible searches of a key literature sources used in the comprehensive systematic review described in Chapter 4.
* I have contrasted medrxivr with other available interfaces to medRxiv/bioRxiv data to highlight the added functionality it offers. I have also discussed the tools reception to date, its limitations, and the important role of open-source tools like medrxivr in evidence synthesis.

## References

# Systematic review of all evidence available on the association between blood lipids (and treatment) and dementia outcomes

## Lay summary

Systematic reviews are a type of research that aim to use all existing evidence to provide the best answer to an important research question. They do this by finding and combining the results from many related primary research studies. Reviews involve multiple steps including: searching of existing studies; assessment of the studies against predefined inclusion criteria; collection of data from each study; assessment of each study’s methods.

This chapter presents a systematic review of primary studies that have examined the relationship between the levels of blood lipids (such as cholesterol and triglycerides), and treatments that change these levels, and dementia.

There were n\_included primary studies that contained information on this relationship. I found that statins reduce the risk of Alzheimer’s disease, but had no effect of vascular dementia. Lipids were not associated with any outcome. The methods used in some of the primary studies meant that I was less confident in the accuracy of their results.

The use of the results of this review in subsequent chapters is dicussed.

## Introduction

In this chapter, I describe a comprehensive systematic review of the relationship between blood lipid levels, and treatments that modify them, and the subsequent risk of dementia and related outcomes. This analysis sought to address two specific aims.

Firstly, as discussed in the Introduction to this thesis (Section 2.5), several diverse forms of evidence on the relationship of lipids and dementia exist. These include randomised controlled trials, observational studies of different analytical design, and Mendelian randomisation studies. However, based on a scoping review of existing literature, no previous evidence synthesis exercise has attempted to examine the association of lipids/statins with dementia outcomes across these distinct evidence types. Collating these diverse evidence sources is important, as if the observed association between lipids and dementia is constant across them, it increases our confidence in the association. As such, the primary aim of this analysis was to systematically review all available literature, regardless of study design.

Secondly, I explicitly sought to include health-related preprint servers as a potential evidence source in this review, as they are infrequently considered by evidence synthesists but may contain important unpublished studies. As a sensitivity analysis to the systematic review presented in this chapter, I sought to quantify the additional evidential value of including preprints. This inclusion of preprint serves makes use of the preprint search tool presented in Chapter 3.

The results of this review are used to guide the primary analysis presented in Chapter 5, in addition to forming a key evidence source used in the triangulation exercise presented in Chapter 8.

## Methods

### Protocol

A pre-specified protocol for this analysis was registered using the Open Science Framework, and is available for inspection.[123](#ref-mcguinnessluke2020) Deviations from this protocol are detailed in the relevant sections.

### Contributions

In line with best-practice guidance, secondary reviewers were used to check the accuracy of screening, data extraction and risk-of-bias assessment processes. Due to the scale of the project, this systematic review was performed in conjunction with a team of secondary reviewers and an information specialist (see Acknowledgments and Author declaration).

### Search strategy

I systematically searched several electronic bibliographic databases to identify potentially relevant entries (hereafter referred to as “records”). The following databases were searched from inception onwards: Medline, EMBASE, Psychinfo, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science Core Collection. As the contents of the Web of Science Core Collection can vary by institution,[124](#ref-gusenbauer2020a) the specific databases searched via this platform are listed in Appendix 10.3.2. The search strategy used in each database was developed in an iterative manner using a combination of free text and controlled vocabulary (MeSH/EMTREE)[72](#ref-lefebvre2019searching) terms to identify studies which have examined the relationship between blood lipids levels and dementia, incorporating input from an information specialist. The strategy included terms related to lipids, lipid modifying treatments, and dementia, and was designed for MEDLINE before being adapted for use in the other bibliography databases listed. An outline of the general strategy is presented in the Table 6 below and the full search strategies for each database are presented in Appendix 10.3.1.

Table 6: Summary of systematic search by topic. The full search strategy including all terms and the number of hits per term is included in Appendix 10.3.1.

|  |  |
| --- | --- |
| No. | Concept |
| 1 | Dementia |
| 2 | Lipids |
| 3 | Lipid-modifying treatments |
| 4 | 1 AND 2 |
| 5 | 1 AND 3 |
| 6 | 4 OR 5 |
| 7 | Animals NOT (Animals AND Humans) |
| 8 | 6 NOT 7 |
| 9 | Observational filter |
| 10 | Randomised controlled trial (RCT) filter |
| 11 | Mendelian randomisation/Instrumental variable filter |
| 12 | OR/ 9-11 |
| 13 | 8 AND 12 |

When searching the bibliographic databases, study design filters were employed to try and reduce the screening load. To ensure that the study design filters are not excluding potentially relevant records, a random sample of 500 records identified by the main search but excluded by the filters (defined as “8 NOT 12” in Table 6) was screened.

I also searched clinical trial registries, for example ClinicalTrials.gov, to identify relevant randomized controlled trials. In addition, I searched the bioRxiv and medRxiv preprint repositories using the tool developed in Chapter 3 to identify potentially relevant preprinted studies (see Appendix 10.3.3 for the code used to search these preprint repositories).

Grey literature was searched via ProQuest, OpenGrey and Web of Science Conference Proceedings Citation Index, while theses were accessed using the Open Access Theses and Dissertations portal. In addition, the abstracts list of relevant conferences (e.g. the proceedings of the Alzheimer’s Association International Conference, published in the journal Alzheimer’s & Dementia) were searched by hand. Finally, the reference lists of included studies were searched by hand while studies citing included studies was examined using Google Scholar (forward and reverse citation searching or “snowballing”).

### Study selection

Records were imported into Endnote and de-duplicated using the method outlined in Bramer et al. (2016).[125](#ref-bramer2016) In summary, this method uses multiple stages to identify potential duplicates, beginning with automatic deletion of records matching on multiple fields (“Author” + “Year” + “Title” + “Journal”), followed by manual review of less similar articles (e.g. those matched based on the “Title” field alone).

Following deduplication of records, screening (both title/abstract and full-text) was performed using a combination of Endnote, a citation management tool,[126](#ref-hupe2019) and Rayyan, a web-based screening application.[127](#ref-ouzzani2016) Title and abstract screening to remove obviously irrelevant records was performed primarily by me, with a random ~10% sample of excluded records being screened in duplicate to ensure consistency with the inclusion criteria. Additionally, records were rescreened by me with a 1 month lag to intra-rater consistency.

Similarly, I completed all full-text screening, with a random ~10% being screened in duplicate by a second reviewer. In addition, any records identified I identified as being difficult to assess against the inclusion criteria were screened in duplicate. Reasons for exclusion at this stage were recorded. Disagreements occurring during either stage of the screening process were resolved through discussion with a senior colleague. A PRIMSA flow diagram was produced to document how records moved through the review.[82](#ref-page2021)

The criteria used to assess eligibility are presented in the subsequent sections.

#### Inclusion criteria

I sought to include studies that examine the relationship between blood lipid levels (or any specific lipid fraction, including total cholesterol, HDL, LDL, and triglycerides) and risk of incident dementia and its subtypes. Eligible study designs included randomized controlled trials and non-randomized observational studies of lipid modifying treatments, longitudinal studies examining the effect of increased/decreased blood lipid levels, and genetic instrumental variable (Mendelian randomization) studies examining the effect of genetically increased/decreased blood lipid levels.

Participants were screened for dementia at baseline and prevalent cases excluded. Alternatively, where no baseline screening was employed, participants were assumed to be dementia free if less than 50 years of age at baseline. Studies of any duration were included to allow for exploration of the effect of length of follow-up on the effect estimate using meta-regression. No limits were placed on the sample size of included studies.

Eligible studies defined dementia according to recognised criteria, for example the International Classification of Diseases (ICD),[128](#ref-organizationwho1993) National Institute of Neurological Disorders and Stroke Association-Internationale pour la Recherche en l’Enseignement en Neurosciences (NINDS-AIREN),[129](#ref-roman1993) or Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria.[130](#ref-edition2013) Studies utilising electronic health records were the exception to this, as it was assumed that these criteria were used when entering the outcome into the EHR.

No limitations were imposed on publication status, publication date, venue or language, although sufficiently detailed reports of the studies to be able to examine their methods were required for inclusion.

#### Exclusion criteria

Due to the significant impact of a memory-related outcome such as dementia on exposure recall, case-control studies were excluded, though nested case-control studies, where historical records are used to determine the exposure status, were eligible for inclusion. Cross-sectional studies, qualitative studies, case reports/series and narrative reviews were also excluded. Studies which presented no evidence of attempting to exclude prevalent cases from their analyses were also excluded. Studies that measure change in continuous cognitive measures (e.g. MoCA score) without attempt to map these scores to ordinal groups (e.g. no dementia/dementia) were excluded. Conference abstracts with no corresponding full-text publication were examined, and where required, I contacted authors to obtain information on the study’s status. Previous systematic reviews were not eligible for inclusion, but their reference lists were screened to identify any potentially relevant articles.

Studies with outcomes not directly related to the clinical syndrome of dementia (e.g., neuroimaging), studies implementing a “multi-domain intervention” where a lipid-regulating agent is included in each arms (e.g. for example, a study examining exercise + statins vs statins alone, but a study examining exercise + statins vs exercise alone would be included), and studies where there was no screening for dementia at baseline except if the sample was initially assessed in mid-life (i.e. below the age of 50) were excluded. Finally, studies using a dietary intervention, for example omega-3 fatty acid enriched diet, were excluded as it is difficult to disentangle the effect of other elements contained within the diet. Note, this is distinct from studies which delivered a simple tablet-based omega-3 intervention, which would have been eligible for inclusion.

### Validation of screening process

Inter- and intra-rater reliability during the screening stages were assessed for a 10% sub-sample of records. Intra-rater reliability involved a single reviewer applying the inclusion criteria to the same set of records while blinded to their previous decisions (i.e. assessment of consistency), while inter-rater reliability involved two reviewers independently screening the same set of records (i.e. assessment of accuracy).

Rater reliability was assessed using Gwet’s agreement coefficient (AC1).[131](#ref-gwet2008) This measure was chosen over other methods such as percent agreement (number of agreements divided by total number of assessments), as it accounts for chance agreement between reviewers but does not suffer from bias due to severely imbalanced marginal totals in the same way that Cohen’s value does.[131](#ref-gwet2008) Given the small number of included studies in this review as a proportion of the total number screened, this is an important characteristic.

How to interpret agreement co-efficients is widely debated, and while arbitary cut-off values may mislead readers,[134](#ref-brennan1992) they provide a useful rubric by which to assess inter-rater agreement. Here, I used guidelines based on a stricter interpretation of the Cohen’s coefficient,[135](#ref-mchugh2012) presented in Table 7.

Table 7: Suggested ranges to aid in interpretation of Gwet’s AC1 inter-rater reliability metric

|  |  |
| --- | --- |
| Kappa | Interpretation |
| 0 – 0.20 | None |
| 0.21 – 0.39 | Minimal |
| 0.40 – 0.59 | Weak |
| 0.60 – 0.79 | Moderate |
| 0.80 – 0.90 | Strong |
| > 0.90 | Almost perfect |

Intra- and inter-rater reliability was assessed against these cut-offs. If this assessment demonstrated issues with the screening process (defined as an AC1 of less than .9), a larger proportion of records would have been dual-screened.

### Data extraction

Data extraction was performed using a piloted data extraction form. Extracted items included: article metadata (year of publication, author list, journal), study characteristics (study location, data source, exposure, outcomes, outcome criteria used), patient characteristics (age, sex, baseline cognition scores, baseline education scores), and results (exposure-outcome pairing, effect measure, effect estimate, error estimate, p-value). I extracted all data in the first instance, which was subsequently checked for accuracy by a second member of the review team.

#### Study-fication

As part of the data extraction process, multiple resords resulting from the analysis of the same data were included and grouped into single units, hereafter called studies. This is likely in the advent of multiple papers reporting results on the same cohort, but say, at different time points. Study-fication builds out the most comprehensive accounts of the studies and results from as many published articles were applicable.

This was particularly relevant to preprints and published papers reporting the same study, which were not considered to be duplicate records but instead different reports of the same study. This is due to the potential for the published version to offer some information that the preprint did not, and vice versa.

#### Combining across groups

Following best practice, where summary data was presented across two groups (e.g. age at baseline stratified by hypercholesterolemia status), the following approach was used to combine the groups.[136](#ref-higgins2019)

This was implemented in a systematic manner, with the raw group data being extracted and a cleaning script written to combine the groups for analysis.

#### Harmonisation of cholesterol measures

Where necessary, lipid levels reported in *mmol/L* were converted in *mg/dL* using the following formula:

where for total cholesterol, LDL-c and HDL-c, and for triglycerides. For widely-used categorises of lipids levels on the *mg/dL* scale, see Table 2 in Section 2.4.1.

#### Following up with authors

Where additional data points not included in the report of an analysis were required either for the analysis or risk-of-bias assessment, the corresponding author of the study was contacted. This approach was taken due to the potentially large impact of following up with authors on the results of the review.[137](#ref-reynders2019)

#### Analysis of varying effect measures

The range of effect measures presented by studies (odds ratios, risk ratios, hazard ratios, etc) are not directly interchangeable in the context of systematic review. If the outcome is rare, as is the case for dementia outcomes at and estimated prevalence of odds and risk ratios approximate each other. However, hazard ratios provide a very different interpretation, taking into account person-timea-at-risk in each treatment group. As such, different effect estimates can be one potential problem that precludes a meta-analysis of all studies.[138](#ref-mckenzie2019)

Several existing reviews do not distinguish between the types of effect measures and include all existing studies in a single meta-analysis to produce an overall effect. In addition, there is some evidence of manipulation of effect estimates in previous reviews,(e.g. Chou, Sci Reports - at least one study disagrees with) but this is not accurately documented in the review text.

In this review, studies reporting hazard ratios were synthesised separately to those reporting odds/risk ratios.

### Risk-of-bias assessment

A key use of the review presented in this chapter is to identify different sources of evidence at risk of a diverse range of biases, and to contrast and compare findings across them (see Section 8.1.1 for an overview of triangulation and Section 2.6.2 for the results of this qualitative analysis). To enable this triangulation exercise, a detailed and structured risk-of-bias assessment formed an important part of this review.

There has been a recent movement within the evidence synthesis community from examining *methodological quality* to assessing *risk of bias*,[83](#ref-mcguinness2018),[139](#ref-sterne2016) and thus directly evaluating the internal validity of a study. Internal validity is defined here as the absence of systematic error (or bias) in a study, which may influence its results.[140](#ref-campbell1957),[141](#ref-juni2001)

This move was prompted by a unclear definition of “methodological quality” which could include facets such as unclear reporting, and challenges in the comparison of results from different tools. As part of this shift, the community also moved from checklist or score based tools towards domain-based methods, in which different potential sources of bias in a study are assessed in order. Additionally, bias should be assessed at the result (defined as a a specific outcome at a specific timepoint) rather than the study level. For example, a study may report on the efficacy of an intervention at six months and two years follow-up. In this case, missing outcome data that is not an issue at six months may introduce bias at 2 year follow-up, and assigning a bias judgement to the study as a whole masks the different level of bias for each unique result.

In this review, domain-based tools were used to assess the risk of bias for each result in each included study. The study design-specific tools are introduced and discussed in more detail in the following sections.

#### Randomised controlled trials

Randomized controlled trials were assessed using the RoB2 tool.[142](#ref-sterne2019) The tool assess the risk of bias across five domains: Bias arising from the randomization process, Bias due to deviations from intended intervention, Bias due to missing outcome data, Bias in measurement of the outcome, Bias in selection of the reported result. Acceptable judgements include: low risk of bias, some concerns, high risk of bias. Each of the 5 domains contains a series of signalling questions or prompts, which guide the user through the tool. Once a domain-level judgement for each domain has been assigned, an overall judgement, using the same three levels of risk of bias, is assigned to the result.

#### Non-randomised studies of interventions/exposures

For non-randomised studies of interventions (NRSI), I used the ROBINS-I (Risk Of Bias In Non-randomised Studies - of Interventions) tool.[139](#ref-sterne2016) This tool assess the risk of bias across seven domains: Bias due to confounding, Bias due to selection of participants, Bias in classification of interventions, Bias due to deviations from intended interventions, Bias due to missing data, Bias in measurement of outcomes, and Bias in selection of the reported result. Similar to RoB 2, it has a number of prompting questions per domain, with acceptable judgements including “Low risk”, “Moderate risk”, “Serious risk” and “Critical risk”. Ideally, observational studies should be assessed in reference to an idealised randomised controlled trial. Under this approach, the (rare) overall judgement of “Low” indicates that the results should be considered equivalent to produced by a randomised controlled trial.

While a risk-of-bias tool for non-randomised studies of exposures (NRSE) is currently under development,[143](#ref-morganr2020) but was insufficiently developed at the time the risk-of-bias assessments for this review were performed. Instead, I used a version of the ROBINS-I tool informed by the preliminary ROBINS-E tool (“Risk of Bias In Non-randomised Studies – of Exposure”), which I had applied in a published review.[144](#ref-french2019) The version had no signalling questions and so judgements were made at the domain level. The motivation for this using this tool above other established tools such as the Newcastle-Ottowa scale (NOS).[145](#ref-wells2000) was two-fold. In the first instance, as mentioned in the introduction to this section, using a domain-based tool has distinct advantages over better-developed checklist-type tools including the NOS. Additionally, using a domain-based tool for non-randomised studies of exposures enabled better comparison with risk-of-bias assessments performed for the other study designs.

#### Mendelian randomisation studies

At present, no formalised risk-of-bias assessment tool for Mendelian randomization studies is available. Assessment of the risk of bias in Mendelian randomisation studies was informed by the approach used in a previous systematic review of Mendelian randomisation,[146](#ref-mamluk2020) as identified by a review of risk-of-bias assessments in systematic reviews of Mendelian randomisation studies (advance results from this review were obtained from contact with the authors.). A copy of this tool is available in Appendix 10.3.5, but in summary, results were assessed for bias arising from weak instruments, genetic and other confounding, pleiotropy, and selection of participants.

#### Risk of bias due to missing evidence

A recent shift towards the assessment of missing evidence due to selective non-reporting - as distinct from the selective reporting of a single result from multiple planned - is demonstrated via the forthcoming RoB-ME (Risk of Bias due to Missing Evidence in a synthesis) tool.[147](#ref-zotero-15123) The tool is in development stages, and as part of this review, I piloted the tool, and provided feedback to the developers.

This additional appraisal marks a departure from the registered protocol, as there was initially no intention to try and examine the risk of bias due to missing evidence. This is largely because the tool did not exist when the protocol was originally registered.

### Analysis methods

An inital qualiatative synthesis of evidence was performed, summarising the data extracted from studies stratified by study design

Where individual studies were deemed comparable, they were incorporated into a quantitative analysis or “meta-analysis”. Meta-analysis provides a summary or pooled effect estimate across studies.

Of note, studies were not combined across different study designs (i.e. RCTs were not combined in a meta-analysis with results from observational studies). The results from each individual analytical approach were summarised, but are compare and contrasted more fully in the triangulation exercise presented in Chapter 8

#### Standard meta-analysis

A random-effects meta-analysis model was employed to combine the different included studies. The fixed-effect method was implemented as:

Results were stratified into subgroups on the basis of the overall risk of bias assessment, and summary estimates for each subgroup, in addition to an overall effect estimate, are displayed. Additional descriptive statistics are presented, while prediction intervals are shown as a dotted line around the overall effect estimate. Finally, a test subgroup differences between studies at different levels of risk of bias was performed (see subsequent Section 4.3.8.4).

[Do I need to include]

Random-effects analyses assume that differences in study design and execution mean that the study effects are normally distributed around a common treatment effect () with a variance of

Random-effects methods estimate to estimate the common effect (). There are many estimators of with varying assumptions,[**Veroniki2016?**](#ref-Veroniki2016),[**Bakbergenuly2020?**](#ref-Bakbergenuly2020) the details of which are beyond the scope of this article. The estimate of is incorporated into the weighting of each study

#### Dose-response analyses

This was particularly important for the dose response meta-analysis, where the number of participants and the cut-offs per category were often not reported.

Several of the included studies presented data on multiple categories of lipid levels, but provided an overall effect estimate based on a comparison of only two of these categories (e.g. for example, highest vs lowest quartile). While this allows for easy interpretation of the resulting effect estimate, it ignores any potential non-linear relationships between the exposure and outcome, in addition to discarding useful information contain in the interim groups. In order to address this limitation, I performed a dose-response meta-analysis in those studies reporting more than two categories for lipid levels.

Studies were excluded from this analysis if the number of categories was less than three, if the exposure cut-off points for for each category were not reported (e.g. if the study reports splitting participants into quartiles and comparing the highest vs lowest without giving the quartile bands).

A restricted cubic spline model was fitted to allow for a non-linear relationship, for example a U or J-shaped relationship, where low and high levels of the exposure can have different effects versus a “normal” reference dose. The locations of the knots in the model wer identified using fixed percentiles (25th, 50th, 75th) of the exposure data. Reference doses were defined *a priori* as the cut-off of the “Normal”/“Optimal” categories for each fractions, as detailed in Table 2. Under this approach, the reference dose was defined as 200 mg/dL for total cholesterol, 100 mg/dL for LDL-c, 40 mg/dL for HDL-c, and 150 mg/dL for triglycerides.

Due to the requirements for the dose response analysis, studies were excluded from this secondary analysis if they did not provide the require information: cut-off points.

Where this was not reported in the study, I contacted the corresponding author to attempt to obtain the required information (see Section 4.3.6.4).

When the highest category was open ended (e.g LDL-c 200 mg/dL), I calculated category midpoint by assuming the width of the highest category was the same as the one immediately below it. Similarly, when, the lowest category was open-ended (e.g LDL-c 100 mg/dL), I set the lower boundary for this category to zero (though this is unlikely to occur natually, it was difficult to define).

#### Additional analyses

Where there was evidence of heterogeneity between results included in a meta-analysis, I investigated this further using meta-regression against reported characteristics. *A priori*, I was interested in the effect that the age at baseline, sex and risk-of-bias judgement had on the results.

Finally, I investigated the potential for small study effects, which may be caused by publication bias, both visually using funnel plots and statistically using Egger’s regression test.

#### Visualisation of results

Evidence maps are useful way to explore the distribution of research cohorts included in a systematic review.[148](#ref-saran2018) As such, the location of each individual study contributing to the evidence base was quantified and visualised on a world map.

One of the limitations of current risk-of-bias assessments in systematic reviews is that they are often divorced from the results to which they refer, and are infrequently incorporated into the analysis. In response to this criticism, I developed a new visualisation tool was designed to allow for “paired” forest plots, as recommended by the ROB2 publication, where the risk-of-bias assessment is presented alongside the results.[142](#ref-sterne2019) This tool was developed as an adjunct to this thesis to aid in creating standardised risk-of-bias figures,[149](#ref-mcguinness2020robvisPaper) and the “paired” forest plot functionality grew out of a collaboration with other researchers to design a modular method for creating custom forest plots.[150](#ref-zotero-14999) A summary of this tool is contained in Appendix 11.2, and all forest plots presented in this Chapter were created using this tool.

#### Assessment of added value of including preprints

**[Note: Julian, I am particularly interested in your feedback on this section, and the corresponding results section (Section ??), as I am not convinced on the language I am using]**

Preprints are considered a valuable evidence source within this thesis (see Introduction, Section 2.6.1) but their inclusion in a systematic review.

As a sensitivity analysis, I explored the additional evidential value of including preprints in each meta-analysis performed, assessed using the fixed effect weight from a standard meta-analysis.

Additionally, I followed preprints up over time to investigate whether all identified preprints included in the review were subsequently published (in which case preprints provide a snapshot into the future, and a systematic review update would capture these reports) or alternatively, if some preprints were not published, then preprints provide a distinct evidence source.

## Results

### Initial search and validation of search filters

The database search identified 23,447 records, of which

Of the random sample of 500 records screened to ensure the accuracy of the study design filters, no eligible records were identified. Many of those excluded by the filters were basic science studies, commentaries or educational articles, as expected.

### Screening results

Following de-duplication, the titles and abstracts of 16,109 records were assessed for eligibility. 387 were deemed potentially eligible, and the full text records for these were accessed and screened.

A PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) flow diagram,[82](#ref-page2021) presented in Figure 4, illustrates the movement of articles through the review. To highlight the contribution of preprint archives to the review, the flow diagram delineates between those records captured through databases searches (presented on the right of the diagram) and those captured by the search tool described in the previous chapter (presented in grey on the left of the diagram).

Common reasons for exclusion at the full text-stage included studies that reported on the wrong exposures (n = XXX; most commonly a inelgible lipid fraction), used the wrong study design (n= XXX), or reported on a wrong outcome (n=24; e.g. change in cognitive scores).

### Validation of screening




Figure 4: PRISMA flow diagram illustrating how records moved through the systematic review process. The different contributions of standard bibliographic databases and preprint servers to the review are indicated.

For the assessment of the intra-/inter-rater reliability, the estimated values of were interpreted against the categories presented in Table 7. For the inter-rater reliability, agreement was “almost perfect” ( = 0.97, = 0.54, Table 8). Similarly for intra-rater reliability, agreement was “almost perfect” ( = 0.99, = 0.65, Table 9). The discrepancy between the and coefficients illustrates the sensitivity of to imbalanced marginals, caused in this sample by a large imbalance towards exclusion.[151](#ref-feinstein1990)

(ref:agreeInter-caption) Inter-rater agreement on a subset of records, indicating high accuracy.

Table 8: (ref:agreeInter-caption)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| group | reviewer | Exclude | Include | Total |
| Second reviewer decision | Exclude | 1244 | 9 | 1253 |
| Second reviewer decision | Include | 26 | 22 | 48 |
| Second reviewer decision | Total | 1270 | 31 | 1301 |

Table 9: Intra-rater agreement on subset of records, indicating high consistency.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| group | reviewer | Exclude | Include | Total |
| Same reviewer decision | Exclude | 1266 | 14 | 1280 |
| Same reviewer decision | Include | 4 | 17 | 21 |
| Same reviewer decision | Total | 1270 | 31 | 1301 |

Those records which were excluded in the initial screening, but were included by the second reviewer (n=26, Table 8) were investigated. This discrepancy between the two reviewers was explained in all cases by differing interpretations of the inclusion criteria, specifically around the definition of cognitive decline/MCI versus dementia, and the definition of eligible lipids fractions.

### Characteristics of included studies

Following full-text screening, 80 unique studies (described across 94 reports) met the criteria for inclusion in the review.[49](#ref-li2005a),[52](#ref-tan2003a),[54](#ref-reitz2004a),[152](#ref-ancelin2012a)–[227](#ref-zimetbaum1992)

Table 10 presents a summary of the characteristics of each study.

The majority of included studies described non-randomised analyses, with the sole two included randomised controlled trials (the Heart Protection Study/British Heart Foundation trial,[175](#X49f9892f062f4edfe92b37e5c1639cb4f6c013f) and the JUPITER trial[204](#ref-ridker2008)) both examining statins use on all-cause dementia in older adults. A similarly small number of Mendelian randomisation studies were identified, several of which employed a two-sample approach using the identical summary statistics from published GWAS, leading to complications in the synthesis (see Section 4.4.7).

Of the r\_nrsi\_included non-randomised studies examining treatments that modify lipid levels, all examined statin use (n = 31; 100%), while a small number also examined other non-statins agents such as fibrates (n = 2; 6.45%). In the 43 non-randomised studies of exposure, hypercholesterolemia n = 19; 44.19% and n = 21; 48.84% were the most frequently reported risk factors.


In terms of outcomes, the vast majority of studies examined either all-cause dementia (n = 61; 76.25%) or Alzheimer’s disease (n = 50; 62.5%), with only a small proportion examining vascular dementia n = 16; 20%. Some rarer outcome classifications such as vascular-component or mixed dementia were also investigated.

Three included reports were preprints (denoted in the Table 10 using an asterisk),[204](#ref-ridker2008),[208](#ref-so2017),[228](#ref-zhu2017) one of which had subsequently been published and was captured by the primary literature search.[229](#ref-zhu2018) All three included preprints were obtained from the bioRxiv preprint server and described a Mendelian randomisation analysis.

Table 10: Characteristics of included studies, stratified by study design. Note that three studies reported on multiple study designs, and these have been duplicated across the relevant sub-sections.

| **Study** | **Location** | **N** | **Age at baseline** | **Female (%)** | **Exposures** | **Outcomes** | **Diagnostic criteria** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **HPS 2002** | United Kingdom | 20536 | >70 | 24.8 | Simvastatin | Dementia | NR |
| **JUPITER 2009** | Multiple | 17902 | 66 (median) 60-71 (range) | 38 | Rosuvastatin | Dementia | NR |
| **Ancelin 2012** | France | 7056 | NR | 67 | Fibrate; Statin | Dementia; AD | DSM-IV; NINCDS-ADRDA |
| **Arvanitakis 2008** | United States | 929 | 74.9 (NR) | 68.7 | Statin | AD | Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) |
| **Bettermann 2012** | United States | 3069 | 78.6 (3.3) | 46.2 | Non-statin LRA ; Statin | Dementia; AD; Vascular component | Consensus panel - criteria not reported |
| **Beydoun 2011** | United States | 1604 | 57.6 (18.4) | 38.5 | Statin; TC | Dementia | DSM-III-R |
| **Chao 2015** | Taiwan | 256265 | 73.2 (7.4) | 50.3 | Statin | Non-vascular dementia | ICD-9 |
| **Chen 2014** | Taiwan | 18100 | 67 (8.6) | 47.9 | Statin | Dementia; AD; Non-AD | ICD-9 |
| **Chitnis 2015** | United States | 8062 | 74.47 (9.21) | 53.04 | Statin | Dementia | ICD-9 |
| **Chou 2014** | Taiwan | 33398 | >60 | 53.9 | Statin | Dementia; AD; VaD; Non-vascular dementia | ICD-9 |
| **Chuang 2015** | Taiwan | 123300 | 54 (13) | 49.1 | Statin | Dementia | ICD-9 |
| **Cramer 2008** | United States | 1674 | 70 (6.8) | 58 | Statin | Dementia/CIND | DSM-IV |
| **Gnjidic 2016** | Sweden | 2056 | >60 | NR | Statin | Dementia | DSM-IV |
| **Haag 2009** | Netherlands | 6992 | 69.4 (9.1) | 60 | Non-statin LRA ; Statin | AD | NINCDS-ADRDA |
| **Hendrie 2015** | United States | 974 | 76.6 (4.9) | 69.7 | Statin | Dementia; AD | DSM-IV; Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) |
| **Hippisley-Cox 2010** | United Kingdom | 2004692 | 46 (14) | 51 | Statin | Dementia | EHR codelist |
| **Jick 2000** | United Kingdom | 1364 | 50-89 | 61 | Non-statin LRA ; Statin | Dementia | EHR codelist |
| **Li 2004** | United States | 2356 | 75.1 (6.1) | 59.8 | Non-statin LRA; Statin | Dementia; AD | DSM-IV; NINCDS-ADRDA |
| **Li 2010** | United States | 3392 | 75 (6.2) | 59 | Statin | AD | NINCDS-ADRDA |
| **Liao 2013** | NR | 5221 | NR | NR | Statin | Dementia | NR |
| **Liu 2019** | Taiwan | 2012 | 74 (7.5) | NR | Statin | Dementia | ICD |
| **Pan 2018** | Taiwan | 14807 | 65 (13) | 43 | Statin | Dementia | ICD-9 |
| **Parikh 2011** | United States | 377838 | 75.53 (6.07) | 2 | Statin | Dementia | ICD-9 |
| **Rea 2005** | United States | 2798 | NR | NR | Non-statin LRA ; Statin | Dementia; AD; Mixed; VaD | NINCDS; NINCDS-ADRDA; Combination; State of California Alzheimer’s Disease Diagnostic and Treatment Centers |
| **Redelmeier 2019** | Canada | 28815 | 76 (NR) | 61.3 | Statin | Dementia | ICD-9 |
| **Reitz 2004** | United States | 1168 | 78.4 (6.2) | 68.3 | HDL-c; LDL-c; Non-HDL-c; Statin; TC; TG | VaD; AD | Cohort criteria; NINCDS-ADRDA |
| **Smeeth 2009** | United Kingdom | 729529 | 50 (NR) | 40-81 | Statin | Dementia; AD; Non-AD | EHR codelist |
| **Solomon 2010** | Finland | 17597 | 68 (5.8) | 57 | Statin | Dementia | EHR codelist |
| **Sparks 2008** | United States | 2068 | 75 (3.8) | 54 | Statin | AD | NINCDS-ADRDA |
| **Szwast 2007** | United States | 1416 | 77.3 (5.3) | 69.3 | Statin | Dementia | DSM-IV |
| **Yang 2015** | Taiwan | 45973 | 82 (5.3) | 48 | Fibrate; LRA (exlc. statin + fibrates); Statin | Dementia | ICD-9 |
| **Zamrini 2004** | United States | 3397 | 73 (NR) | 0 | Statin | AD | ICD-9 |
| **Zandi 2005** | United States | 3308 | NR | NR | Non-statin LRA; Statin | Dementia; AD | DSM-III-R; NINCDS-ADRDA |
| **Ancelin 2013** | France | 7053 | 74 (5.3) | 61.1 | Hypercholesterolemia | AD; Dementia | NINCDS-ADRDA; DSM-IV |
| **Batty 2014** | United Kingdom | 103764 | 47.3 (18.1) | 55 | Non-HDL-c; Hypercholesterolemia | Dementia | ICD |
| **Benn 2017** | NR | 111194 | 56 (median) 46-66 (range) | 55 | HMGCR; LDL-c; PCSK-9 | AD; VaD; Dementia | NR; ICD; ICD-10 |
| **Beydoun 2011** | United States | 1604 | 57.6 (18.4) | 38.5 | Statin; TC | Dementia | DSM-III-R |
| **Bruce 2017** | Australia | 217 | 63.6 (8.4) | 45.6 | HDL-c; TC; TG | Dementia | NR |
| **Chiang 2007** | Taiwan | 785 | 58 (7.4) | 41.4 | TC; TG | Dementia; AD; VaD | ICD-9; NR |
| **Dodge 2011** | United States | 822 | 71.6 (4.7) | 64.4 | Hypercholesterolemia | Dementia; AD | DSM-III-R; Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) |
| **Forti 2010** | Italy | 749 | 73 (6.1) | 53 | Hypercholesterolemia; TG | Dementia; AD; VaD | DSM-IV; NINCDS-ADRDA; NINCDS-AIREN |
| **Gottesman 2017** | United States | 15407 | 54.2 (5.8) | 55 | TC | Dementia | Combination |
| **Gustafson 2012** | Sweden | NR | NR | 100 | TC | AD | NR |
| **Hayden 2006** | United States | 3308 | 74.0 (6.4) | 58.2 | Hypercholesterolemia | Dementia; AD; VaD | DSM-III-R; NINCDS-ADRDA; NINCDS-AIREN |
| **Kimm 2011** | South Korea | 848505 | 53 (9.3) | 42.2 | TC | AD; VaD; Dementia | ICD-10 |
| **Kivipelto 2001** | Finland | 1499 | 50.4 (6.0) | 62 | Hypercholesterolemia | AD | NINCDS-ADRDA |
| **Kivipelto 2005** | Finland | 1449 | 50.6 (6.0) | 62 | Hypercholesterolemia | Dementia | DSM-IV |
| **Kuo 2015** | Taiwan | 67066 | 62.1(11.4) | 48.4 | Hypercholesterolemia | Dementia | ICD-9 |
| **Li 2005** | United States | 2141 | 74.9 (5.9) | 60.5 | HDL-c; TC | Dementia; AD | DSM-IV; NINCDS-ADRDA |
| **Mainous 2005** | United States | 6558 | NR | NR | Hypercholesterolemia | Dementia; AD | ICD-9 |
| **Mielke 2005** | Sweden | 382 | NR | 70 | TC; TG | Dementia | DSM-III-R |
| **Mielke 2010** | France | 1460 | 38-60 (range) | 100 | Hypercholesterolemia; TC | Dementia; AD | DSM-III-R; NINCDS-ADRDA |
| **Mielke 2012** | United States | 99 | 74 (2.5) | 100 | HDL-c; TC; TG | Dementia; AD | DSM-IV; NINCDS-ADRDA |
| **Muller 2007** | United States | 542 | NR | NR | HDL-c; TG | Dementia; AD | DSM-IV; NINCDS-ADRDA |
| **Noale 2013** | Italy | 5632 | 71.3(5.3) | 56.3 | Hypercholesterolemia; TG | Dementia | DSM-III-R |
| **Notkola 1998** | Finland | 444 | 40-59 (range) | 0 | Hypercholesterolemia | AD | Combination |
| **Peters 2009** | Mutliple | 3336 | >80 | 60.4 | HDL-c; TC | Dementia | DSM-IV |
| **Raffaitin 2009** | France | 7087 | 73.4 (4.9) | 61 | Hypercholesterolemia; TG | Dementia; AD; VaD | DSM-IV; NINCDS-ADRDA; Combination |
| **Rantanen 2017** | Finland | 3309 | 42 (median) 39–46 (range) | 0 | TC; Hypercholesterolemia | Dementia; AD; VaD | NR |
| **Reitz 2004** | United States | 1168 | 78.4 (6.2) | 68.3 | HDL-c; LDL-c; Non-HDL-c; Statin; TC; TG | VaD; AD | Cohort criteria; NINCDS-ADRDA |
| **Reitz 2010** | United States | 1130 | 75.7(6.3) | 65.7 | HDL-c; LDL-c; TC | AD | NINCDS-ADRDA |
| **Ronnemaa 2011** | United States | 2268 | 49.6 (0.6) | 0 | Hypercholesterolemia | AD; VaD; Dementia | NINCDS-ADRDA; ADDTC; DSM-IV |
| **Schilling 2017** | France | 9294 | 73.8 (5.3) | 61 | HDL-c; LDL-c; TC; TG | Dementia; AD; Mixed | DSM-IV; NINCDS-ADRDA; NINCDS-AIREN |
| **Solomon 2007** | Finland | 1449 | 50.4 (6.0) | 62.1 | Hypercholesterolemia | Dementia | NR |
| **Solomon 2009** | United States | 9844 | 43 (1.7) | 54 | TC | AD; VaD | ICD-9 |
| **Strand 2013** | Norway | 48793 | 42.6 (4.3) | 49 | TC | Dementia; AD | ICD |
| **Su 2017** | United Kingdom | 212085 | NR | NR | NR | Dementia | NR |
| **Svensson 2019** | Japan | 781 | 54.1 (5.6) | NR | HDL-c; Hypercholesterolemia | Dementia | DSM-IV |
| **Tan 2003** | United States | 1026 | 76.1 (5.3) | 63 | HDL-C; TC | AD | NINCDS-ADRDA |
| **Tynkkynen 2016** | Finland | 13725 | 48.4 (13.3) | 51.6 | HDL-c | Dementia; AD | ICD-10 |
| **Tynkkynen 2018** | Multiple | 22623 | 57 (9.2) | 47 | HDL-c; LDL-c; TC; TG | Dementia; AD | ICD-10 |
| **Wang 2012** | Taiwan | 1230400 | 60 (13) | 52 | Hypercholesterolemia | AD | ICD-9 |
| **Whitmer 2005** | United States | 8845 | 68 (2.6) | 53.7 | Hypercholesterolemia | Dementia | ICD-9 |
| **Yamada 2009** | Japan | 1637 | >60 | 100 | NR | Dementia; VaD | NR |
| **Yoshitake 1995** | Japan | 828 | 74 (5.9) | 59.5 | HDL-c; LDL-c; TC; TG | VaD; AD | NINCDS-AIREN; NINCDS-ADRDA |
| **Zimetbaum 1992** | United States | 350 | 79 (median) 75-85 (range) | 64.5 | HDL-c; LDL-c; TC; TG | Dementia | DSM-III-R |
| **Andrews 2019\*** | NR | NR | NR | NR | HDL-c; LDL-c; TC; TG | AD | NR |
| **Benn 2017** | NR | 111194; 54162 | NR | NR | HMGCR; LDL-c; PCSK-9 | AD; VaD; Dementia | NR; ICD; ICD-10 |
| **Burgess 2017** | NR | 21165 | NR | NR | HDL-c; LDL-c; TG | AD | NR |
| **Mukherjee 2013** | NR | 54162 | 76 (7.9) | 59 | HDL-c; LDL-c; TG | AD | NR |
| **Ostergaard 2017** | NR | 54162 | NR | NR | HDL-c; LDL-c; TC; TG | AD | NR |
| **So 2017\*** | NR | NR | NR | NR | HMGCR | AD | NR |
| **Zhu 2018\*** | NR | 54162 | NR | NR | HDL-c; LDL-c; TG | AD | NR |

As illustrated in Figure 5, the majority of reports described studies conducted in high-income countries. Of interest, several of the included studies were conducted in Taiwan (n = 10; 12.5%), all but one of which made use of the Taiwan National Health Insurance database.



Finally, several eligible studies reported as conference abstracts did not present numerical results. These reports were included in the analysis to enable assessment of risk of bias due to missing evidence (see Section 4.3.7.4).

### Risk of bias

As discussed above, the results of the risk-of-bias assessments are presented alongside their corresponding result. A more detailed discussion fo the sources and directions of bias is presented in Chapter 7, and so this section

However, as a brief summary of the biases at play:

### All-cause dementia

#### Statins

The two randomised controlled trials provided very weak evidence (OR: 1.07, 95%CI: 0.70-1.66) of an effect on statin use on all-cause dementia risk (Figure 6).





Figure 6: Random effects meta-analysis of randomised controlled trials examining statin statins on all-cause dementia

In contrast, a meta-analysis of 15 prospective observational studies provided evidence of a protective effect of statins use on all-cause dementia risk (HR: 0.77, 95%CI: 0.65-0.90, Figure 7).




Finally, a single Mendelian randomisation analysis was identified examining the effect of genetically lowered LDL-c levels via HMGCR inhibition on the risk of all-cause dementia, which provided weak evidence for an effect (RR: 0.90, 95%CI: 0.29-2.81).

#### Lipids

Across all outcomes, lipid levels were categorised in a number of ways. The most common categorisation was hypercholesterolemia at baseline, defined most frequently as a total cholesterol measurement of greater than 6.5 mmol/L.

11 studies reported on the association of hypercholesterolemia with all-cause dementia and provided weak evidence for an effect (HR: 1.05, 95%CI: 0.94-1.18, Figure 8)




Several studies analysed individual lipid fractions by estimating the risk of dementia per 1 standard deviation increase in that fraction. Very weak evidence for an effect on all-cause dementia was found for total cholesterol (N = 5; HR: 0.97, 95%CI: 0.87-1.07), LDL-c (N = 4; HR: 1.04, 95%CI: 0.96-1.13), HDL-c (N = 4; HR: 1.04, 95%CI: 0.96-1.13) or triglycerides (N = 4; HR: 1.04, 95%CI: 0.96-1.13). Forest plots for these analyses are presented in Appendix 10.3.6.

Finally, there were no identified Mendelian randomisation analysis examining the effect of lipid levels on all-cause dementia risk.


### Alzheimer’s disease

#### Statins

There were no randomised trials of statin, or any other lipid regulating agent, use on Alzheimer’s disease, though several observational studies reported on this outcome and provid evidence for a protective effect (N = 11; HR: 0.83, 95%CI: 0.69-1.00; Figure 9).




Two Mendelian randomisation studies looked at specifically as a result of by HMGCR inhibition (mediated by a single SNP; rs17238484). The first used a one sample approach (SNP-exposure and SNP-outcome associations are estimated using the same dataset) in a large Copenhagen-based cohort, while the second made use of summary level data obtained from the Global Lipids Genetic Consortium (SNP-exposure) and the International Genomics of Alzheimer’s Project (SNP-outcome).




#### Lipids

9 studies reported on the association of hypercholesterolemia with all-cause dementia and provided weak evidence for an effect (HR: 0.91, 95%CI: 0.76-1.10, Figure 11)



Similarly to all-cause dementia everal studies analysed individual lipid fractions by estimating the risk of dementia per 1 standard deviation increase in that fraction. Very weak evidence for an effect on all-cause dementia was found for total cholesterol (N = 5; HR: 1.00, 95%CI: 0.93-1.07), LDL-c (N = 4; HR: 0.99, 95%CI: 0.91-1.07), HDL-c (N = 4; HR: 0.99, 95%CI: 0.91-1.07) or triglycerides (N = 4; HR: 0.99, 95%CI: 0.91-1.07). Forest plots for these analyses are presented in Appendix 10.3.6.

Finally, there were several identified Mendelian randomisation studies examining the effect of genetically lowered LDL-c on Alzheimer’s disease risk (Figure (mrDuplication)). However, all of these studies used a two-sample approach, making use of summary statistics from the GLGC and IGAP consortia. Due to this overlap, which would result in a falsely precise estimate caused by multiple counting of participants, no meta-analysis of these studies was performed. However, across all analysis, using varying number of SNPS, no evidence for an effect was observed (Figure (mrDuplication)).




### Vascular dementia

#### Statins

As noted above, there was substantially less literature available on the association of my risk factors of interest and vascular dementia.


There were no randomised trials for this outcome. Three prospective cohort studies examined statin use and vascular dementia, though meta-analysis of these studies provided very weak evidence for an effect (N = 3; HR: 1.02, 95%CI: 0.77-1.36; Figure ??).



A single Mendelian randomisation analysis was identified that examining the effect of genetically lowered LDL-c levels via HMGCR inhibition on the risk of vascular dementia, which provided weak evidence for an effect (RR: 0.44, 95%CI: 0.21-0.91).

#### Lipids

3 studies reported on the association of hypercholesterolemia with all-cause dementia and provided weak evidence for an effect (HR: 1.20, 95%CI: 1.00-1.44, Figure 14)



Similarly to all-cause dementia everal studies analysed individual lipid fractions by estimating the risk of dementia per 1 standard deviation increase in that fraction. Very weak evidence for an effect on all-cause dementia was found for total cholesterol (N = 2; HR: 1.05, 95%CI: 0.79-1.41), LDL-c (N = 1; HR: 0.83, 95%CI: 0.60-1.14), HDL-c (N = 1; HR: 0.83, 95%CI: 0.60-1.14) or triglycerides (N = 1; HR: 0.83, 95%CI: 0.60-1.14). Forest plots for these analyses are presented in Appendix 10.3.6.

Finally, there were no identified Mendelian randomisation analysis examining the effect of lipid levels on vascular dementia risk.

### Dose response meta-analysis of lipid levels

Several studies were excluded from the dose-response meta-analysis, as the number of cases/controls per dose group could not be calculated and the corresponding author for the study did not respond to clarification requests. The results from the dose response analysis can be seen in Figure ??.

### Sources of heterogeneity

Data on another potentially important source of heterogeneity Plus other such as education level and baseline cognitive scores, but data were either not reported for most studies or when reported, were too diverse to synthesize.

Across all analysis with

### Small study effects

There was little evidence of small study effects across the evidence base (Figure 15).




Figure 15: Funnel plot of results examining the relationship between statins and any dementia

### Added evidental value of including preprints

As show in Figure ??, the number of hits returned by the preprint searching was not substantial (bioRxiv = 256, medRxiv = 0). From these hits, three preprinted reports of eligible studies were included in the review, of which two described unique studies not captured by the main search.[208](#ref-so2017),[**andrews2019a?**](#ref-andrews2019a)

All identified preprinted studies were. However, including preprints did provide useful additional evidence value in a number of meta-analysis. For example, re-analysing the results of available for the effect of HMGCR SNPS on Alzheimer’s disease (Figure @ref) in Mendelian randomisation studies, illustrates that the result only available from a preprint contributed 78% of the weight in a fixed-effect meta-analysis.

(ref:preprintWeights-caption) Amount of information added by inclusion of preprinted results, estimated from the weight assigned to the study in a random-effect meta-analysis

Table 11: (ref:preprintWeights-caption)

| **Design** | **Exposure** | **Outcome** | **Weight** |
| --- | --- | --- | --- |
| **MR** | HMGCR | AD | 78% |
| **MR** | LDL-c | AD |  |
| **MR** | LDL-c | AD |  |
| **MR** | LDL-c | AD |  |

Investigation of the publication status of the two unique preprints indicated that one has since been published (in late 2019 date),[230](#ref-andrews2019),[**andrews2021?**](#ref-andrews2021). The final preprint has not yet been published.[208](#ref-so2017)

## Discussion

This review has presented a summary of the available evidence on the association between lipids, and treatments that modify lipids such as statins, and the subsequent risk of dementia.

The discussion seeks to to summarise the key findings in terms of literature sources and results as reported. A detailed comparison across the evidence sources, exposure measures and sources of bias reported here is presented as part of the triangulation exercise (Chapter 7).


### Summary of findings

There was some evidence of protective effect of statins on all-cause and Alzheimer’s disease dementia when looking at solely at observational studies. This finding was not supported by evidence from the two available RCTs, or by studies that emulated statin treatment using a genetic proxy, suggesting that these findings may be a result of heterogenity in exposure (e.g. mid-life in studies of lipids with late-life lipid reduction in RCTs) or alternatively due to biases within the non-randomised studies.

Some evidence that age has impact on observed lipid-dementia relationship - use to link

The majority of studies were non-randomised studies of lipids, or treatments that affect lipid levels such as statins. This distribution of evidence between analytical designs is to be expected. Randomised controlled trials of dementia are particularly challenging, as the long follow-up, necessary due to the long latent period of the condition, makes trials logistically challenging and financial expensive. Similarly, Mendelian randomisation is a comparatively new study design (as illustrated in Figure 16), and so only appears in the literature in recent years, driven by the availability of Alzheimer’s disease summary genome wide association studies (GWAS) that form the basis of two-sample Mendelian randomisation approach.

(ref:typeByYear-cap) **Study designs by year of publication** -



A common theme across the evidence base was a lack of data on the association of vascular dementia. This is particularly interesting given that lipids and statins are primarily related to vascular disease. **Can’t look forward to other chapter** There is the potential that studies encountered similar difficulties in address the unexpected results observed in the CPRD analysis in Chapter 5, likely due to confounding by indication, and so may suffer from the “file-drawer effect”.[75](#ref-rosenthal1979) For vascular dementia, few Mendelian randomisation studies examined this outcome, primarily because of the absence (until recently) of GWAS of this outcome.

Of note, this review did not include the commonly cited PROSPER study, which examined the effect of pravastatin on CVD risk,[231](#ref-shepherd2002a) reporting on cognitive outcomes as one of several secondary outcomes. While widely cited in relation to the effect of statins on dementia and included in the Cochrane review of RCTs on this topic,[232](#ref-mcguinness2016) the trial only reported on the change in a range of cognitive measures (MMSE, Stroop test, Picture-Word Learning test and others) over follow-up. Though an useful indicator of general cognitive decline, it is not equivalent to a dementia diagnosis using recognised criteria, as cognitive tests should feed into a broader diagnostic pathway (see Section 2.3.2). As such, this trial did not met the inclusion criteria for this review.

Questions over missing results - evidence from one of the conference abstract analysis pairs that a non-significant results are being suppressed.[233](#ref-yamada2009),[234](#ref-yamada2009a) In addition, there were some concerns over the potential for estimates to be missing from the meta-analysis of observational studies not at random, given the preferential reporting of significant results observed in a number of analysis (see Section 4.4.5).

Generalisability was aided by the large number of studies performed using the Taiwan health database, which represents a good sources of evidence on non-Caucasian populations

### Comparison with previous reviews

**This section will be completed once Georgia has completed her analysis, and can also be cross-references with the meta-meta analysis published is Brain Sciences recently.**

While conducting this review, I identified several previous systematic reviews of this topic.[57](#ref-chu2018),[235](#ref-yang2020)–[238](#ref-kuzma2018a),[238](#ref-kuzma2018a) However, this review is the first to use established domain based assessments tools (for example, the RoB 2 tool for randomized controlled trials)[142](#ref-sterne2019) to assess the risk of bias in included studies, and explore the heterogeneity of results across different levels of risk of bias levels. Some previous reviews did assess risk of bias, but used non-domain based assessment tools, such as the Newcastle-Ottowa scale.[56](#ref-anstey2015),[237](#ref-poly2020)


Similar the on previous review of Mendelian randomisation studies examining risk factors for Alzhiemer’s disease was conducted prior to the majority of MR studies included in this review being published, and extracted results including SNPs in APoE4 (see the following section for a discussion of the bias this introduces).

However, despite these differences in timescales and methodology, the duplication of work across reviews (including this review) is substantial. In retrospect, an alternative approach to conducting a further systematic review from scratch could have been employed. Known as an umbrella review, or review-of-reviews, these studies use other systematic reviews rather than primary studies as the unit of analysis.[239](#ref-aromataris2015),[240](#ref-smith2011) This approach would have enabled more efficient identification of relevant primary studies to which the methods which sets this review apart from other published reviews could have been applied.

### Inclusion of Mendelian randomisations studies

One of the strengths of this review is it’s inclusion of Mendelian randomisation studies as a source of evidence.

Mendelian randomisation is a powerful analytical technique, using natural variation in participants genomes to (assuming the assumptions of the method are valid), though it’s inclusion as an acceptable study design in this review was complicated by a number of factors.



Firstly, this study design is relatively new, particularly when compared to randomised trials or cohort studies. Figure 16 demonstrates that Mendelian randomisation studies only begin to appear in the evidence base much later than NRSE/NRSI. As such, the process and tools for systematically assessing them are not as well developed, likely due to the limited availabilt of large scale GWAS datasets needed for two sample MR. A key example of this is in the absence of validated search filters for Mendelian randomisations studies. This limitation is further complicated by the varying terminology used to describe the method, particularly in the early years of it’s application.

Additionally, there is currently no widely used risk-of-bias assessment tool for Mendelian randomisation studies. A recent commentary provided a checklist interpreting Mendelian randomisation studies, this guide includes reporting items in their quality checklist. While reporting quality is important, it is a separate consideration to internal validity, as discussed in Section @ref(). Similarly, a previous review of Mendelian randomisation studies used the Q-Genie tool, which was validated to assess the quality of genetic association studies in meta-analysis.[241](#ref-sohani2015) While this tool addresses the studies used, it does not access the additional methodological considerations of the analysis of the Mendelian randomisation analysis itself. For this review, I utilised the best available author-devised tool, sourced on a recent review of systematic reviews of Mendelian randomisation studies.

As a further stumbling block, Mendelian randomisation, particularly when using a two-sample summary data design, is a form of analysis that lends itself to multiple exposure-outcome comparisons. This is particularly relevant to the consideration of bias due to missing evidence. As an example, through snowballing and other measures, I identified at least one relevant Mendelian randomisation study that had not been identified by the search strategy.[242](#ref-larsson2017b) On review of this paper, the search would not have been expected to find it given the absence of any lipid-related keywords in the title and abstract. The study examined the association between lipid fractions with Alzheimer’s disease as one of many risk factors for the condition. Studies such as this can introduce bias into a systematic review, as it is commonly only those risk factors that show a statistically significant result that are reported in the abstract and so are captured by the search. This may bias systematic reviews, including this one, as the analysis of multiple risk factors against a single outcome within a single publication becomes more common. These studies are described as “unknown unknown’s” in the context of the RoB-ME tool, and are particularly challenging (as opposed to an analysis that was insufficiently reported to be included in the statistical analysis, or the “known unknown’s”).

Useful future work to improve the methodology for inclusion of Mendelian randomisation studies in systematic reviews should involve the development of a validated search filter for this study design.[243](#ref-waffenschmidt2020),[244](#ref-wagner2020) Alternatively, in better-resourced reviews, a dedicated search for “risk factors” and “dementia” and “Mendelian randomisation”, followed by manual review of studies that look across multiple risk factors, would be advisable. This was not feasible in the context of this review, given the large number of records to be screened, even when using study design filters (n=16,109). Additionally, the value of methods that supporting the traditional bibliographic database search, such as snowballing (forwards and backwards citation chasing) and communication with relevant topic experts should not be underestimated. Finally, development of a risk-of-bias assessment tool by a panel of methodologists and analysts would be of substantial benefit.

Talk about problem with studies sharing underlying datasets in two sample Mendelian randomisation frameworks - c.f. EHR databases, which contain the same underlying sample but use different sub-samples on account of the distinct codes/conditions and timepoints used to defined the study cohorts, Mendelian randomisation analysis can be multiple studies using the exact same summary statistics from the same cohorts

One item of particular interest is the attenuation of any effects observed by Mendelian randomisation studies following the adjustment for/exclusion of genetic variation in the Apoe4 gene region. As covered in the introduction (see Section @ref()), increasing number of ApoE4 alleles is a major independent risk factor for Alzheimer’s disease, and so violates the exclusion restriction criteria of .

Introduce assumptions underlying Mendelian randomisation (with image). Higlight that most if not all included analysis initially describing a protective effect of LDL-c, which attenuates to the NULL once ApoE4 gene regions are removed. Note the region must be quite wide - talk about controversy surrounding Benn paper

Additionally many of the studies suggested a link between, but then in the sensitivity analyses or in the Discussion disclaim that when adjusted for ApoE4, any association was attenuated to the null. This point is important given one of the core assumptions of


MR are limited by the need for SNP to be present in both datasets (for TSMR).

Recommend future large scale GWAS of other dementia outcomes, notably vascular dementia, or the use of existing GWAS to

A key example of the importance of . In almost all cases, Mendelian randomisation studies examine. A clear exampe of this is Ben et al, 2017, where the ApoE variants were not sufficient identified and excluded, and the published paper detailed evidence for a protective effect of LDL-c was identified (estimate(0.83, .75,.92,"RR")).[66](#ref-benn2017) Following several rapid responses, the data was re-analysed excluding a larger area around ApoE4 which attenuated this finding towards the null.[245](#ref-benn2017a)

### Inclusion of preprints

As highlighted in Section 2.6.1, this review explicitly sought to synthesize evidence across different publication statuses (preprinted vs. published). Using the tool described in Chapter 3.2, two preprint serves related to health and biomedical sciences were search as part of this review. The small number of studies return by the searches (or the absence of any hits in the medRxiv database - see Figure 4) is due to the timing of the preprint searches. The searches for this review were performed in mid-July 2019, but the medRxiv repository, an offshoot of the Epidemiology and Clinical Trials categories of the bioRxiv preprint server, only registered its first preprint 25th June 2019. As such, at the point it was searched, the medRxiv database contained only a very small number of records (n=148).



Three relevant preprints from the bioRxiv hits were identified. The added evidential value of including these preprints was described in Section (sys-rev-including-preprints-res), and indicated that results available only via preprinted reports can contribute substantially to a meta-analysis. Of note, all three included preprints described Mendelian randomisation analysis, potentially indicating that more biologically-focused study designs are over-represented in the bioRxiv repository.

Of the three identified preprints, two were subsequently published as of September 2020. This fits well with the analysis presented in Section 3.5.3 that, allowing for a two-year lag, approximately two-thirds of preprints are published, and nicely illustrates the dual advantages of preprinted reports to evidence syntheses. Firstly, preprints provide an advance snapshot of the literature, capturing preprinted articles that are subsequently published but were not . Secondly, inclusion of preprints allows for results that may never be formally published to be included in an evidence synthesis exercise.

Consider the example of one of the Mendelian randomisation analyses of the effect of LDl-c on Alzheimer’s disease, which found no impact of LDL-c on AD following removal of APOE4. The manuscript was initially published in bioRxiv in July 2017[228](#ref-zhu2017) which was subsequently published in Nature Communications in January 2018, following peer-review.[229](#ref-zhu2018) While this study was captured by both the preprint and published searches in this review, had the searches been run within this window, the preprint would have contributed unique data to the review. This illustrates that while it may not have aided this review, if the aim is to find the current state of the art in the topic area at the time of searching, inclusion of preprints is a necessity.

More recently, inclusion of preprints in systematic reviews has become significantly more widespread. This is largely due to the role of preprint servers, in particular medRxiv, as a key evidence dissemination venue during the early stages of the COVID-19 pandemic. How well this adoption of preprints will transfer to other less-urgent topics, where the speed of research does not put the same focus on preprinted articles, is currently unknown.

### Open data sharing

As discussed in Section 4.4.9, many primary studies did not report important elements, and so these could not be extracted. This limiation was compounded by the expected low response rate to requests for further information from primary authors (although, in hindsight, the form of contact used (email) has been shown to be less successful in eliciting responses from authors when compared with telephoning[246](#ref-danko2019)).

While contacting authors is worthwhile, as it can substantially change the conclusion of a systematic review[247](#ref-meursingereynders2019) and is not too costly to systematic reviewers,[248](#ref-cooper2019) a far preferable option is that the authors of primary studies readily deposit all relevant study data at the point of publication.

Based on my experience of extracting data for this review, I co-wrote an guidance article to aid primary prevention scientists in preparing and sharing their data so that it can easily be incorporated into a evidence synthesis exercise, using a trial of mindfulness interventions as an case study.[249](#ref-hennessy2021)

Similarly, a substantial amount of time and effort has gone into making the data obtained by this review openly available to other researchers.

### Strengths and limitations

#### Strengths

I believe there are four aspects where this review is distinct from those reviews already available in the published literature (as identified by ):

* *Comprehensiveness:* While several reviews of this research topic exist,[57](#ref-chu2018),[235](#ref-yang2020)–[237](#ref-poly2020) the overlap between the list of studies included in each is not 100%. As part of this review, I have not only performed a original search of primary literature databases, but have also screened the reference lists of comparable reviews to ensure no study has been omitted. In addition
* *Structured risk-of-bias assessment:* The majority of the highly cited reviews on this topic either do not formally consider the risk of bias in the observational studies they include or do not use an appropriate domain-based assessment tool (e.g. ROBINS-I/E). This is important area in which this thesis can add value, as based on the risk-of-bias assessments I have performed to date, several primary studies are at high risk of bias and this should be reflected in the findings of any review on this topic.
* *Inclusion of preprints:* Unlike other available reviews and enabled by the tool described in Chapter 3, this review systematically searched preprinted health-related manuscripts as a source of grey literature. As part of this chapter, I plan to examine the extent of the additional information provided to the review by the inclusion of preprints.
* *Contribution to methods work:* A large part of this review was the associated work on improving research synthesis methods. This work is detailed as relevant throughout the Chapter, often referring to additional work detailed in the . In addition this review was used to pilot an upcoming risk of bias tool

#### Limitations

The primary limitation of this review is that several included studies used data from EHR databases, which come with serious concerns regarding validity[250](#ref-hsieh2019) [251](#ref-mcguinness2019validity),[252](#ref-wilkinson2018) Relatedly, several studies which made use of electronic health record database did not report the specific code lists used, potentially introducing substantial heterogeneity between effect estimates. An empirical example of the effect of differing EHR code list is presented as part of the analysis in Chapter 4 (see Section 5.4.4.7).

In addition, the fact that only a sample of records were dual screened at the title/abstract and full-text stages is a potential limitation, as there is a chance that some eligible records could have been excluded. However, evidence from assessments of inter- and intra-rater reliability indicate that is is not a major concern.

One particular limitiation with regards to the risk-of-bias assessment is the fact that the ROBINS-E assessments were performed without the tool being finalised. This meant that there were no signalling questions to guide the domain-level risk-of-bias assessment, which may have influenced the accuracy with which domain-level judgements were assigned. However, there is no published empirical evidence supporting the need for signalling questions, and assessment of inter-rater reliability across the different tools did not indicate a specific problem with the ROBINS-E assessments. In fact, low agreement was common across the tools, though this is expected based on the available literature.[253](#ref-jeyaraman2020)

One further limitation is the fact that the risk of bias due to missing evidence assessment, combined with some empirical evidence that some studies were missed by the search but contained relevant studies is a definite limitation of this review (see Section @Ref(rev-discussion-MR) above for a fuller discussion of this issue with respect to Mendelian randomisations studies). Unfortunately, this is probably a common limitation across all reviews, based on the way in which increased sensitivity must be balanced with a reasonable workload.

## Conclusions

In this chapter I have presented a comprehensive systematic review of the different sources of evidence available which examined the relationship between lipid levels and dementia use.

This work built on the tool introduced in the preceeding chapter (Chapter (sys-rev-tools-heading)), and findings from this review are used though out the subsequent chapters: in Chapter 5, summary of the evidence guided the choice of analysis approach, ensuring that the new analysis was at risk of a different source of bias; while in Chapter 6, prospective cohorts identified by the review were contacted in an attempt to obtain individual participant data; finally, the cumulative effect measures calculated here are used as a key source of evidence for the triangulation exercise presented in Chapter (discussion-heading).

## References

# Primary analysis of lipid regulating agents and dementia outcomes

## Lay summary

Electronic health record (EHR) databases are large collections of patients data, used to manage patient administration and care. Under these systems, whenever a patient attends their GP, their clinical data is recorded in a central database using a standard set of codes. These databases have several advantages over traditional methods of data collection, including the number of people they contain and the length of time for which participants are followed. This is particularly important when studying diseases such as dementia, which may begin to develop in patients long before symptoms are seen.

This analysis makes use of the Clinical Practice Research Datalink (CPRD), which contains the electronic medical records of more than 3 million people from general practices across the UK. Using this data, the analysis presented in this chapter examined the effect of treatment which lower cholesterol levels, such as statins, on the risk of dementia and related outcomes.

Little evidence for an effect of lipid regulating agents effect on the risk of Alzheimer’s disease was found, with the exception of a slightly increased risk in those prescribed a certain type of drugs called fibrates. In contrast, I found an increased risk of vascular and other (i.e. non-Alzheimer’s) dementia with lipid regulating agent use.

This increased risk is unexpected, and is very likely to be due to the presence of bias in the analysis. This bias, called “confounding by indication”, is caused when those who are prescribed a statin are more at risk of vascular dementia for a range of reasons, and so it appears as if statins are harmful. However, despite this limitation, the analysis presented provides an important source of information which will be used in later chapters.

## Introduction

In this Chapter, I present the results of an analysis of a large population-based electronic health record dataset to investigate the relationship between lipid regulating agent (LRA) use and dementia outcomes.

The analysis aims to address important two limitations of the current evidence base as identified by the systematic review presented in Chapter ??.

Firstly, it explicitly examines vascular dementia as an outcome. The systematic review presented in the previous chapter identified an evidence gap around the effect of lipid regulating agents on the risk of vascular dementia. As triangulation exercises require as many diverse sources of evidence as possible, this analysis provides a source of information on this outcome.

Secondly, and in a similar vein, the analysis intentionally takes a different analytical approach to that most commonly used to examine the effect of statins on dementia (as identified by the systematic review). Specifically, this involved a concerted effort to address immortal time bias though use of a Cox Proportional time-varying treatment indicator. This approach provides a evidence source at risk of a distinct set of biases due to the alternative analytical strategy that will be incorporated into the triangulation exercise presented in Chapter 8.

## Methods

### Study protocol

An *a priori* protocol for this study was published,[254](#ref-walker2016) and amendments to this are recorded in Appendix 10.4.1.[255](#ref-vonelm2008)

### Data source

Previously known as the General Practice Research Database (GPRD), the Clinical Practice Research Datalink (CPRD) is a large population-based, electronic health record (EHR) database.[256](#ref-herrett2015) The database has been collecting primary care data from participating practices across England since 1987.[257](#ref-williams2012),[258](#ref-wood2001revitalizing) It contains the primary care records for more than 10 million primary care patients in England, and is broadly representative of the UK population in terms of age, sex and ethnicity.[256](#ref-herrett2015),[259](#ref-mathur2014)

To avoid the ambiguity of interpreting free-text clinical notes and to allow for easy analysis of the resulting data, the CPRD primarily collects data using a predefined coding system known as Read codes.[260](#ref-booth1994) All clinical events, included clinical test results and diagnoses, can be identified by a specific Read code. The codes use a nested approach (see Table 12), with the initial characters defining broad diagnostic topics (e.g. Eu… - Mental and behavioural disorders), while subsequent characters provide additional information on the specific condition diagnosed (e.g. Eu001 - Dementia in Alzheimer’s disease with late onset).

Table 12: Example of CPRD Read code hierarchy, showing how "Dementia in Alzheimer’s disease with late onset" (\_Eu001\_) is nested under the top-level of "Mental disorders" (\_Eu...\_). Broad topics are specified using the initial two alpha-numeric characters of the Read code, while subsequent characters are used to define specific conditions and context.

| **Level** | **Read code** | **Term** |
| --- | --- | --- |
| **1** | E.... | Mental disorders |
| **2** | Eu... | Mental and behavioral disorders |
| **3** | Eu0.. | Organic mental disorder |
| **4** | Eu00. | Dementia in Alzheimer's disease |
| **5** | Eu001 | Dementia in Alzheimer's disease with late onset |

Lists of relevant codes for each of the index events, exposures and outcomes used in the analysis were created. Each of these are described in more detail in the following sections.

### Cohort definition

This analysis included all participants registered at a participating practice between 1 January 1995 and 29 February 2016 who had a flag for “research quality” data. Records pre-dating the 1995 cutoff were included in the original CPRD extract obtained for this analysis. However, these were excluded from the analysis as data quality and reliability is thought to be higher after this date.[261](#ref-wolf2019) Additionally, individuals with less than 12 months of continuous records prior to cohort entry were excluded, making the effective start date of the cohort 1 January 1996.

Participants were included in the study cohort if their record contained any of the following index events: a Read code for a diagnosis of hypercholesterolemia or related condition; a Read code for prescription of a lipid-regulating agent (such as statins); a total cholesterol test result of >4 mmol/L; or an LDL-c test result of >2 mmol/L. These index events allowed me to define a population of participants who were either at risk of hypercholesterolemia, as indicated by the elevated total or LDL cholesterol test results, or had already been diagnosed with it, as indicated by a diagnostic code/related prescription.

All events of interest were identified using predetermined code lists, which are available for inspection from the archived repository accompanying this analysis (data/code availability is discussed in Section 5.5.4).

The index date for a participant was defined as the date where the first relevant code or test result was recorded on their clinical record, and participants were followed up until the earliest of: an outcome of interest; death; end of follow-up (29 February 2016); or last registration date with their GP practice. Participants were removed from the sample if they were less than 40 years of age, had less than 12 months of “research quality” data, were simultaneously prescribed more than one lipid-regulating agent (due to the difficult of assigning these to a single exposure group), or were diagnosed with an outcome of interest before or on the date of the index event (i.e. had less than one full day of follow-up).

### Exposures

We considered seven lipid-regulating drug classes based on groupings in the British National Formulary (BNF),[262](#ref-wishart2017) namely: statins, fibrates, bile acid sequestrants, ezetimibe, nicotinic acid groups, ezetimibe and statin (representing one treatment containing both drugs, rather than the two classes being prescribed concurrently), and omega-3 fatty acid groups.

A participant’s drug class was assigned based on their first recorded prescription, and any drug switching was ignored in an effort to mimic an intention-to-treat approach. We did however examine how often the initial drug class altered according to one of three criteria:

* **stopped**: defined as the last prescription of the primary class being followed by at least six months of observation;
* **added**: defined as a second drug class being prescribed before the last prescription of the initial class; and
* **switched**: defined as a second drug class being prescribed after the last prescription of the initial class.

### Outcomes

We considered five outcomes as part of this analysis: probable Alzheimer’s disease, possible Alzheimer’s disease, vascular dementia, other dementia, and a composite all-cause dementia outcome. When two or more outcomes were coded in a participant’s clinical record, a decision tree was used to differentiate between them (see Figure 19). The diagnosis date of the outcome was determined by the first record of a relevant code.



Participants were censored at the earliest of date of: diagnosis; death; transfer out of the study cohort; or end of follow-up (29th February 2016).

### Covariates

A range of additional variables were included in the analysis, intended to address the different distributions of potential confounding variables between those who were prescribed an lipid-regulating agent and those who were not.

Demographic covariates adjusted for included age and gender. Age was calculated at date of entry into the cohort. Socioeconomic status was proxied using the Index of Multiple Deprivation (IMD) 2010, which draws on seven domains (income; employment; education, skills and training; health and disability; crime; barriers to housing and services; living environment) to create an overall deprivation score for each of 32844 statistical geography areas in England. To help preserve patient privacy, IMD score is only available from the CPRD in twentiles, with 1 indicating the least deprived and 20 indicating the most deprived. Smoking and alcohol use was determined at index, and participants were categorised as current, former, or never users of each.

Body mass index (a summary measure calculated as ), baseline total cholesterol and baseline LDL cholesterol measures were obtained, using the last recorded value prior to the index date. A variable indicating grouped year of entry into the cohort (<2000, 2000-2004, 2005-2009, >2010) was included to allow for changes in prescribing trends across the lifetime of the cohort. To assess healthcare utilisation, I adjusted for the average annual number of consultations between the beginning of a patients data and their entry into the cohort.

Finally, presence of a range of related conditions at baseline were accounted for, including cardiovascular disease, coronary bypass surgery, coronary artery disease, peripheral arterial disease, hypertension, chronic kidney disease, and Type 1 and Type 2 diabetes. In addition to adjusting for these covariates individually, a Charlson co-morbidity index (CCI) score was calculated for each participant. The CCI is a weighted index that uses presence and severity of a number of conditions to enable adjustment for the general health of a participant in terms of their mortality risk.[263](#ref-charlson1987new) Inclusion of this index allowed me to attempt to adjust for the general health of patients included in the analysis.

Codelists for all covariates can be found in the archived data repository accompanying this analysis (see Section 5.5.4).

### Missing data

Missing data are a recognised issue in electronic health records databases,[264](#ref-wells2013strategies) given that they contain administrative data, collected primarily for the purposes of patient management and care rather than academic research.

In this analysis, missing data were handled using a multiple imputation approach. Variables with missing observations were identified, and 20 imputed datasets were created.[265](#ref-sterne2009) Nominal variables with missing values were modelled using multinomial logistic regression, while continuous variables were modelled using linear regression. As per best practice, all variables used in the analytic model, including the outcome, were included in the imputation model.[266](#ref-moons2006using) Imputation was performed using the MICE (Multiple Imputation by Chained Equations) command in STATA16.

Missing data was only considered an issue for variables where a numerical test result was expected (e.g. BMI), or where a code existed for the absence of the condition (e.g. categorical smoking status). This approach was necessary, as absence of a code for other treatments or conditions (e.g. statin use or dementia) was assumed to indicate absence of the treatment/condition, rather than being considered missing.[264](#ref-wells2013strategies)

Using multiple imputation to handle missing data is an alternative to a “complete case” approach,[267](#ref-pigott2001review) where participants missing any covariate are dropped from the dataset. As a sensitivity analysis, I preformed and compared the results of both methods,[268](#ref-hughes2019) to investigate the impact of multiple imputation on the results.

### Estimation methods

A Cox proportional hazards (PR) model was used to estimate the effect of statins on dementia outcomes. Cox PR models are defined, in general terms, as:

where:

* is the survival time;
* is the hazard function; and
* are the covariates which determine the hazard function, while are the coefficients for each covariate.
* is the baseline hazard - when all are zero, the function resolves to 1.

As the values of increases, value of (i.e. the hazard ratio) increases in tandem, thus reducing the survival time, .

A Cox PR model was chosen for this analysis as it inherently accounts for the length of time participants spend in each exposure group. Using this approach, time-at-risk can be properly attributed, thus mitigating the impact of immortal time bias. This is discussed in detail in the following section.


### Immortal time bias and time-varying treatment indicators

Immortal time bias covers two distinct but related types of bias. The first presentation, the selection bias aspect (Panel A, Figure 20), occurs when time prior to the exposure is excluded leading to the exposed and control groups being followed up from different time points.[269](#ref-levesque2010) For example, if the unexposed group are followed from a cholesterol test result, while the exposed group is followed from date of LRA prescription, any events that occur in the exposed group prior to the exposure event will be inappropriately excluded from the analysis.

The second presentation of immortal time bias is as a type of misclassification bias (Panel B, Figure 20). It occurs when the exposure time prior to the exposure date, and any events occurring within it, is inappropriately assigned to the exposed group. This second presentation appears to be common in the existing literature, as several of the studies included in the systematic review presented in Chapter 4 were identified as being at risk of immortal time bias following formal risk of bias assessment using the ROBINS-I tool (see Section ??).

This analysis is primarily concerned with the second presentation of immortal time bias, as all participants were followed from a common index date (earliest of: date of raised cholesterol test results; hypercholesterolemeia diagnosis; or LRA prescription). To address the potential for this second form of immortal time bias in the analysis, I employed a time-varying indicator of treatment status to correctly allocate time-at-risk to the exposed and unexposed groups.[269](#ref-levesque2010)

Under this approach, all patients start in the unexposed group, & contribute time-at-risk until they are prescribed a lipid regulating agent and move into the exposed group. Note, patients for whom prescription of a lipid regulating agent was the index event only contribute time to the exposed group (i.e. they enter the cohort and move into the exposed group on the same day).



### Time axis

As part of a Cox proportional hazard model, there is the option to use either absolute time in cohort or participants age as the time scale of interest.[270](#ref-lamarca1998)–[272](#ref-pencina2007) A model using age as the time axis inherently accounts, or adjusts, for participants age as a potential confounder of the exposure-outcome relationship. As such, the main analyses presented all used age as the time axis.

### Sensitivity analyses

The primary analysis examined the effect of a lipid regulating agent on dementia risk, stratified by outcome and drug class. To assess the robustness of the results, a number of sensitivity analyses were performed. These are described in the following sections.


#### Control outcomes

In addition to the primary outcomes of interest (described in Section 5.3.5), I extracted data on two additional control outcomes. The inclusion of control outcomes in observational analyses are a useful technique to assess the strength of uncontrolled confounding,[273](#ref-lipsitch2010) and these outcomes are usually class as either “negative” or “positive” outcomes. Negative outcomes are those without a likely causal path between the exposure and outcome (see Figure 21 for a directed acyclic graph describing an ideal negative outcome).

Conversely, positive control outcomes are those with a known causal association with the exposure of interest, ideally sourced from large well conducted randomised controlled trials. Positive control outcomes are useful in observational epidemiology, as if the analysis can reproduce a known result for the control outcome, confidence in the result for the outcome of interest is increased.

Due to the wealth of data available on statins as a lipid regulating agent, control outcomes were chosen in reference to this drug class. Muscular backpain was chosen as a negative control outcome in this analysis. Despite observational analyses suggesting a link between statins and muscle pain (as opposed to more serious complications such as myopathy),[274](#ref-selva-ocallaghan2018) systematic reviews of the adverse events of statin use[30](#ref-collins2016a) and N-of-1 trials explicitly exploring the association of statin use with muscle pain[275](#ref-herrett2021) have found little evidence supporting an effect. As such, if statins are not associated with backpain in this analysis, then confidence in the results for the dementia outcomes is increased.

Additionally, incident ischemic heart disease was included as a positive control outcome, given the well-established protective effect of lipid-lowering treatment, via statins, on the risk of this condition.[30](#ref-collins2016a) Similar to the backpain outcome, if the analysis strategy can reproduce this known protective association, this will provide evidence that potential confounders have been sufficiently adjusted for.



#### Impact of additional covariates

To observe the effect of adjusting for additional covariates, I ran a model unadjusted except for age (captured via the time axis in the Cox model) and gender, and compared the results with the full adjusted model.

#### Sensitivity cohorts

Two sensitivity cohorts were also created. The first stratified by year of entry into the cohort in an attempt to assess for time period effects. The second removed participants who may have been pregnant (coded as under 55 and female) to assess the robustness of the estimates, as statins are contraindicated in pregnancy, .[276](#ref-karalis2016)

#### Statin properties

As detailed in the introduction, the properties of statins may be important in their effect, based on the ability of lipophilic statins to cross the blood brain barrier (see Section 2.4.2 in the Introductory Chapter).

To explore whether any observed associations in the statin analysis varied by statin property, a sensitivity analysis was performed, stratifying by statin lipophilicity.

#### Impact of dementia code lists

As part of an exploratory analysis of the effect of the choice of code lists on the analysis, I created an alternative Alzheimer’s disease and non-Alzheimer’s dementia outcome using code lists from a previous study published in 2009 by Smeeth *et al*.[277](#ref-smeeth2009)


This previous study used a propensity matching approach to estimate the association of statins with a range of outcomes, and found evidence for a protective effect of statin use on all-cause dementia (HR: 0.81, 95%CI: 0.69-0.96) and non-AD dementia (HR: 0.82, 95%CI: 0.69-0.97), but little evidence of an effect on AD (HR: 0.81, 95%CI: 0.49-1.35).

The code lists used were obtained through correspondence with the authors of that study, and are available for inspection (see Section 5.5.4).

## Results

### Patient characteristics

Of the 3,179,733 participants included in the extract, 1,684,564 met the inclusion criteria (Figure 22), with a total follow-up of 10,835,685 patient years at risk.



The median participant age at index was 57 years (Inter quartile range (IQR):48-67) and participants were followed up for a median of 5.9 years (IQR:2.7-9.7). During follow-up, an all-cause dementia diagnosis was recorded for 41,830 patients (12,647 probable AD, 9,954 possible AD, 8,466 vascular dementia, 10,763 other dementia: Table 15). The distribution of baseline characteristics across the seven drug classes can be seen in Table 13.

Table 13: Patient characteristics by drug class. Summary statistics are presented as "% (N)" unless otherwise specified in the variable name.

|  | **Whole Sample** | **None** | **Statins** | **Bile acid sequestrants** | **Ezetimibe** | **Ezetimibe & Statins** | **Fibrates** | **Nicotinic acid groups** | **Omega-3 Fatty Acid Groups** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Sample size (N)** | 1,684,564 | 1,087,704 | 585,528 | 5,396 | 763 | 127 | 3,889 | 165 | 992 |
| **Year of cohort entry (median)** | 2006 | 2007 | 2004 | 2005 | 2004 | 2005 | 2001 | 2001 | 2005 |
| **Female** | 53.0% (893174) | 56.2% (610950) | 47.1% (276043) | 66.4% (3585) | 54.5% (416) | 52.8% (67) | 38.6% (1500) | 55.2% (91) | 52.6% (522) |
| **Age at cohort entry (median)** | 57 | 54 | 62 | 57 | 60 | 57 | 58 | 62 | 56 |
| **CAD** | 0.4% (7133) | 0.1% (589) | 1.1% (6465) | 0.1% (6) | 0.9% (7) | 0.0% (0) | 1.4% (53) | 0.0% (0) | 1.3% (13) |
| **CBS** | 0.3% (5699) | 0.1% (682) | 0.8% (4926) | 0.1% (4) | 0.4% (3) | 0.0% (0) | 2.0% (78) | 0.0% (0) | 0.6% (6) |
| **CVD** | 2.1% (34899) | 1.1% (11619) | 3.9% (22977) | 1.6% (86) | 2.6% (20) | 2.4% (3) | 4.4% (170) | 4.2% (7) | 1.7% (17) |
| **Charlson (ever > 0)** | 30.6% (516135) | 25.1% (272642) | 40.7% (238403) | 42.5% (2292) | 41.7% (318) | 24.4% (31) | 50.8% (1976) | 43.6% (72) | 40.4% (401) |
| **IMD-2010 (median)** | 9 | 8 | 9 | 8 | 9 | 13 | 10 | 10 | 10 |
| **Consultation rate (mean/SD)** | 5.4 (5.4) | 5.0 (5.0) | 6.2 (6.1) | 8.6 (7.4) | 7.4 (6.6) | 4.8 (4.3) | 7.1 (6.2) | 9.2 (7.8) | 8.0 (8.0) |
| **Alcohol (ever)** | 85.9% (1447151) | 86.6% (941648) | 84.7% (496110) | 82.8% (4468) | 84.0% (641) | 87.4% (111) | 82.9% (3223) | 83.0% (137) | 82.0% (813) |
| **Smoking (ever)** | 51.1% (861355) | 47.1% (511826) | 58.6% (343074) | 55.2% (2978) | 57.5% (439) | 60.6% (77) | 60.2% (2341) | 52.7% (87) | 53.7% (533) |
| **BMI (mean/SD)** | 27.0 (5.3) | 26.7 (5.2) | 27.7 (5.3) | 26.8 (5.8) | 28.1 (5.7) | 28.1 (4.9) | 29.0 (5.2) | 26.4 (5.0) | 26.9 (5.5) |
| **PAD** | 0.7% (12613) | 0.4% (4039) | 1.4% (8424) | 0.9% (47) | 0.9% (7) | 0.8% (1) | 1.9% (75) | 6.1% (10) | 1.0% (10) |
| **Hypertension** | 16.0% (269804) | 11.5% (124604) | 24.4% (143101) | 12.8% (692) | 23.9% (182) | 25.2% (32) | 25.8% (1002) | 21.2% (35) | 15.7% (156) |
| **Total cholesterol (mean/SD)** | 5.7 (10.1) | 5.5 (6.4) | 6.2 (15.3) | 5.3 (1.3) | 7.1 (26.5) | 6.7 (1.5) | 6.4 (5.6) | 5.4 (1.5) | 5.6 (1.6) |
| **LDL cholesterol (mean/SD)** | 3.6 (4.9) | 3.4 (5.3) | 4.0 (3.7) | 3.1 (1.0) | 3.9 (1.1) | 4.2 (1.0) | 3.3 (1.8) | 3.4 (0.9) | 3.2 (1.0) |
| **CKD** | 0.1% (1295) | 0.1% (740) | 0.1% (545) | 0.1% (6) | 0.1% (1) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.3% (3) |
| **Type 1 Diabetes** | 0.2% (4037) | 0.1% (785) | 0.5% (3196) | 0.3% (14) | 1.0% (8) | 0.8% (1) | 0.8% (31) | 0.6% (1) | 0.1% (1) |
| **Type 2 Diabetes** | 2.9% (48557) | 1.1% (11797) | 6.1% (35941) | 2.3% (123) | 5.4% (41) | 4.7% (6) | 15.8% (614) | 4.2% (7) | 2.8% (28) |
| LRA - Lipid regulating agent; IMD - Index of Multiple Deprivation; BMI - Body Mass Index; CAD - Coronary Arterial Disease; CBS - Coronary Bypass Surgery; CVD - Cardiovascular disease; PAD - Peripheral arterial disease; CKD - Chronic Kidney Disease; SD - Standard deviation. | | | | | | | | | |

A substantial majority (98.1%) of participants prescribed a lipid-regulating agent were prescribed a statin. I excluded the “Ezetimibe and statins” and “Nicotinic acid groups” classes from subsequent analysis based on the extremely small number of participants in these groups (N=127 & N=168 respectively; see Table 13). Note that the “Ezetimibe and statins” treatment group represent those prescribed a single treatment containing both ezetimibe and statins, rather than those where the two treatments were prescribed concurrently.

Table 14: Participants who stopped, switched or added treatments by initial treatment type.

|  | **Whole Sample** | **Statins** | **Bile acid sequestrants** | **Ezetimibe** | **Ezetimibe & Statins** | **Fibrates** | **Nicotinic acid groups** | **Omega-3 Fatty Acid Groups** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Stopped** | 6.9% (115899) | 19.1% (111798) | 56.1% (3028) | 19.7% (150) | 12.6% (16) | 12.3% (478) | 44.8% (74) | 35.8% (355) |
| **Added** | 1.6% (27441) | 4.4% (25990) | 3.6% (192) | 19.0% (145) | 3.9% (5) | 21.6% (841) | 3.6% (6) | 26.4% (262) |
| **Switched** | 0.9% (14935) | 2.0% (11996) | 11.3% (612) | 34.6% (264) | 64.6% (82) | 44.0% (1713) | 45.5% (75) | 19.5% (193) |

The stopping, addition and switching of drug classes was common across all drug classes (Table 14).

### Missing data

Full covariate information was available for 450,234 participants (26.7%). Six key variables had some missing data: IMD 2010 score was missing for 625,788 participants (37.1%), because it is only recorded for English practices; alcohol status was missing for 269,526 participants (16%); smoking status was missing for 84,424 participants (5%); BMI, or a calculated BMI from height and weight measurements, was missing for 266,672 participants (15.8%); baseline total cholesterol was missing for 119,675 participants (7.1%); and baseline LDL cholesterol was missing for 787,289 participants (46.7%).

### Primary analysis

Crude rate ratios per 100,000 participant-years-at-risk were calculated for each outcome and class of interest and are presented in Table 15.

Table 15: Summary

| **Exposure group** | **Any dementia** | | | **Probable AD** | | | **Possible AD** | | | **Vascular dementia** | | | **Other dementia** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Events** | **Time-at-risk** | **Rate** | **Events** | **Time-at-risk** | **Rate** | **Events** | **Time-at-risk** | **Rate** | **Events** | **Time-at-risk** | **Rate** | **Events** | **Time-at-risk** | **Rate** |
| **No LRA (unexposed)** | 18,608 | 5,872,690 | 317 | 6,368 | 5,817,933 | 109 | 4,790 | 5,806,982 | 82 | 2,637 | 5,801,506 | 45 | 4,813 | 5,812,457 | 83 |
| **By drug class** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Statins | 22,920 | 4,870,637 | 470 | 6,190 | 4,758,385 | 130 | 5,086 | 4,747,433 | 107 | 5,773 | 4,752,909 | 121 | 5,871 | 4,755,647 | 123 |
| Omega-3 Fatty Acid Groups | 19 | 8,034 | 236 | 4 | 7,927 | 50 | 4 | 7,925 | 50 | 7 | 7,950 | 88 | 4 | 7,938 | 50 |
| Fibrates | 141 | 38,003 | 371 | 49 | 37,102 | 132 | 35 | 36,983 | 95 | 21 | 36,835 | 57 | 36 | 37,001 | 97 |
| Ezetimibe | 32 | 6,604 | 485 | 8 | 6,429 | 124 | 5 | 6,393 | 78 | 7 | 6,425 | 109 | 12 | 6,444 | 186 |
| Bile acid sequestrants | 106 | 36,370 | 291 | 28 | 35,808 | 78 | 33 | 35,808 | 92 | 19 | 35,726 | 53 | 26 | 35,768 | 73 |
| **Total** | **41,830** | **10,836,413** | **386** | **12,647** | **10,666,667** | **119** | **9,954** | **10,644,764** | **94** | **8,466** | **10,644,764** | **80** | **10,763** | **10,655,715** | **101** |

The results of the primary analysis using the fully adjusted Cox proportional hazards model with participant age as the time scale are presented for each drug/outcome combination in Figure 23.

For each outcome, the overall “Any drug” estimate was driven by the statin subgroup, based on it’s large size relative to the other drug classes.

(ref:cprdPrimary-scap) Results from primary analyses of CPRD data



**Alzheimer’s disease**

My results show litte evidence was found for an effect of lipid-regulating agents on probable (HR:0.98, 95%CI:0.94-1.01) and possible (HR:0.97, 95%CI:0.93-1.01) Alzheimer’s disease when compared with no treatment, with the sole exception of fibrates on probable Alzheimer’s disease (HR:1.28, 95%CI:1.08-1.52).

**Non-Alzheimer’s disease dementias**

In contrast to the findings for Alzheimer’s disease outcomes, lipid-regulating agents were associated with an increased risk of a subsequent diagnosis of vascular dementia (HR:1.81, 95%CI:1.73-1.89) or other dementia (HR:1.19, 95%CI:1.15-1.24). Again this effect was driven mainly by the statin subgroup, but there was some evidence that ezetimibe was associated with an increased risk of vascular (HR:2.33, 95%CI:1.11-4.89) and other (HR:1.88, 95%CI:1.01-3.5) dementia.

**All-cause dementia**


For the composite all-cause dementia outcome, I found treatment with a lipid-regulating agent was associated with a slightly increased risk (HR:1.17, 95%CI:1.14-1.19), but the magnitude of the association was not as extreme as that observed for the vascular dementia subgroup. There was also some evidence that fibrates were associated with increased risk of all-cause dementia (HR:1.28, 95%CI:1.08-1.52).

### Sensitivity analyses

The results of the series of sensitivity analyses performed are described in the following sections.

#### Complete case versus imputed data

In almost all cases, the use of imputed data resulted in a marginal attenuation of the effects observed when using a complete cases analysis. It should be noted that due to the large amount of missing data (e.g. 787,289 participants (46.7%) were missing a baseline LDL cholesterol measure), the number of participants included in the complete case analysis was substantially smaller than that included when using imputed data. In this case, though the overall position of the effect estimates does not change substantially when using the imputed dataset, there is a noticeable gain in power.[265](#ref-sterne2009)



#### Control outcomes

Following the primary analysis, the fully adjusted model was used to estimate the effect of treatment with a statin on the two control outcomes of back pain (negative) and ischemic heart disease (positive). The results of this analysis are presented in Figure 25.

For the negative control, there was some evidence that treatment with a statin was associated with an increased risk of back pain (HR: 1.04, 95%CI: 1.03-1.05), suggesting there may be some residual confounding. However, statin prescription was also associated with a substantially increased risk of ischemic heart disease (HR: 1.62, 95%CI: 1.59-1.64).



#### Impact of additional covariates

The results of three models adjusted for age only, age and sex, and the full covariates respectively, are presented in Figure 26.


These models were used to estimate the impact of adjustment for additional covariates. Note that obtaining an completely unadjusted model is not possible, as age was used in the Cox model as the time scale.

Adjustment for additional covariates beyond age and sex had a limited impact on the observed effect estimates, with the exception of the Probable AD outcome. In this case, adjustment for the full set of covariates attenuated to the null the protective effect observed when adjusting only for age and sex.



#### Sensitivity cohorts: Entry year

When stratifying based on year of entry to the cohort, I observed no variation in risk by time period in any subgroup except for probable Alzheimer’s disease (Figure 27).



On the assumption that this variation could be caused by changes in the frequency of codes used to define Probable AD in the cohort, I performed a *post-hoc* investigation of the frequency of each diagnoses stratified by year of entry (Table 16). While the total frequency of any dementia outcome declines in more recent strata, likely due to the limited follow-up inherent to these groups, the decline in frequency is relatively constant across all dementia subtypes.

Table 16: Frequency of diagnoses by grouped year of cohort entry

| **Year of cohort entry** | **No dementia** | **Probable AD** | **Possible AD** | **Vascular dementia** | **Other dementia** | **Total** |
| --- | --- | --- | --- | --- | --- | --- |
| **>=1996** | 148550 (95.9%) | 1775 (1.1%) | 1677 (1.1%) | 1345 (0.9%) | 1585 (1.0%) | 154932 |
| **>=2001** | 613009 (96.3%) | 6672 (1.0%) | 5711 (0.9%) | 4857 (0.8%) | 6073 (1.0%) | 636322 |
| **>=2006** | 523913 (98.1%) | 3355 (0.6%) | 2169 (0.4%) | 1890 (0.4%) | 2506 (0.5%) | 533833 |
| **>=2011** | 357262 (99.4%) | 845 (0.2%) | 397 (0.1%) | 374 (0.1%) | 599 (0.2%) | 359477 |
| **Total** | 1642734 (97.5%) | 12647 (0.8%) | 9954 (0.6%) | 8466 (0.5%) | 10763 (0.6%) | 1684564 |

#### Sensitivity cohorts: Pregnancy

In the second sensitivity cohort, removing participants aged 55 and under at index from the analysis had minimal effect on the effect estimates (Figure 28).



#### Statin properties

In the cohort, statins with lipophilic properties were much more frequently prescribed than hydrophilic statins (Table 17). Additionally, there is evidence for a increasing tendency to favour hydrophilic statins in recent years, as the proportion of lipophilic statins prescribed fell from 18.2% in 1996-2000 to <1% in 2011-2016.

Table 17: Summary of statin properties (lipophilicity vs hydrophilicity) by grouped year of prescription.

| **Prescription Year Group** | **Hydrophilic** | **Lipophilic** | **Total** |
| --- | --- | --- | --- |
| **>=1996** | 7037 (18.2%) | 31531 (81.8%) | 38568 |
| **>=2001** | 21427 (10.3%) | 187018 (89.7%) | 208445 |
| **>=2006** | 3566 (1.6%) | 217726 (98.4%) | 221292 |
| **>=2011** | 1115 (0.9%) | 119035 (99.1%) | 120150 |

When stratifying by statin properties, hydrophilic statins were less harmful in the any, vascular and other dementia outcomes compared to lipophilic statins (Figure 29). Additionally, in the AD outcomes, hydrophilic statins were associated with a small reduction in risk, compared to the weak evidence for an effect for lipophilic statins.




#### Comparing codelists

When using the Smeeth et al code lists to define dementia outcomes, effect estimates of HR: 1.19 (95%CI: 1.07-1.32) and HR: 1.33 (95%CI: 1.26-1.42) were obtained for the Alzheimer’s disease and non-Alzheimer’s dementia outcomes respectively.

However, comparison of the results using the two sets of code lists was deemed less useful following a comparison of the codes used. While all of the codes used to define Alzheimer’s in the Smeeth paper are included in the Probable Alzheimer’s code-list (see Figure 30), I included several additional codes used to define this outcome (including, for example, “Eu00013: [X]AD disease type 2”). Additionally, several of the codes used to define “Possible Alzheimer’s” in this analysis are included in the “Other dementia” code list used by Smeeth.

(ref:smeethComparison-cap) Sankey diagram comparing the codes used in this analysis with those used in the Smeeth *et al* paper.[277](#ref-smeeth2009) The outcomes and number of codes contributing to each are presented (the Smeeth *et al* outcomes are on the right hand side of the figure). The joining lines showing the overlap between the categories in the two analyses.



This analysis serves to illustrative the importance of the code lists chosen to define the outcomes of interest, particularly if they are competing (e.g. AD vs non-AD dementia).

## Discussion

### Summary of findings

Lipid-regulating agents showed little evidence of an effect on probable and possible Alzheimer’s disease when compared with no treatment, but were associated with increased risk of an all-cause dementia, vascular dementia and other dementia diagnosis. The effect observed in each case was driven by the statin subgroup, which included a substantial majority of participants. For the other drug classes, no association was found with any outcome, with two exceptions being that ezetimibe was associated with increased risk of vascular and other dementia, while fibrates were associated with increase risk of all-cause dementia and probable Alzheimer’s disease.


The effect estimates were robust to the exclusion of potentially pregnant participants, and for all outcomes except Probable AD, no variation across grouped year of entry was observed. When looking at the statin subgroup alone, statin properties appeared to have a modifying effect, with hydrophilic statins being less harmful in the any, vascular and other dementia outcomes compared to lipophilic statins.

### Interpretation of results

This section will expand on a potential explanation for the observed results detailed above. However, as the comparison of evidence across different sources is the aim of the triangulation exercise presented in later chapters, the section will not provide a detailed comparison with other published literature, except where needed to illustrate a methodological point. For a comparison of the result presented above with those from the systematic review (Chapter 4) and the individual patient data analysis (Chapter 6), see Section 8.

A likely explanation for the observed increased risk of vascular and other dementia with lipid regulating agent use is residual confounding by indication. While the term has been used to describe different source of bias in epidemiological analyses,[278](#ref-salas1999) “confounding by indication” is used here to described the role of risk factors that both prompt treatment (in this case statins) and increase the risk of the outcome (in this case vascular dementia), thus causing a distorted positive association between the treatment and outcome (see Figure 31). In causal inference language, statins and dementia are said to be d-connected as there is an open “backdoor” path between them via the uncontrolled confounders.[279](#ref-suttorp2015)

(ref:indicationBias-cap) Causal diagram (directed acyclic graph) illustrating confounding by indication.



In the case of this analysis, the confounding variable (or, more likely, variables) would prompt prescription of statins (or another lipid regulating agent) but also represent a vascular risk factor that contributes to the development of the vascular dementia.

Supporting evidence for this interpretation comes from a variety of sources, including the results of the control outcome analyses. The slight harmful effect for the backpain outcome is substantially smaller that that observed for the ischemic heart disease outcome, indicating that the majority of the uncontrolled confounding is likely related to vascular factors. This is supported by the increasingly harmful effect moving from Probable/Possible AD to other dementia to vascular dementia, indicating that the confounding by indication likely increases as the proportion of vascular outcomes increase. This is supported by the decision tree for assigning outcomes in the presence of greater than one dementia code, where the Alzheimer’s disease outcomes require a “pure” condition, and the presence of any vascular or other dementia codes excludes participants from this group (Figure 19).

A review of other available literature suggests that this observation (a harmful effect of lipid regulating agents on vascular-related outcome) is not unusual. Using a conventional epidemiological technique, a previous analysis also found an increased risk of coronary heart disease (analogous to ischemic heart disease) in those taking statins (HR: 1.31, 95%CI: 1.04-1.66).[280](#ref-danaei2013b) Following control for confounding by indication through use of a trial emulation analysis, the expected protective effect of statins was observed.

Conditioning entry into the study on being either “at-risk” or already diagnosed with hypercholesterolemia was employed in a pre-emptive attempt to mitigate confounding by indication, but evidence from the control outcomes suggests this was unsuccessful. I also adjusted for several additional potential baseline variables. However, important confounding variables for which I have not adjusted could include genetic factors. A recent preprint of a study in the UK Biobank demonstrated that an Alzheimer’s disease polygenic risk score was associated with an increased risk of vascular dementia, and also with an increased frequency of self-reported raised cholesterol levels, a diagnosis of hypercholesterolaemia, and a history of taking lipid-regulating agents such as statins or ezetimibe.[281](#ref-korologou-linden2020)

On a more general note, the unexpected increase in vascular dementia risk with statin use is particularly interesting given the absence of vascular dementia in the published literature, as highlighted in the previous chapter (see Section 4.4.11). It is possible that previous research identified a similar effect to this analysis, and via a publication bias mechanism, these results did not make it into the evidence base.

In summary, despite best efforts to account for strong confounding, participants prescribed a lipid regulating agent likely have a different vascular risk profile that those who are not, which may induce a spurious harmful association between lipid regulating agent use and vascular dementia outcomes.

### Strengths and limitations

The primary strength of this analysis compared to others available in the literature is the relative size of the CPRD and length of follow-up. Having reviewed the other studies identified by the systematic review in Chapter 4, this analysis of 1,684,564 participants is one of the largest available studies of this research question. Additionally, this analysis followed LRA users and non-users from a common index date, using a time-updating treatment indicator to correctly assign time-at-risk to the exposed and unexposed groups. This approach has been less commonly used in the literature and allows for the mitigation of potential immortal time bias.

However, the findings of this analysis are subject to several limitations. There is a strong possibility of differential misclassification[282](#ref-porta2014dictionary) of dementia-related conditions based on the exposure. As an illustrative example, those with memory complaints may be more likely to be classified as vascular dementia than Alzheimer’s disease if their medical records contains prescriptions for lipid-regulating agents. Further, there is a potential for general non-differential misclassification of the outcome based on varying positive predictive value of electronic health record code lists to identify dementia cases.[251](#ref-mcguinness2019validity),[252](#ref-wilkinson2018)

Misclassification of outcomes is not the only issue introduced by the use of EHR codes to define outcomes. Comparing and contrasting between different studies is particularly difficult because of the impact that the use of different code list can have on the analysis. This is a particular challenge in comparing research across different time-periods and coding systems, as illustrated by the discrepancy between the results when using the codes lists defined for this study and those used by Smeeth *et al*.

### Enabling easy synthesis of this analysis

In light of my own experiences in attempting to extract information for papers assessing preventative treatments, as documented in Section 4.5.5, the outputs from this analysis are readily available.

All code, Read codelists and summary statistics (i.e. the tables presented in this chapter, plus summary tables of effect estimates) are readily available in machine readable formats (i.e. as comma separated values, or CSV, files) from the archived repository for this project (Zotero DOI: XXXX-XXXX).

The raw data supporting this analysis is not available, as access to the CPRD data is controlled by a data monitoring committee. In the context of access-controlled data, sharing the analysis code represents a way for readers to validate the findings.[283](#ref-goldacre2019c)

Additionally, to help ensure accurate reporting of this analysis, the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines were used[284](#ref-vandenbroucke2007) (see Appendix ?? for the STROBE checklist).

This open approach will enable easy inclusion of this analysis in future evidence synthesis exercises, allowing new work to readily build on that presented here.

### Conclusions

This chapter has provided new evidence on the potential repurposing of lipid-regulating agents for the prevention of all-cause dementia, Alzheimer’s disease, vascular dementia, and other dementia. It made use of a large scale electronic health record database, the CPRD, and employed a time-varying Cox proportional hazards model to account for the potential immortal time bias.

It found little evidence for an effect of lipid-regulating agents on probable or possible Alzheimer’s disease. However, lipid regulating agent use was associated with an increased risk of all-cause, vascular and other dementias. In all cases, the estimated associations were driven by those observed in the statin subgroup, which comprised the majority of exposed participants in this cohort.

This chapter attempted to account for important sources of bias and provide a comparison with other available literature, as identified in the systematic review presented in Chapter 4. However, there is a strong potential for uncontrolled confounding by indication and differential misclassification of the outcome on the basis of exposure, which raises questions about the findings, in particular the unexpected increase in risk of vascular dementia associated with statin use. This is supported by our findings for the negative and positive control outcomes used, which provide some evidence of uncontrolled vascular confounders that may both prompt LRA prescription and increase risk of vascular dementia. Future research using large scale electronic health records should aim to address these limitations, potentially by using a analytical design that more closely emulates a trial.[280](#ref-danaei2013b)

Regardless, this analysis has provided an additional source of evidence for the triangulation exercise presented in Chapter 8. In the following Chapter, the dataset described here is incorporated along with several other datasets as part of an IPD analysis to investigate the effect of blood lipid levels on dementia outcomes directly, rather than via the proxy of treatment.

## References

— Hold — Hold

# Individual participant data meta-analysis

## Lay Summary

As part of a broader investigation into the relationship between lipid levels and dementia risk, I applied for access to 37 unique data sources containing information on these variables. However, only a small proportion of these data sources (n = 3, 8.1%) provided me with access.

The resulting analysis did not suggest an effect of any lipid fraction (total cholesterol, LDL-c, HDL-c, or triglycerides) on any dementia outcome. In addition, patients characteristics such as age and sex did not have any impact on the relationship of lipid fractions and dementia outcomes.

Finally, the reasons for the low response rate are explored and future studies to investigate how data access rates could be improved are suggested.

## Introduction

Individual patient data meta-analyses are considered to be the gold standard form of evidence synthesis, allowing for the application of a common selection model and analytical approach across all identified cohorts. They are particularly useful for investigating the impact of patient-level characteristics, something that is not possible with aggregate data unless the results have been explicitly stratified by the characteristic of interest.

While the systematic review presented in Chapter 4 did not provide strong evidence for an effect of age at lipid measurement or patient sex on the relationship between lipids and dementia, the number of included studies in the lipid fraction meta-analyses were very small, due to both the relatively small number of studies reporting on this exposure and the poor reporting of smmary statistics of patient characteristics.

As such, the aims of this analysis were two fold: firstly, to perform a individual patient data meta-analysis across identified cohorts to examine the impact of patient age-at-measurement and sex on the effect of lipids on dementia; and secondly, to expand the evidence base for the effect of lipids on dementia outcomes by incorporating previously unanalysed cohorts contained in the Dementia Platform UK, a large consortia of dementia cohorts.

## Methods

### Eligibility criteria

Eligible data sources were defined as those that contained lipid measurements and lipids reported/available as a continuous measure, Data sources which were cross-sectional, either by design or due to the available data (e.g. a study conducted multiple waves, but onyl data from a single wave could be accessed) were excluded. Similarly, due to the limited time-frame, studies making use of population-level electronic health records, which often require an extensive project proposals in order to gain access to the data, were ineligible due to the time and cost involved in applying. The one exception to this was data from the CPRD, which I already had access to as part of the analysis reported in Chapter (cprd-analysis-heading).

### Applying for data access

Potentially eligible data sources were identified via two mechanisms with a distinct focus. For each approach, the number of cohorts responding to the request, and where applciable, the reasons given for a lack of data sharing were recorded.

#### Systematic review

The first approach focused on previously analysed data sources. The systematic review detailed in Chapter 4 identified several observational prospective cohort studies examining the effect of blood lipid levels on dementia outcomes. The data sources used in each of these cohort analyses were screened against the criteria listed in the previous section, and eligible cohorts were approached for data access. In the first instance, the first/corresponding author of the publication was emailed (see Appendix 10.5.1 for a copy of the text and documentation sent to potentially collaborators) in Autumn 2020. If this approach did not elicit a response within two months, the last author was contacted, on the basis that the first/corresponding author may have been a more junior member of the research group who has moved to a different institution.

#### Dementia Platform UK

The second approach focused on incorporating previously unanalysed data, thus providing additional evidence on the relationship between statins and dementia risk.

This was achieved through the Dementia Platform UK (DPUK), a collaborative grouping of existing dementia cohorts established by the MRC which works with data owners to make their data readily accessible for secondary analysis.[98](#ref-bauermeister2020) It provides access to 42 cohorts with over 3 million participants, and makes use of a central streamlined application processs for all cohorts with the intent of making it easier to access data from existing data sources.

Cohorts included in the DPUK were assessed against the eligibility criteria, and in Autumn 2020, an application for access to a subset of 16 cohorts was made via the common-access procedure.

### Risk of bias assessment

Risk of bias assessment was performed for each of the included cohorts using the risk-of-bias assessment tool for non-randomised studies of exposures introduced previously (for a more detailed discussion of this tool, see Section 4.3.7.2).

Due to the inherent conflict of interest in assessing my own analysis, the result were also assessed by two independent reviewers.

### Missing data

In this analysis, missing data were handled using a multiple imputation approach. Variables with missing observations were identified, and 20 imputed datasets were created.[265](#ref-sterne2009) Nominal variables with missing values were modelled using multinomial logistic regression, while continuous variables were modelled using linear regression. As per best practice, all variables used in the analytic model, including the outcome, were included in the imputation model.[266](#ref-moons2006using) Imputation was performed using the MICE (Multiple Imputation by Chained Equations) using the XXX command in R.

### Variable definition

#### Exposure

To aid interpretability of the outcome, all analyses were standardised to refer to a 1-standard deviation increase in the lipid fraction under investigation.

#### Outcomes

Similar to the analyses presented in othe chapters, th endpoints in this analysis was incidience of dementia and related sub-types (AD, vascular dementia).

#### Covariates

Relevant covariates were adjusted for in all models. these included age, sex,education and comorbities. For information on how these were defined across cohorts, see Appendix ??.

### Statistical analysis

#### Descriptive statistics

All IPD obtained was examined and recoded as necessary to ensure they comply with the coding guideline for the IPD database. As recommended , summary statistics for each data source were calculated and compared to publicly available statistics to ensure no errors were introduced in the data cleaning process.[285](#ref-levis2021) Any discrepancies were investigated.

#### Data cleaning and harmonisation

Across all cohorts, data cleaning was performed in a similar manner, using commonly named variables, so that a single model could be applied using functional programming. The one exception to this is the CPRD data, which was held in a different system to the rest. However, an identical model was applied within this cohort. The advantage of this approach is that it reduces the likelihood of errors in model mis-specification if needing to change variables names from cohort to cohort.

#### Individual patient data analysis

In this analysis, an two-stage individual patient data model was used out of necessity, with the one-stage model being precluded by the included datasets being in protected data silos. It also allows for each studys’ data to be analysed according to a common analysis plan, which is particularly important in this topic, due to the differing definitions between studies of the serum concentrations above or below which lipids are deemed to be at abnormal levels.

Under a two-stage approach, estimates for the effect of each lipid fraction on available dementia outcomes in each study were first calculated for each data source. Effect estimates for the associations between lipid fractions and incident dementia, adjusted for identical covariates, were obtained by applying a common model to each data source. More specifically, hazard ratios were used to quantify the effect of a 1-SD lower exposure to a lipid fraction on dementia outcomes. A discrete proportional hazards model was employed to account for the interval censoring introduced by design of the longitudinal cohort studies.[286](#ref-wang2017) An overall effect estimate was then produced by combining data-source-specific estimtes in a random-effects meta-analysis (see Section ?? in Chapter ?? for a broader discussion of meta-analysis methods). Following best practice, clustering within studies was accounted for.[287](#ref-abo-zaid2013)

#### Investigating effect of patient-level covariates

In order to investigate the interaction of patient-level characteristics with lipid levels, interaction terms for lipid-covariate terms were included in the model above. These were extracted and synthesised using a random effects meta-analysis.

#### Combining published aggregate data and individual participant data

Where a data source did not provided their individual participant data, but stratified by a patient characteristic of interest in the published data, the aggregate data and individual data were combined.

### Comparison with published findings

Where an included data source had previously been analysed and results for the association between lipid levels and dementia outcomes reported, these were compared to the results of this analysis. If discrepancies were identified, these were investigated.

### Secondary analyses

#### Amount of information added

The proportion of new information added to the evidence base via incorporation of the unanalysed datasets was quantified, by addding the additional results to the lipid-dementia meta-analyses presented in Section ??, and extracting the combined weights assigned to the new data in a fixed-effect model.

#### Data availability statements

As a sensitivity analysis, I examined the data sharing statements for each using a predefined categories used in a similar previous analysis.[288](#ref-mcguinness2020DAScomparison)


## Results

### Data access

Of the 37 studies to which I applied for data access, only three (8.1%) provided data and were included in the analysis. Figure 32 details whether the cohorts eventually included in the review were identified by the systematic review or via DPUK portal. In addition, the reasons for cohorts not being included in the analysis are presented, stratified by application approach.

In summary, the requests for data from cohorts identified by the systematic review was characterised by a very low response rate. For the minority who did respond, common reasons given by corresponding authors for not sharing the data included that they no longer worked with the same group and did not know if the data were available or how to obtain it, had access to the data, or that they were currently or intended to perform a similar analysis as the one proposed.

With respect to the application to DPUK cohorts, where a dedicated project manager liaises with data owners on the applicants’ behalf, the overall response rate was higher resulting in eventual access to three cohorts (one of which was also identified by the systematic review). However, even using this streamlined approach, a response was obtained for only half of the approach cohorts.



As highlighted in Figure 32, there was little overlap between cohorts identified by the systematic review and those contained in the DPUK (n = 1, 2.7%), indicating that the DPUK is a useful source of unanalysed data with respect to this question.

### Included data sources

The four data sources used in this analysis are summarised in Table 18 and are described in detail in the following sections. Of note, all included data sources were based in the United Kingdom. This is likely due to the majority of included datasets coming from the Dementia Platform UK route (Figure 32), which as implied by the name, has a geographical focus on cohorts performed in the United Kingdom.[98](#ref-bauermeister2020)

Table 18: Summary of cohorts for which data were available

| **Cohort** | **N** | **Dementia events (all-cause)** | **Age (mean)** | **Male (%)** |
| --- | --- | --- | --- | --- |
| **CaPS** | 2512 | 1034 | 52 | 100 |
| **CPRD** | X | X | X | X |
| **EPIC** | 1001 | 5 | 52 | 45 |
| **Whitehall II** | 8022 | 181 | 50 | 69 |

#### Caerphilly Prospective Study

The Caerphilly Prospective Study is a longitudinal study of men in the

Cholesterol measures (total, LDL-c, HDL-c and triglyceride) were measured at baseline in 1979-1983. As the study population has aged, additional outcomes. Of particular relevance to this analysis, from Phase III (1989-1993) onwards, a battery of cognitive tests were introduced.

#### CPRD

The Clinical Practice Research Datalink (CPRD) is a large population-based, electronic health record (EHR) database.[256](#ref-herrett2015) containing the primary care records for more than 10 million primary care patients in England, and is broadly representative of the UK population in terms of age, sex and ethnicity.[256](#ref-herrett2015),[259](#ref-mathur2014)

The CPRD is introduced more fully in Chapter @ref(). Briefly, a similar approach to the cohort definition as used in Chapter

Participants were included from the first date of lipid measurement, so no issues with immortal time bias as discussed in Chapter …

Additionally, other number of participants is larger in this analysis as there is no restriction on the level which lipids should be in order to be included in the analysis.

the

#### Epic Norfolk

The European Prospective Investigation of Cancer - Norfolk is a[289](#ref-riboli1997),[290](#ref-riboli2002)

The added evidental value of the EPIC cohort is small, given the relatively small number of participants and the fact that the cohort has only 8 dementia events.

#### Whitehall II

*The Whitehall II study is a prospective cohort study of 10 308 participants (70% men), aged 35–55 years and recruited between 1985 and 1989 from 20 London-based Civil service departments (*[*https://www.ucl.ac.uk/whitehallII*](https://www.ucl.ac.uk/whitehallII)*). Clinical examinations have been performed in 1991-1994, 1997-1999, 2002-2004, 2007-2009, 2012-2013, 2015-2016 with the data from circulating metabolomic traits and cognitive testing for the present study obtained from the 1997-1999 clinic phase.* - taken from EN ID: 2140

This data source was analysed in one of the included studies identified by the systematic review presented in Chapter 4,[218](#ref-tynkkynen2018) meaning that a comparison between the published result and the analysis reported here was was possible.

### Excluded data sources

#### Cohorts identified the systematic review but excluded from the IPD analysis

The main reason for exclusion within this records was use of an electronic health record database. Examples included the Taiwan National Health Insurance database and studies run in the US making use of Medicare data.

#### Cohorts identified in the DPUK but excluded from the IPD analysis

Several additional cohorts are present in the DPUK collection but were not formally approached with a request for data access. This was primarily due to the information obtained via the online data dictionary system or via initial contact with the cohort owners indicating that the study was relatively new (and so was yet to collect more than 1 wave of data) or that the exposure variables of interest were not recorded.

#### Cohorts providing data but ultimately excluded

As highlighted in Figure 32, several cohorts from the DPUK responding positively but on inspection of data provided these cohorts were excluded for a range of reason. The exclusion reason for each cohort for which data were provided is illustrated in Table 19.

"“,”Cohort“,”Reason" “1”,“NICOLA”,“Cross-sectional - only one wave of data available” “2”,“TRACK HD”,“Participants carried HTT gene (i.e. premanifest Huntington’s Disease). Cohort owners indicated that this is likely to overshadw”

Table 19: Exclusion reasons for cohorts providing data

| **Cohort** | **Reason** |
| --- | --- |
| **NICOLA** | Cross-sectional - only one wave of data available |
| **TRACK HD** | Participants carried HTT gene (i.e. premanifest Huntington's Disease). Cohort owners indicated that this is likely to overshadw |

BRACE is a memory-complaint-based cohort, suggesting that it is unlikely they were dementia-free at baseline). Similarly, the Memento study was excluded as it’s criteria for entry required participants to be outpatients from a memory clinic. The Generation Scotland provided only cross-sectional data only for the variables of interest, as did the the NICOLA study. Finally, the ELSA study was excluded based on the definition of the exposure variable. This study provided a “high cholesterol” a binary variable rather than the raw continuous lipid measurement data.


#### Cohorts approach but received no answer

This was particularly common among the cohorts identified via the systematic review and included studies with a dedicated access process or data access committee. A cohort of particular interest, having been used in multiple studies identified by the systematic review, is the Three City Study in France. Despite multiple attempts to contact the team, there was no response received. This study was approach at multiple points over the curse of this analysis, and no answer was received.

This was also a problem for cohorts approach via the DPUK - half of the cohorts applied to did not respond to the application within a year.

### Analytical results

There was no evidence for an effect of any lipid fraction on any dementia outcome (Figure 33). Additionally, meta-analysis of the interaction coefficients for age-at-lipid-measurement and participant sex did not reveal an evidence for an varying effect across these variables.



## Discussion

### Summary of findings

This analysis requested data from 37 data sources, but only obtained data from n = 3, 8.1%, all of which were based in the United Kingdom. No evidence for an effect of lipids on the risk of dementia or related outcomes was identified. Similalarly, there was no evidence for an effect of age-at-measurement or sex on the lipid-dementia relationship.

Additionally analyses revealed that authors of cohorts indentified by the systematic review rarely stated that the data underpinning their analyses would be freely available, while a review of corresponding authors of these publications demonstrated that for many, the institutional email address provided was out of date.

### Limitations

#### Low response rate to request for data

A key limitation of this analysis is the very low response rate to requests for data access. This finding is not unexpected however, given that a review of IPD studies published between 1987 and 2015 found that fewer than half managed to obtained data from greater than 80% of studies, and that in many cases, the exact percentage of studies for which data were obtained was not accurately reported.

There are likely several likely reasons for this low response rate. In general terms, there are a several well-documented reasons why data are not made readily available, including concerns regarding participant privacy, concerns around scoping or “parasitic” behaviour, and a lack of trust between primary and secondary researchers.

More specific to this analysis, individual participant data meta-analysis including studies other than randomised controlled trials have less success in obtaining individual participant data from studies.[93](#ref-nevitt2017a) Additionally, while no evidence is available on whether the characteristics of the researcher requesting data access influences the response rate and eventual decision, there is the possibility that my position as a PhD student meant I was less likely to elicit the response rate than a well-known professor might. The timing of the requests for data access, coinciding with a global pandemic, may also have affected the response rate as researchers prioritised other work.

*Many authors claim that their data can be made “available on request”, despite previous work establishing that these statements are demonstrably untrue in the majority of cases - that when data is requested, it is not actually made available.*[*291*](#ref-krawczyk2012)*–*[*293*](#ref-naudet2018) *Additionally, previous work found that the availability of data “available on request” declines with article age, indicating that this approach is not a valid long term option for data sharing.*[*96*](#ref-vines2014) *Several of the included studies are greater than 10 years old, and so obtaining data from these cohorts is less likely compared with more recently published studies.*

One of the reasons for this may be that the email addresses reported on publications are more likely to be out of date for older publications. Qualitatively, investigation of a subset of cohorts revealed that several corresponding/first authors were no longer at the same institution as when the study was reported, and as a result, were unlikely to have access to the institutional email address listed on the study publication.

These challenges are in theory what the DPUK was built to address. However, even with the help of the streamlined application process afforded by the DPUK, accessing sufficient data was a challenge. The response rate among DPUK cohorts a year after application was just 50%. In addition, some cohorts responded that that the proposed study question was already under investigation by another group, and that they would not share the data on this basis. In light of this, a centralised database of ongoing analysis being performed in DPUK would be of enormous help. Finally, the DPUK should more clearly distinguish between those cohorts that are “DPUK native” versus externally hosted, as the response time for externally hosted cohorts is likely to be much longer.

Whether or not to press ahead with an IPD analysis in the absence of all (or even most) data is a personal decision, and some previous analyses have highlighted where they decided not to pursue an IPD study.[294](#ref-jaspers2014)

For the purposes of this thesis, conducting the IPD analysis was useful as it afforded me the opportunity to gain experience in applying the methodology. In addition, it allowed me to analysed two addition previously unanalysed cohort studies which were then utilised in the triangulation study detailed in Chapter 7.

#### Risk of bias assessment

There is some concerns about performing risk of bias assessments on your own analysis, and so two secondary reviewers

### Strengths

While this analysis did not manage to systematically obtain and analyse a large proportion of identified data, it did enable an analysis of two previously unanalysed datasets - the CaPS study and the EPIC Norfolk study - providing additional data that is incorporated into the triangulation exercise reported in Chapter 7.

### Reflections on the process

In hindsight, attempting to undertake a large-scale IPD meta-analysis as part of a larger PhD project may have been overly ambitious. Data harmonization between cohorts in an IPD analysis is an often under-appreciated challenge,[285](#ref-levis2021) and in line with this, data cleaning for this analysis took substantially longer than expected.

## Conclusion

This analysis provided very weak evidence for an effect of lipid fractions on dementia outcomes. However, it does provide an analysis two previous unanalysed data sources that are subsequently used in Chapter 7.

## References

— Hold — Hold

# Aetiological triangulation across evidence sources

## Lay Summary

## Introduction

This chapter will attempt to triangulate the evidence identified by the systematic review in Chapter (sys-rev-heading)

### Data sources

This chapter builds on the comprehensive systematic review presented in CHapter @re(sys-rev-heading), and incorporates the results of the analyses presented in Chapters ?? & 6.

### Background to the causal question

Following best practice guidance, three

Table with columns describing exposure, outcome, timepoint, other aspects (cumulative), and

This was also guideded by the forthcoming ROBINS-E tool, which has

### Definition of the causal question

### Summary of triangulation

Need to check how much I talk about this in the introduction

Describe in detail

### Risk of bias tool

In addition, the tool also aim to capture the potential direction of bias for each result. Possible responses included: “Favours experimental”, “Favours comparator”, “Towards null”, “Away from null”, and “Unpredictable”. Highlight that this is slightly different for the confounding domain in non-randomised studies.

These levels only apply to existing tools, not the MR tool. However, a similar approach was employed.

While the triangulation framework provides for inclusion of multiple distinct types of evidence, based on the scoping search, it is likely that the three main sources will be RCTs of statins, multivariable regression of prospective cohorts, and the use of genetic instruments in observational data (Mendelian Randomisation studies). One important difference between these approaches that will need to be addressed in the triangulation is that RCTs relate to short-term modification of lipid levels, whereas Mendelian randomisation studies typically refer to lifelong exposures; and traditional observational epidemiology approaches may refer to short or longterm exposure (although are often not explicit about this). The triangulation will take these into account, for example by superimposing the studies on a hypothetical model for exposure-outcome relationship across the life course.

### Graphical representation

For the graphs, the direction of bias is important.

Where the direction of bias was unclear/could not be determined from the report, this is indicated

In order to aid with the triangulation exercise, a new method of presentation of these results was developed to enable detailed comparison across different studies contributing to the causal question. The level of bias in each study is reported using coloured blocks, while the predicted direction of bias in that domain, categorised as towards or away from the null, is indicated using an arrow

Of note, a different approach was required for the confounding domains in the assesment tools used for non-randomised studies. Confounding in a study will either pull to the left or right, regardless of where the effect estimate is, while other domains will pull towards/away from the null (e.g. non-differential misclassification). In this case, the program accounted for the position of the effect estimate when assigning a directional arrow in relation to the positon of the effect estimate. For example, see Figure @ref(), which shows an example study under the same confounding structure (protective), but with protective and harmful effect estimates. In this case, when the estimated effect is protective (Study 1), the arrow for the confounding domain indicates that the bias is pulling it away from the null. If the estimated effect is harmful, the arrow indicates that the results is being biased towards the null.

These graphs were built using the risk of bias tool described in Appendix ()

### Standardisation across study designs

Standardising across different measures of ex

Want best information across lipids, and so standardised across differnt measures

Fixing directions of effect - get everything pointing the same way

### Analyses

Bias-adjusted meta-analysis[295](#ref-higgins2008a)

## Results

Summary of risk-of-bias/triangulation results

Percentage of domains for which a direction of bias could be assigned?

Compare bias-adjusted and

See what happens if using additive (l=1,m=2,s=3,c=4) vs multiplicative/log scale (l=1,m=2,s=4,c=8). Present adjusted results and meta-analysis of adjusted results.

Applicability/indirectness as an issue Compare with GRADE and cite George’s example of 40% of effect predicted by MR seen when using statins for 5 years

## Discussion

I hope this presents step forward in how researchers think about and visualise triangulation at the result level, rather than simply saying that certain

### Challenges of real-life data

Compare and contrast with the nice example presented in the triangulation paper - realities of non-exemplars is that it is very hard to get this right. ALso highlight the issue with assigning a direct of bias in many studies

### Need for new methods

Can I suggest any empirical studies that need to be performed? Average strength of immortal time bias/etc?

— Hold — Hold

# Discussion

## Triangulation across exisiting evidence and evidence produced in this thesis

### Overview of triangulation

Using the review of the literature as a guide to identify useful further studies that could be performed, I then performed .

Summary table of different studies and results

## Qualitative vs qunatitative triangulation

### Researcher positionality statement

## Discussion of E-values

How strong unmeasured confounding would have to be in order to explain the observed effect.

Heavily criticised in a range of papers.

## Use of concensus panel to bring everything together

## Additional topics for the discussion

There are several addition topics I would like to cover:

* The difference between the peer review of the software vs. the peer review of papers. A conversation until everything is fixed/clear reporting guidelines/checklists, with acceptance dependent on them being implemented /built-in version control, and cross linking discussion points to changes through the linking of commits and comments. Essentially, a more transparent and open

## Summary of findings (and implications for policy makers)

## Strengths and Limitations

There are several strengths and limitations to the work presented in this thesis. One particularly strength is the lengths gone to find all available published and unpublished evidence around the question, and to integrate this evidence in a coherent framework, taking into account the limitations of ach source and how these limitations may be used to provide

Need for large simple trials for common disease where small treatment effect can have large effect -[296](#ref-yusuf1984)

## Reproducible research

Reproducible and science has been a key theme running through this thesis, as reflected by the development of an open source tool to help search medRxiv and bioRxiv preprint metadata. In line with this, an open source copy of the code used to produce this thesis is available on GitHub, as is the code used to perform the analysis contained within it.

Containerisation was used to ensure that the code is reproducible, in line iwht best practices

Commentary on the fact that the best you can do is replicate vs reproducible (due the closed nature of the data).

One is the ability to recreate the results given the same data and code, the other is the ability to recreate the results given the same code but a different dataset. IN theory it is possible to gain access the dataset given the information presented in Chapter @(ref:cprd-analysis-heading). However, access is dependency on an ISAC application to the managing body of the CPRD.

## Public involvement and engagement

Involving and engaging the public and patients has been a central theme to this thesis.

Public engagement activities included

Public involvement also steered the creation of the topic

P

## Future work

## Overall conclusions

# Bibliography

# Bibliography

1. Cerejeira, J., Lagarto, L. & Mukaetova-Ladinska, E. B. Behavioral and Psychological Symptoms of Dementia. *Frontiers in Neurology* **3**, (2012).

2. Kumar, C. S. & Kuriakose, J. R. End-of-life care issues in advanced dementia. *Mental Health in Family Medicine* **10**, 129–132 (2013).

3. Burns, A. & Iliffe, S. Dementia. *BMJ* **338**, b75 (2009).

4. Robinson, L., Tang, E. & Taylor, J.-P. Dementia: Timely diagnosis and early intervention. *BMJ* **350**, h3029 (2015).

5. Iadecola, C. The pathobiology of vascular dementia. *Neuron* **80**, (2013).

6. Venkat, P., Chopp, M. & Chen, J. Models and Mechanisms of Vascular Dementia. *Experimental neurology* **272**, 97–108 (2015).

7. Custodio, N. *et al.* Mixed dementia: A review of the evidence. *Dementia & Neuropsychologia* **11**, 364–370 (2017).

8. Sheehan, B. Assessment scales in dementia. *Therapeutic Advances in Neurological Disorders* **5**, 349–358 (2012).

9. Dubois, B. *et al.* Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDSADRDA criteria. *The Lancet Neurology* **6**, 734–746 (2007).

10. Prince, M. *et al.* Recent global trends in the prevalence and incidence of dementia, and survival with dementia. *Alzheimer’s Research & Therapy* **8**, 23 (2016).

11. Flier, W. M. van der & Scheltens, P. Epidemiology and risk factors of dementia. *Journal of Neurology, Neurosurgery & Psychiatry* **76**, v2–v7 (2005).

12. Baker, C., Jarrett, T. & Powell, T. *Dementia: Policy, services and statistics overview*. (2019).

13. Wittenberg, R. *et al.* The costs of dementia in England. *International Journal of Geriatric Psychiatry* **34**, 1095–1103 (2019).

14. Cummings, J., Lee, G., Ritter, A., Sabbagh, M. & Zhong, K. Alzheimer’s disease drug development pipeline: 2020. *Alzheimer’s & Dementia: Translational Research & Clinical Interventions* **6**, e12050 (2020).

15. Hampel, H. *et al.* The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. *Brain* **141**, 1917–1933 (2018).

16. Pariente, A. *et al.* Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. *Pharmacoepidemiology and Drug Safety* **17**, 655–660 (2008).

17. Marucci, G. *et al.* Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease. *Neuropharmacology* 108352 (2020). doi:[10.1016/j.neuropharm.2020.108352](https://doi.org/10.1016/j.neuropharm.2020.108352)

18. Francis, P. T., Ramírez, M. J. & Lai, M. K. Neurochemical basis for symptomatic treatment of Alzheimer’s disease. *Neuropharmacology* **59**, 221–229 (2010).

19. Feingold, K. R. Introduction to Lipids and Lipoproteins. in *Endotext* (eds. Feingold, K. R. et al.) (MDText.com, Inc., 2000).

20. Peters, R. *et al.* Combining modifiable risk factors and risk of dementia: A systematic review and meta-analysis. *BMJ Open* **9**, e022846 (2019).

21. Anstey, K. J., Ee, N., Eramudugolla, R., Jagger, C. & Peters, R. A Systematic Review of Meta-Analyses that Evaluate Risk Factors for Dementia to Evaluate the Quantity, Quality, and Global Representativeness of Evidence. *Journal of Alzheimer’s Disease* **70**, S165–S186 (2019).

22. Norton, S., Matthews, F. E., Barnes, D. E., Yaffe, K. & Brayne, C. Potential for primary prevention of Alzheimer’s disease: An analysis of population-based data. *The Lancet Neurology* **13**, 788–794 (2014).

23. Laufs, U., Parhofer, K. G., Ginsberg, H. N. & Hegele, R. A. Clinical review on triglycerides. *European Heart Journal* **41**, 99–109c (2020).

24. Zampelas, A. & Magriplis, E. New Insights into Cholesterol Functions: A Friend or an Enemy? *Nutrients* **11**, (2019).

25. Friedewald, W. T., Levy, R. I. & Fredrickson, D. S. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. *Clinical Chemistry* **18**, 499–502 (1972).

26. Detection, N. C. E. P. (US). E. P. on. *Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)*. (The Program, 2002).

27. Nelson, R. H. Hyperlipidemia as a Risk Factor for Cardiovascular Disease. *Primary care* **40**, 195–211 (2013).

28. Libby, P. *et al.* Atherosclerosis. *Nature Reviews Disease Primers* **5**, 1–18 (2019).

29. Collins, R. *et al.* Interpretation of the evidence for the efficacy and safety of statin therapy. *The Lancet* **388**, 2532–2561 (2016).

30. Collins, R. *et al.* Interpretation of the evidence for the efficacy and safety of statin therapy. *The Lancet* **388**, 2532–2561 (2016).

31. Law, M. R., Wald, N. J. & Rudnicka, A. R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. *BMJ* **326**, 1423 (2003).

32. Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. *Fundamental & Clinical Pharmacology* **19**, 117–125 (2005).

33. Sierra, S. *et al.* Statins as neuroprotectants: A comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. *Journal of Alzheimer’s disease: JAD* **23**, 307–318 (2011).

34. Kosoglou, T. *et al.* Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions. *Clinical Pharmacokinetics* **44**, 467–494 (2005).

35. Genest, J. Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. *The Canadian Journal of Cardiology* **22**, 863–867 (2006).

36. Chaudhary, R., Garg, J., Shah, N. & Sumner, A. PCSK9 inhibitors: A new era of lipid lowering therapy. *World Journal of Cardiology* **9**, 76–91 (2017).

37. McKenney, J. New perspectives on the use of niacin in the treatment of lipid disorders. *Archives of internal medicine* **164**, 697–705 (2004).

38. Skulas-Ray Ann C. *et al.* Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. *Circulation* **140**, e673–e691 (2019).

39. Burns, M. P. *et al.* Co-localization of cholesterol, apolipoprotein E and fibrillar A in amyloid plaques. *Molecular Brain Research* **110**, 119–125 (2003).

40. Mizuno, T. *et al.* Cholesterol-dependent Generation of a Seeding Amyloid -Protein in Cell Culture \*. *Journal of Biological Chemistry* **274**, 15110–15114 (1999).

41. Beecham, G. W. *et al.* Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer’s Disease and Related Dementias. *PLoS Genetics* **10**, (2014).

42. Harold, D. *et al.* Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease, and shows evidence for additional susceptibility genes. *Nature genetics* **41**, 1088–1093 (2009).

43. Meng, Y. *et al.* Association between SORL1 and Alzheimer disease in a genome-wide study. *Neuroreport* **18**, 1761–1764 (2007).

44. Kivipelto, M. *et al.* Apolipoprotein E 4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease. *Annals of Internal Medicine* **137**, 149–155 (2002).

45. Kivipelto, M. *et al.* Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. *Archives of Neurology* **62**, 1556–1560 (2005).

46. Schilling, S. *et al.* Differential associations of plasma lipids with incident dementia and dementia subtypes in the 3C Study: A longitudinal, population-based prospective cohort study. *PLoS medicine* **14**, e1002265 (2017).

47. Solomon, A., Kivipelto, M., Wolozin, B., Zhou, J. & Whitmer, R. A. Midlife Serum Cholesterol and Increased Risk of Alzheimer’s and Vascular Dementia Three Decades Later. *Dementia and Geriatric Cognitive Disorders* **28**, 75–80 (2009).

48. Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C. & Yaffe, K. Midlife cardiovascular risk factors and risk of dementia in late life. *Neurology* **64**, 277–281 (2005).

49. Li, G. *et al.* Serum cholesterol and risk of Alzheimer disease: A community-based cohort study. *Neurology* **65**, 1045–1050 (2005).

50. Mainous, A. G., Eschenbach, S. L., Wells, B. J., Everett, C. J. & Gill, J. M. Cholesterol, transferrin saturation, and the development of dementia and Alzheimer’s disease: Results from an 18-year population-based cohort. *Family Medicine* **37**, 36–42 (2005).

51. Mielke, M. M. *et al.* The 32-year relationship between cholesterol and dementia from midlife to late life. *Neurology* **75**, 1888–1895 (2010).

52. Tan, Z. S. *et al.* Plasma total cholesterol level as a risk factor for Alzheimer disease - The Framingham study. *Archives of Internal Medicine* **163**, 1053–+ (2003).

53. Mielke, M. M. *et al.* High total cholesterol levels in late life associated with a reduced risk of dementia. *Neurology* **64**, 1689–1695 (2005).

54. Reitz, C., Tang, M. X., Luchsinger, J. & Mayeux, R. Relation of plasma lipids to Alzheimer disease and vascular dementia. *Archives of Neurology* **61**, 705–714 (2004).

55. Moroney, J. T. Low-Density Lipoprotein Cholesterol and the Risk of Dementia With Stroke. *JAMA* **282**, 254 (1999).

56. Anstey, K. J., Ashby-Mitchell, K. & Peters, R. Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis. *Journal of Alzheimer’s Disease* **56**, 215–228 (2015).

57. Chu, C.-S. *et al.* Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. *Scientific Reports* **8**, 5804 (2018).

58. Ritchie, C. W., Terrera, G. M. & Quinn, T. J. Dementia trials and dementia tribulations: Methodological and analytical challenges in dementia research. *Alzheimer’s Research & Therapy* **7**, 31 (2015).

59. Trompet, S. *et al.* Pravastatin and cognitive function in the elderly. Results of the PROSPER study. *Journal of Neurology* **257**, 85–90 (2010).

60. Davey Smith, G. & Hemani, G. Mendelian randomization: Genetic anchors for causal inference in epidemiological studies. *Human Molecular Genetics* **23**, R89–R98 (2014).

61. Greenland, S. An introduction to instrumental variables for epidemiologists. *International Journal of Epidemiology* **29**, 722–729 (2000).

62. Davies, N. M., Holmes, M. V. & Smith, G. D. Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians. *BMJ* **362**, k601 (2018).

63. Larsson, S. C. *et al.* Modifiable pathways in Alzheimer’s disease: Mendelian randomisation analysis. *BMJ* **359**, j5375 (2017).

64. Østergaard, S. D. *et al.* Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study. *PLOS Medicine* **12**, e1001841 (2015).

65. Kim, J., Basak, J. M. & Holtzman, D. M. The Role of Apolipoprotein E in Alzheimer’s Disease. *Neuron* **63**, 287–303 (2009).

66. Benn, M., Nordestgaard, B. G., Frikke-Schmidt, R. & Tybjærg-Hansen, A. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study. *BMJ* **357**, j1648 (2017).

67. Donnelly, C. A. *et al.* Four principles to make evidence synthesis more useful for policy. *Nature* **558**, 361–364 (2018).

68. Chandler, J., Higgins, J., Deeks, J., Davenport, C. & Clarke, M. J. Chapter 1: Introduction. in *Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021)* **5**, (Cochrane, 2020).

69. Conn, V. S., Valentine, J. C., Cooper, H. M. & Rantz, M. J. Grey literature in meta-analyses. *Nursing Research* **52**, 256–261 (2003 Jul-Aug).

70. McAuley, L., Pham, B., Tugwell, P. & Moher, D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? *Lancet (London, England)* **356**, 1228–1231 (2000).

71. Hopewell, S., McDonald, S., Clarke, M. & Egger, M. Grey literature in meta-analyses of randomized trials of health care interventions. *The Cochrane Database of Systematic Reviews* MR000010 (2007). doi:[10.1002/14651858.MR000010.pub3](https://doi.org/10.1002/14651858.MR000010.pub3)

72. Lefebvre, C. *et al.* Chapter 4: Searching for and selecting studies. in *Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021)* 67–107 (Cochrane, 2020).

73. Committee on Publication Ethics (COPE). *Discussion Document: Preprints*. (2018).

74. Vale, R. D. & Hyman, A. A. Priority of discovery in the life sciences. *eLife* **5**, e16931 (2016).

75. Rosenthal, R. The file drawer problem and tolerance for null results. *Psychological Bulletin* **86**, 638–641 (1979).

76. Maslove, D. M. Medical PreprintsA Debate Worth Having. *JAMA* **319**, 443–444 (2018).

77. Schalkwyk, M. C. I. van, Hird, T. R., Maani, N., Petticrew, M. & Gilmore, A. B. The perils of preprints. *BMJ* **370**, m3111 (2020).

78. Mahood, Q., Eerd, D. V. & Irvin, E. Searching for grey literature for systematic reviews: Challenges and benefits. *Research Synthesis Methods* **5**, 221–234 (2014).

79. Klein, M., Broadwell, P., Farb, S. E. & Grappone, T. Comparing published scientific journal articles to their pre-print versions. *International Journal on Digital Libraries* **20**, 335–350 (2019).

80. Nicholson, D. N. *et al.* Linguistic Analysis of the bioRxiv Preprint Landscape. *bioRxiv* 2021.03.04.433874 (2021). doi:[10.1101/2021.03.04.433874](https://doi.org/10.1101/2021.03.04.433874)

81. Munafò, M. R. & Smith, G. D. Robust research needs many lines of evidence. *Nature* **553**, 399–401 (2018).

82. Page, M. J. *et al.* The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* **372**, n71 (2021).

83. McGuinness, L. A., Higgins, J. P. T. & Sterne, J. A. C. Assessing the Credibility of Findings From Nonrandomized Studies of Interventions. *JAMA Cardiology* **3**, 905–906 (2018).

84. Riley, R. D., Lambert, P. C. & Abo-Zaid, G. Meta-analysis of individual participant data: Rationale, conduct, and reporting. *BMJ* **340**, c221 (2010).

85. Stewart, L. A. & Parmar, M. K. B. Meta-analysis of the literature or of individual patient data: Is there a difference? *The Lancet* **341**, 418–422 (1993).

86. Arain, F. A., Kuniyoshi, F. H., Abdalrhim, A. D. & Miller, V. M. Sex/gender medicine. The biological basis for personalized care in cardiovascular medicine. *Circulation Journal: Official Journal of the Japanese Circulation Society* **73**, 1774–1782 (2009).

87. Clayton, J. A. Applying the new SABV (sex as a biological variable) policy to research and clinical care. *Physiology & Behavior* **187**, 2–5 (2018).

88. McCartney, M., Treadwell, J., Maskrey, N. & Lehman, R. Making evidence based medicine work for individual patients. *BMJ* **353**, i2452 (2016).

89. Letenneur, L. *et al.* Are sex and educational level independent predictors of dementia and Alzheimer’s disease? Incidence data from the PAQUID project. *Journal of Neurology, Neurosurgery & Psychiatry* **66**, 177–183 (1999).

90. Riley, R. D. *et al.* Individual participant data meta-analysis to examine interactions between treatment effect and participant-level covariates: Statistical recommendations for conduct and planning. *Statistics in Medicine* **39**, 2115–2137 (2020).

91. Stewart, L. A. & Tierney, J. F. To IPD or not to IPD?: Advantages and Disadvantages of Systematic Reviews Using Individual Patient Data. *Evaluation & the Health Professions* **25**, 76–97 (2002).

92. Tugwell, P. & Knottnerus, J. A. Advantages of individual patient data analysis in systematic reviews. *Journal of Clinical Epidemiology* **63**, 233–234 (2010).

93. Nevitt, S. J. *et al.* Exploring changes over time and characteristics associated with data retrieval across individual participant data meta-analyses: Systematic review. *The BMJ* **357**, j1390 (2017).

94. Ventresca, M. *et al.* Obtaining and managing data sets for individual participant data meta-analysis: Scoping review and practical guide. *BMC Medical Research Methodology* **20**, 113 (2020).

95. Alsheikh-Ali, A. A., Qureshi, W., Al-Mallah, M. H. & Ioannidis, J. P. A. Public Availability of Published Research Data in High-Impact Journals. *PLoS ONE* **6**, e24357 (2011).

96. Vines, T. H. *et al.* The Availability of Research Data Declines Rapidly with Article Age. *Current Biology* **24**, 94–97 (2014).

97. Wartenberg, D. & Thompson, W. D. Privacy Versus Public Health: The Impact of Current Confidentiality Rules. *American Journal of Public Health* **100**, 407–412 (2010).

98. Bauermeister, S. *et al.* The Dementias Platform UK (DPUK) Data Portal. *European Journal of Epidemiology* **35**, 601–611 (2020).

99. Rawlinson, C. & Bloom, T. New preprint server for medical research. *BMJ* **365**, (2019).

100. Sever, R. *et al.* *bioRxiv: The preprint server for biology*. (Scientific Communication and Education, 2019). doi:[10.1101/833400](https://doi.org/10.1101/833400)

101. Bramer, W. M., De Jonge, G. B., Rethlefsen, M. L., Mast, F. & Kleijnen, J. A systematic approach to searching: An efficient and complete method to develop literature searches. *Journal of the Medical Library Association* **106**, (2018).

102. Gusenbauer, M. & Haddaway, N. R. Which academic search systems are suitable for systematic reviews or meta-analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources. *Research Synthesis Methods* **11**, 181–217 (2020).

103. Ropensci/medrxivr: Access and search medRxiv and bioRxiv preprint data.

104. Wateridge, J. IT projects: A basis for success. *International Journal of Project Management* **13**, 169–172 (1995).

105. Abdill, R. J. & Blekhman, R. Rxivist.org: Sorting biology preprints using social media and readership metrics. *PLOS Biology* **17**, e3000269 (2019).

106. Rxivist: Explore popular biology preprints.

107. Iwema, C. L., LaDue, J., Zack, A. & Chattopadhyay, A. Search.bioPreprint: A discovery tool for cutting edge, preprint biomedical research articles. *F1000Research* **5**, 1396 (2016).

108. Shaw, M. "Self-healing": Softening precision to avoid brittleness: Position paper for WOSS ’02: Workshop on self-healing systems. *Proceedings of the first workshop on Self-healing systems* 111–114 (2002). doi:[10.1145/582128.582152](https://doi.org/10.1145/582128.582152)

109. Laprie, J. C. Dependability: Basic Concepts and Terminology. in *Dependability: Basic Concepts and Terminology: In English, French, German, Italian and Japanese* (ed. Laprie, J. C.) 3–245 (Springer, 1992).

110. R Core Team. *R: A language and environment for statistical computing*. (R Foundation for Statistical Computing, 2019).

111. Git scraping: Track changes over time by scraping to a Git repository.

112. Rethlefsen, M. L. *et al.* PRISMA-S: An extension to the PRISMA statement for reporting literature searches in systematic reviews. *Systematic reviews* **10**, 1–19 (2021).

113. Bramer, W. M., de Jonge, G. B., Rethlefsen, M. L., Mast, F. & Kleijnen, J. A systematic approach to searching: An efficient and complete method to develop literature searches. *Journal of the Medical Library Association : JMLA* **106**, 531–541 (2018).

114. Kodvanj, I., Homolak, J., Virag, D. & Trkulja, V. Publishing of COVID-19 Preprints in Peer-reviewed Journals, Preprinting Trends, Public Discussion and Quality Issues. *bioRxiv* 2020.11.23.394577 (2020). doi:[10.1101/2020.11.23.394577](https://doi.org/10.1101/2020.11.23.394577)

115. Noone, C. *et al.* Investigating and evaluating evidence of the behavioural determinants of adherence to social distancing measures A protocol for a scoping review of COVID-19 research. *HRB Open Research* **3**, 46 (2020).

116. Grassly, N. C. *et al.* Comparison of molecular testing strategies for COVID-19 control: A mathematical modelling study. *The Lancet Infectious Diseases* **20**, 1381–1389 (2020).

117. Boettiger, C., Chamberlain, S., Hart, E. & Ram, K. Building Software, Building Community: Lessons from the rOpenSci Project. *Journal of Open Research Software* **3**, e8 (2015).

118. Issue #380 - medrxivr: Accessing and searching medRxiv preprint data in R ropensci/software-review GitHub. *GitHub ropensci/software-review*

119. Bong, S. M., McKay, J. L., Factor, S. A. & Ting, L. H. *Perception of whole-body motion during balance perturbations is impaired in Parkinson’s disease and is associated with balance impairment*. (Neurology, 2019). doi:[10.1101/19000265](https://doi.org/10.1101/19000265)

120. Song, F. *et al.* Dissemination and publication of research findings: An updated review of related biases. *Health Technology Assessment* **14**, (2010).

121. Abdill, R. J. & Blekhman, R. Tracking the popularity and outcomes of all bioRxiv preprints. *eLife* **8**, e45133 (2019).

122. Vuorre, M. & Crump, M. J. C. Sharing and organizing research products as R packages. *Behavior Research Methods* (2020). doi:[10.3758/s13428-020-01436-x](https://doi.org/10.3758/s13428-020-01436-x)

123. McGuinness, L., Higgins, J., Ben-Shlomo, Yoav, Coulthard, L. & Smith, G. The relationship between blood lipid levels and dementia: Protocol for a systematic review and triangulation of all available evidence. *OSF* (2020). doi:[10.17605/OSF.IO/VTW5Y](https://doi.org/10.17605/OSF.IO/VTW5Y)

124. Gusenbauer, M. & Haddaway, N. R. Which academic search systems are suitable for systematic reviews or meta-analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources. *Research Synthesis Methods* **11**, 181–217 (2020).

125. Bramer, W. M., Giustini, D., de Jonge, G. B., Holland, L. & Bekhuis, T. De-duplication of database search results for systematic reviews in EndNote. *Journal of the Medical Library Association : JMLA* **104**, 240–243 (2016).

126. Hupe, M. EndNote X9. *Journal of Electronic Resources in Medical Libraries* **16**, 117–119 (2019).

127. Ouzzani, M., Hammady, H., Fedorowicz, Z. & Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. *Systematic Reviews* **5**, 210 (2016).

128. Organization(WHO), W. H. *The ICD-10 classification of mental and behavioural disorders: Diagnostic criteria for research*. (World Health Organization, 1993).

129. Román, G. C. *et al.* Vascular dementia: Diagnostic criteria for research studies: Report of the NINDS-AIREN International Workshop. *Neurology* **43**, 250–250 (1993).

130. Edition, F. & others. Diagnostic and statistical manual of mental disorders. *Am Psychiatric Assoc* **21**, (2013).

131. Gwet, K. L. Computing inter-rater reliability and its variance in the presence of high agreement. *British Journal of Mathematical and Statistical Psychology* **61**, 29–48 (2008).

132. Cohen, J. A Coefficient of Agreement for Nominal Scales. *Educational and Psychological Measurement* **20**, 37–46 (1960).

133. Wongpakaran, N., Wongpakaran, T., Wedding, D. & Gwet, K. L. A comparison of Cohen’s Kappa and Gwet’s AC1 when calculating inter-rater reliability coefficients: A study conducted with personality disorder samples. *BMC Medical Research Methodology* **13**, 61 (2013).

134. Brennan, P. & Silman, A. Statistical methods for assessing observer variability in clinical measures. *BMJ : British Medical Journal* **304**, 1491–1494 (1992).

135. McHugh, M. L. Interrater reliability: The kappa statistic. *Biochemia Medica* **22**, 276–282 (2012).

136. Higgins, J. P., Li, T. & Deeks, J. J. Section 6.5.2.10 : Combining groups. in *Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019)* (eds. Higgins, J. P. T. et al.) (Cochrane, 2019).

137. Reynders, R. M., Ladu, L. & Girolamo, N. D. Contacting of authors modified crucial outcomes of systematic reviews but was poorly reported, not systematic, and produced conflicting results. *Journal of Clinical Epidemiology* **115**, 64–76 (2019).

138. McKenzie, J. E. & Brennan, S. E. Section 12.1: Why a meta-analysis of effect estimates may not be possible. in *Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019)* (eds. Higgins, J. P. T. et al.) (Cochrane, 2019).

139. Sterne, J. A. *et al.* ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* **355**, i4919 (2016).

140. Campbell, D. T. Factors relevant to the validity of experiments in social settings. *Psychological Bulletin* **54**, 297–312 (1957).

141. Jüni, P., Altman, D. G. & Egger, M. Assessing the quality of controlled clinical trials. *BMJ* **323**, 42–46 (2001).

142. Sterne, J. A. C. *et al.* RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ* **366**, (2019).

143. Morgan R *et al.* A tool to assess Risk Of Bias In Non-randomised Studies - of Exposures (ROBINS-E). in *Advances in Evidence Synthesis: Special issue, Cochrane Database of Systematic Reviews* **9 Supp 1**, 320 (2020).

144. French, C. E. *et al.* Cannabis use and the risk of tuberculosis: A systematic review. *BMC Public Health* **19**, 1006 (2019).

145. Wells, G. A. *et al.* The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2000).

146. Mamluk, L. *et al.* Evidence of detrimental effects of prenatal alcohol exposure on offspring birthweight and neurodevelopment from a systematic review of quasi-experimental studies. *International Journal of Epidemiology* **49**, 1972–1995 (2020).

147. Risk Of Bias due to Missing Evidence (ROB-ME).

148. Saran, A. & White, H. Evidence and gap maps: A comparison of different approaches. *Campbell Systematic Reviews* **14**, 1–38 (2018).

149. McGuinness, L. A. & Higgins, J. P. T. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. *Research Synthesis Methods* **12**, 55–61 (2021).

150. Issue #102 - Feature request: Paired forest/risk-of-bias plot. *GitHub mcguinlu/robvis*

151. Feinstein, A. R. & Cicchetti, D. V. High agreement but low kappa: I. The problems of two paradoxes. *Journal of Clinical Epidemiology* **43**, 543–549 (1990).

152. Ancelin, M. L. *et al.* Lipid lowering agents, cognitive decline, and dementia: The three-city study. *Journal of Alzheimer’s Disease* **30**, 629–637 (2012).

153. Ancelin, M. L. *et al.* Sex differences in the associations between lipid levels and incident dementia. *Journal of Alzheimer’s Disease* **34**, 519–528 (2013).

154. Arvanitakis, Z. *et al.* Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. *Neurology* **70**, 1795–1802 (2008).

155. Batty, G. D., Russ, T. C., Starr, J. M., Stamatakis, E. & Kivimaki, M. Modifiable cardiovascular disease risk factors as predictors of dementia death: Pooling of ten general population-based cohort studies. *Journal of Negative Results in Biomedicine* **13**, 8 (2014).

156. Benn, M., Nordestgaard, B. G., Frikke-Schmidt, R. & Tybjaerg-Hansen, A. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study. *BMJ (Clinical research ed.)* **357**, j1648 (2017).

157. Bettermann, K. *et al.* Statins, risk of dementia, and cognitive function: Secondary analysis of the ginkgo evaluation of memory study. *Journal of stroke and cerebrovascular diseases* **21**, 436–444 (2012).

158. Beydoun, M. A. *et al.* Statins and serum cholesterol’s associations with incident dementia and mild cognitive impairment. *Journal of Epidemiology & Community Health* **65**, 949–957 (2011).

159. Bruce, D. G., Davis, W. A. & Davis, T. M. E. Low serum HDL-cholesterol concentrations in mid-life predict late-life cognitive impairment in type 2 diabetes: The Fremantle diabetes study. *Journal of Diabetes & its Complications* **31**, 945–947 (2017).

160. Burgess, S. & Davey Smith, G. Mendelian randomization implicates high-density lipoprotein cholesterol-associated mechanisms in etiology of age-related macular degeneration. *Ophthalmology* **124**, 1165–1174 (2017).

161. Chao, T. F. *et al.* Statins and the risk of dementia in patients with atrial fibrillation: A nationwide population-based cohort study. *International Journal of Cardiology* **196**, 91–97 (2015).

162. Chen, J. M. *et al.* Effects of statins on incident dementia in patients with type 2 DM: A population-based retrospective cohort study in Taiwan. *PLoS ONE [Electronic Resource]* **9**, e88434 (2014).

163. Chiang, C. J. *et al.* Midlife risk factors for subtypes of dementia: A nested case-control study in Taiwan. *American Journal of Geriatric Psychiatry* **15**, 762–771 (2007).

164. Chitnis, A. S. *et al.* Use of statins and risk of dementia in heart failure: A retrospective cohort study. *Drugs & Aging* **32**, 743–754 (2015).

165. Chou, C. Y., Chou, Y. C., Chou, Y. J., Yang, Y. F. & Huang, N. Statin use and incident dementia: A nationwide cohort study of Taiwan. *International Journal of Cardiology* **173**, 305–310 (2014).

166. Chuang, C. S., Lin, C. L., Lin, M. C., Sung, F. C. & Kao, C. H. Decreased prevalence of dementia associated with statins: A national population-based study. *European Journal of Neurology* **22**, 912–918 (2015).

167. Cramer, C., Haan, M. N., Galea, S., Langa, K. M. & Kalbfleisch, J. D. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. *Neurology* **71**, 344–350 (2008).

168. Dodge, H. H., Chang, C. C. H., Kamboh, I. M. & Ganguli, M. Risk of Alzheimer’s disease incidence attributable to vascular disease in the population. *Alzheimer’s and Dementia* **7**, 356–360 (2011).

169. Forti, P. *et al.* Metabolic syndrome and risk of dementia in older adults. *Journal of the American Geriatrics Society* **58**, 487–492 (2010).

170. Gnjidic, D. *et al.* STATIN THERAPY AND DEMENTIA IN OLDER ADULTS: ROLE OF DISEASE SEVERITY AND MULTIMORBIDITY. *Journal of the American Geriatrics Society* **64**, 223–224 (2016).

171. Gottesman, R. F. *et al.* Associations between midlife vascular risk factors and 25-Year incident dementia in the atherosclerosis risk in communities (ARIC) cohort. *JAMA Neurology* **74**, 1246–1254 (2017).

172. Gustafson, D. R. *et al.* Epidemiological evidence for lipid-based dementia prevention: The Lipididiet approach. *Journal of Molecular Neuroscience* **1)**, S45 (2012).

173. Haag, M. D., Hofman, A., Koudstaal, P. J., Stricker, B. H. & Breteler, M. M. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. *Journal of Neurology, Neurosurgery & Psychiatry* **80**, 13–17 (2009).

174. Hayden, K. M. *et al.* Vascular risk factors for incident Alzheimer disease and vascular dementia - The Cache County study. *Alzheimer Disease & Associated Disorders* **20**, 93–100 (2006).

175. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebocontrolled trial. *The Lancet* **360**, 7–22 (2002).

176. Hendrie, H. C. *et al.* Statin use, incident dementia and alzheimer disease in elderly african americans. *Ethnicity & Disease* **25**, 345–354 (2015).

177. Hippisley-Cox, J. & Coupland, C. Unintended effects of statins in men and women in England and Wales: Population based cohort study using the QResearch database. *BMJ (Clinical research ed.)* **340**, c2197 (2010).

178. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. & Drachman, D. A. Statins and the risk of dementia. *Lancet (London, England)* **356**, 1627–1631 (2000).

179. Kimm, H. *et al.* Mid-life and late-life vascular risk factors and dementia in Korean men and women. *Archives of Gerontology & Geriatrics* **52**, e117–122 (2011).

180. Kivipelto, M. *et al.* Midlife vascular risk factors and Alzheimer’s disease in later life: Longitudinal, population based study. *BMJ (Clinical research ed.)* **322**, 1447–1451 (2001).

181. Kivipelto, M. *et al.* Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. *Archives of Neurology* **62**, 1556–1560 (2005).

182. Kuo, S. C. *et al.* Association between comorbidities and dementia in diabetes mellitus patients: Population-based retrospective cohort study. *Journal of Diabetes & its Complications* **29**, 1071–1076 (2015).

183. Li, G. *et al.* Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study. *Neurology* **63**, 1624–1628 (2004).

184. Li, G. *et al.* Age-varying association between statin use and incident Alzheimer’s disease. *Journal of the American Geriatrics Society* **58**, 1311–1317 (2010).

185. Liao, M. T., Tsai, C. T. & Lin, J. L. Statins reduce the incidence of dementia in patients with atrial fibrillation: A nationwide cohort study. *European Heart Journal* **34**, 740–741 (2013).

186. Liu, J. M., Chen, T. H., Chuang, H. C., Wu, C. T. & Hsu, R. J. Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer. *Prostate Cancer & Prostatic Diseases* **22**, 276–283 (2019).

187. Mainous, 3rd., A. G., Eschenbach, S. L., Wells, B. J., Everett, C. J. & Gill, J. M. Cholesterol, transferrin saturation, and the development of dementia and Alzheimer’s disease: Results from an 18-year population-based cohort. *Family Medicine* **37**, 36–42 (2005).

188. Mielke, M. M. *et al.* High total cholesterol levels in late life associated with a reduced risk of dementia. *Neurology* **64**, 1689–1695 (2005).

189. Mielke, M. M. *et al.* The 32-year relationship between cholesterol and dementia from midlife to late life. *Neurology* **75**, 1888–1895 (2010).

190. Mielke, M. *et al.* Serum ceramides predict incident alzheimer’s disease: The women’s health and aging study (whas) II. *Alzheimer’s and Dementia* **1)**, S607 (2011).

191. Mukherjee, S. *et al.* Vascular disease, vascular risk factors and risk of late-onset Alzheimer’s disease: Mendelian randomization analyses in the combined adgc dataset. *Alzheimer’s and Dementia* **1)**, P694 (2013).

192. Muller, M. *et al.* Metabolic syndrome and dementia risk in a multiethnic elderly cohort. *Dementia & Geriatric Cognitive Disorders* **24**, 185–192 (2007).

193. Noale, M. *et al.* Incidence of dementia: Evidence for an effect modification by gender. The ILSA Study. *International Psychogeriatrics* **25**, 1867–1876 (2013).

194. Notkola, I. L. *et al.* Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. *Neuroepidemiology* **17**, 14–20 (1998).

195. Ostergaard, S. D. *et al.* Associations between potentially modifiable risk factors and Alzheimer disease: A Mendelian randomization study. *European Neuropsychopharmacology* **27 (Supplement 2)**, S166–S167 (2017).

196. Pan, M. L., Hsu, C. C., Chen, Y. M., Yu, H. K. & Hu, G. C. Statin use and the risk of dementia in patients with stroke: A nationwide population-based cohort study. *Journal of Stroke & Cerebrovascular Diseases* **27**, 3001–3007 (2018).

197. Parikh, N. M. *et al.* Risk factors for dementia in patients over 65 with diabetes. *International Journal of Geriatric Psychiatry* **26**, 749–757 (2011).

198. Peters, R. *et al.* Cardiovascular and biochemical risk factors for incident dementia in the Hypertension in the Very Elderly Trial. *Journal of Hypertension* **27**, 2055–2062 (2009).

199. Raffaitin, C. *et al.* Metabolic syndrome and risk for incident Alzheimer’s disease or vascular dementia: The Three-City Study. *Diabetes Care* **32**, 169–174 (2009).

200. Rantanen, K. *et al.* Cardiovascular risk factors and glucose tolerance in midlife and risk of cognitive disorders in old age up to a 49-year follow-up of the Helsinki businessmen study. *Annals of Medicine* **49**, 462–469 (2017).

201. Rea, T. D. *et al.* Statin use and the risk of incident dementia: The Cardiovascular Health Study. *Archives of Neurology* **62**, 1047–1051 (2005).

202. Redelmeier, D. A., Manzoor, F. & Thiruchelvam, D. Association between statin use and risk of dementia after a concussion. *JAMA Neurology* **20**, 20 (2019).

203. Reitz, C. *et al.* Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. *Archives of Neurology* **67**, 1491–1497 (2010).

204. Ridker, P. M. *et al.* Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. *New England Journal of Medicine* **359**, 2195–2207 (2008).

205. Ronnemaa, E., Zethelius, B., Lannfelt, L. & Kilander, L. Vascular risk factors and dementia: 40-year follow-up of a population-based cohort. *Dementia & Geriatric Cognitive Disorders* **31**, 460–466 (2011).

206. Schilling, S. *et al.* Differential associations of plasma lipids with incident dementia and dementia subtypes in the 3C Study: A longitudinal, population-based prospective cohort study. *PLoS Medicine / Public Library of Science* **14**, e1002265 (2017).

207. Smeeth, L., Douglas, I., Hall, A. J., Hubbard, R. & Evans, S. Effect of statins on a wide range of health outcomes: A cohort study validated by comparison with randomized trials. *British journal of clinical pharmacology* **67**, 99–109 (2009).

208. So, H.-C., Chau, C. K. & Zhao, K. Exploring repositioning opportunities and side-effects of statins: A Mendelian randomization study of HMG-CoA reductase inhibition with 55 complex traits. 170241 (2017). doi:[10.1101/170241](https://doi.org/10.1101/170241)

209. Solomon, A. *et al.* Serum cholesterol changes after midlife and late-life cognition: Twenty-one-year follow-up study. *Neurology* **68**, 751–756 (2007).

210. Solomon, A., Kivipelto, M., Wolozin, B., Zhou, J. & Whitmer, R. A. Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. *Dementia & Geriatric Cognitive Disorders* **28**, 75–80 (2009).

211. Solomon, A. *et al.* Lipid-lowering treatment is related to decreased risk of dementia: A population-based study (FINRISK). *Neurodegenerative Diseases* **7**, 180–182 (2010).

212. Sparks, D. L. *et al.* Reduced risk of incident AD with elective statin use in a clinical trial cohort. *Current alzheimer research* **5**, 416–421 (2008).

213. Strand, B. H. *et al.* Midlife vascular risk factors and their association with dementia deaths: Results from a Norwegian prospective study followed up for 35 years. *Journal of the Neurological Sciences* **324**, 124–130 (2013).

214. Su, B. *et al.* [P3]: EXPLORING LATE-LIFE RISK FACTORS OF ALZHEIMER’s DISEASE AND OTHER AGE-RELATED DEMENTIAS IN CPRD. *Alzheimer’s & Dementia* **13**, P1178–P1179 (2017).

215. Svensson, T. *et al.* The association between midlife serum high-density lipoprotein and mild cognitive impairment and dementia after 19 years of follow-up. *Transl Psychiatry Psychiatry* **9**, 26 (2019).

216. Szwast, S. J. *et al.* Association of statin use with cognitive decline in elderly African Americans. *Neurology* **69**, 1873–1880 (2007).

217. Tynkkynen, J. *et al.* Apolipoproteins and HDL cholesterol do not associate with the risk of future dementia and Alzheimer’s disease: The National Finnish population study (FINRISK). *Age (Melbourne, Vic.)* **38**, 465–473 (2016).

218. Tynkkynen, J. *et al.* Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer’s disease: A prospective study in eight cohorts. *Alzheimer’s & Dementia* **14**, 723–733 (2018).

219. Wang, K.-C. *et al.* Risk of Alzheimer’s disease in relation to diabetes: A population-based cohort study. *Neuroepidemiology* **38**, 237–244 (2012).

220. Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C. & Yaffe, K. Midlife cardiovascular risk factors and risk of dementia in late life. *Neurology* **64**, 277–281 (2005).

221. Yamada, M. *et al.* Incidence and risks of dementia in Japanese women: Radiation Effects Research Foundation Adult Health Study. *Journal of the Neurological Sciences* **283**, 57–61 (2009).

222. Yang, Y. H. *et al.* Statins reduces the risk of dementia in patients with late-onset depression: A retrospective cohort study. *PLoS ONE [Electronic Resource]* **10**, e0137914 (2015).

223. Yoshitake, T. *et al.* Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: The Hisayama Study. *Neurology* **45**, 1161–1168 (1995).

224. Zamrini, E., McGwin, G. & Roseman, J. M. Association between statin use and Alzheimer’s disease. *Neuroepidemiology* **23**, 94–98 (2004).

225. Zandi, P. P. *et al.* Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. *Archives of General Psychiatry* **62**, 217–224 (2005).

226. Zhu, Z. *et al.* Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nature communications* **9**, 224 (2018).

227. Zimetbaum, P. *et al.* Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly. The Bronx Aging Study. *Arteriosclerosis & Thrombosis* **12**, 416–423 (1992).

228. Zhu, Z. *et al.* Causal associations between risk factors and common diseases inferred from GWAS summary data. *bioRxiv* (2017). doi:[10.1101/168674](https://doi.org/10.1101/168674)

229. Zhu, Z. *et al.* Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nature Communications* **9**, 224 (2018).

230. Andrews, S. J., Marcora, E. & Goate, A. Causal associations between potentially modifiable risk factors and the Alzheimer’s phenome: A Mendelian randomization study. 689752 (2019). doi:[10.1101/689752](https://doi.org/10.1101/689752)

231. Shepherd, J. *et al.* Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. *The Lancet* **360**, 1623–1630 (2002).

232. McGuinness, B., Craig, D., Bullock, R. & Passmore, P. Statins for the prevention of dementia. *The Cochrane Database of Systematic Reviews* CD003160 (2016). doi:[10.1002/14651858.CD003160.pub3](https://doi.org/10.1002/14651858.CD003160.pub3)

233. Yamada, M. *et al.* Incidence and risks of dementia in Japanese women: Radiation Effects Research Foundation Adult Health Study. *Journal of the Neurological Sciences* **283**, 57–61 (2009).

234. Yamada, M. *et al.* Incidence and risks of dementia in Japanese women: The adult health study. *Journal of the Neurological Sciences* **283**, 306 (2009).

235. Yang, Z. *et al.* Association of blood lipids, atherosclerosis and statin use with dementia and cognitive impairment after stroke: A systematic review and meta-analysis. *Ageing Research Reviews* **57**, 100962 (2020).

236. Muangpaisan, W., Brayne, C. & the Alzheimer’s Society Vascular Dementia Systematic Review Group. Systematic review of statins for the prevention of vascular dementia or dementia. *Geriatrics & Gerontology International* (2010). doi:[10.1111/j.1447-0594.2009.00579.x](https://doi.org/10.1111/j.1447-0594.2009.00579.x)

237. Poly, T. N. *et al.* Association between Use of Statin and Risk of Dementia: A Meta-Analysis of Observational Studies. *Neuroepidemiology* **54**, 214–226 (2020).

238. Kuźma, E. *et al.* Which Risk Factors Causally Influence Dementia? A Systematic Review of Mendelian Randomization Studies. *Journal of Alzheimer’s disease: JAD* **64**, 181–193 (2018).

239. Aromataris, E. *et al.* Summarizing systematic reviews: Methodological development, conduct and reporting of an umbrella review approach. *International Journal of Evidence-Based Healthcare* **13**, 132–140 (2015).

240. Smith, V., Devane, D., Begley, C. M. & Clarke, M. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. *BMC Medical Research Methodology* **11**, 15 (2011).

241. Sohani, Z. N. *et al.* Assessing the quality of published genetic association studies in meta-analyses: The quality of genetic studies (Q-Genie) tool. *BMC Genetics* **16**, 50 (2015).

242. Larsson, S. C. *et al.* Modifiable pathways in Alzheimer’s disease: Mendelian randomisation analysis. *BMJ* **359**, j5375 (2017).

243. Waffenschmidt, S. *et al.* Development and validation of study filters for identifying controlled non-randomized studies in PubMed and Ovid MEDLINE. *Research Synthesis Methods* **11**, 617–626 (2020).

244. Wagner, M., Rosumeck, S., Küffmeier, C., Döring, K. & Euler, U. A validation study revealed differences in design and performance of MEDLINE search filters for qualitative research. *Journal of Clinical Epidemiology* **120**, 17–24 (2020).

245. Benn, M. Re: Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study. *BMJ* (2017).

246. Danko, K. J., Dahabreh, I. J., Ivers, N. M., Moher, D. & Grimshaw, J. M. Contacting authors by telephone increased response proportions compared with emailing: Results of a randomized study. *Journal of Clinical Epidemiology* **115**, 150–159 (2019).

247. Meursinge Reynders, R., Ladu, L. & Di Girolamo, N. Contacting of authors modified crucial outcomes of systematic reviews but was poorly reported, not systematic, and produced conflicting results. *Journal of Clinical Epidemiology* **115**, 64–76 (2019).

248. Cooper, C., Bou, J. T. & Varley-Campbell, J. Evaluating the effectiveness, efficiency, cost and value of contacting study authors in a systematic review: A case study and worked example. *BMC Medical Research Methodology* **19**, 45 (2019).

249. Hennessy, E. A. *et al.* Ensuring Prevention Science Research is Synthesis-Ready for Immediate and Lasting Scientific Impact. *Prevention Science* (2021). doi:[10.1007/s11121-021-01279-8](https://doi.org/10.1007/s11121-021-01279-8)

250. Hsieh, C.-Y. *et al.* Taiwan’s National Health Insurance Research Database: Past and future. *Clinical Epidemiology* **11**, 349–358 (2019).

251. McGuinness, L. A., Warren-Gash, C., Moorhouse, L. R. & Thomas, S. L. The validity of dementia diagnoses in routinely collected electronic health records in the United Kingdom: A systematic review. *Pharmacoepidemiology and Drug Safety* **28**, 244–255 (2019).

252. Wilkinson, T. *et al.* Identifying dementia cases with routinely collected health data: A systematic review. *Alzheimer’s & Dementia* **14**, 1038–1051 (2018).

253. Jeyaraman, M. M. *et al.* Methodologically rigorous risk of bias tools for nonrandomized studies had low reliability and high evaluator burden. *Journal of Clinical Epidemiology* **128**, 140–147 (2020).

254. Walker, V. M., Davies, N. M., Jones, T., Kehoe, P. G. & Martin, R. M. Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimers and other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice Research Datalink. *BMJ Open* **6**, (2016).

255. von Elm, E. *et al.* The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. *Journal of Clinical Epidemiology* **61**, 344–349 (2008).

256. Herrett, E. *et al.* Data Resource Profile: Clinical Practice Research Datalink (CPRD). *International Journal of Epidemiology* **44**, 827–836 (2015).

257. Williams, T., van Staa, T., Puri, S. & Eaton, S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. *Therapeutic Advances in Drug Safety* **3**, 89–99 (2012).

258. Wood, L. & Coulson, R. Revitalizing the general practice research database: Plans, challenges, and opportunities. *Pharmacoepidemiology and drug safety* **10**, 379–383 (2001).

259. Mathur, R. *et al.* Completeness and usability of ethnicity data in UK-based primary care and hospital databases. *Journal of Public Health (Oxford, England)* **36**, 684–692 (2014).

260. Booth, N. What are the Read Codes? *Health Libraries Review* **11**, 177–182 (1994).

261. Wolf, A. *et al.* Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. *International Journal of Epidemiology* **48**, 1740–1740g (2019).

262. Wishart, D. S. *et al.* DrugBank 5.0: A major update to the DrugBank database for 2018. *Nucleic Acids Research* **46**, D1074–D1082 (2017).

263. Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *Journal of chronic diseases* **40**, 373–383 (1987).

264. Wells, B. J., Chagin, K. M., Nowacki, A. S. & Kattan, M. W. Strategies for handling missing data in electronic health record derived data. *Egems* **1**, (2013).

265. Sterne, J. A. C. *et al.* Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls. *BMJ* **338**, b2393 (2009).

266. Moons, K. G., Donders, R. A., Stijnen, T. & Harrell Jr, F. E. Using the outcome for imputation of missing predictor values was preferred. *Journal of clinical epidemiology* **59**, 1092–1101 (2006).

267. Pigott, T. D. A review of methods for missing data. *Educational research and evaluation* **7**, 353–383 (2001).

268. Hughes, R. A., Heron, J., Sterne, J. A. C. & Tilling, K. Accounting for missing data in statistical analyses: Multiple imputation is not always the answer. *International Journal of Epidemiology* **48**, 1294–1304 (2019).

269. Lévesque, L. E., Hanley, J. A., Kezouh, A. & Suissa, S. Problem of immortal time bias in cohort studies: Example using statins for preventing progression of diabetes. *BMJ* **340**, b5087 (2010).

270. Lamarca, R., Alonso, J., Gomez, G. & Munoz, A. Left-truncated Data With Age as Time Scale: An Alternative for Survival Analysis in the Elderly Population. *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences* **53A**, M337–M343 (1998).

271. Gail, M. H., Graubard, B., Williamson, D. F. & Flegal, K. M. Comments on “Choice of time scale and its effect on significance of predictors in longitudinal studies” by Michael J. Pencina, Martin G. Larson and Ralph B. D’Agostino, *Statistics* *in* *Medicine* 2007; **26** :1343-1359. *Statistics in Medicine* **28**, 1315–1317 (2009).

272. Pencina, M. J., Larson, M. G. & D’Agostino, R. B. Choice of time scale and its effect on significance of predictors in longitudinal studies. *Statistics in Medicine* **26**, 1343–1359 (2007).

273. Lipsitch, M., Tchetgen, E. T. & Cohen, T. Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies. *Epidemiology (Cambridge, Mass.)* **21**, 383–388 (2010).

274. Selva-O’Callaghan, A. *et al.* Statin-induced myalgia and myositis: An update on pathogenesis and clinical recommendations. *Expert review of clinical immunology* **14**, 215–224 (2018).

275. Herrett, E. *et al.* Statin treatment and muscle symptoms: Series of randomised, placebo controlled n-of-1 trials. *BMJ* **372**, n135 (2021).

276. Karalis, D. G., Hill, A. N., Clifton, S. & Wild, R. A. The risks of statin use in pregnancy: A systematic review. *Journal of Clinical Lipidology* **10**, 1081–1090 (2016 Sep-Oct).

277. Smeeth, L., Douglas, I., Hall, A. J., Hubbard, R. & Evans, S. Effect of statins on a wide range of health outcomes: A cohort study validated by comparison with randomized trials. *British Journal of Clinical Pharmacology* **67**, 99–109 (2009).

278. Salas, M., Hotman, A. & Stricker, B. H. Confounding by Indication: An Example of Variation in the Use of Epidemiologic Terminology. *American Journal of Epidemiology* **149**, 981–983 (1999).

279. Suttorp, M. M., Siegerink, B., Jager, K. J., Zoccali, C. & Dekker, F. W. Graphical presentation of confounding in directed acyclic graphs. *Nephrology Dialysis Transplantation* **30**, 1418–1423 (2015).

280. Danaei, G., García Rodríguez, L. A., Cantero, O. F., Logan, R. & Hernán, M. A. Observational data for comparative effectiveness research: An emulation of randomised trials to estimate the effect of statins on primary prevention of coronary heart disease. *Statistical methods in medical research* **22**, 70–96 (2013).

281. Korologou-Linden, R. *et al.* The causes and consequences of Alzheimer’s disease: Phenome-wide evidence from Mendelian randomization. *medRxiv* 2019.12.18.19013847 (2020). doi:[10.1101/2019.12.18.19013847](https://doi.org/10.1101/2019.12.18.19013847)

282. Porta, M. *A dictionary of epidemiology*. (Oxford University Press, 2014).

283. Goldacre, B., Morton, C. E. & DeVito, N. J. Why researchers should share their analytic code. *BMJ* **367**, l6365 (2019).

284. Vandenbroucke, J. P. *et al.* Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. *PLOS Medicine* **4**, e297 (2007).

285. Levis, B., Hattle, M. & Riley, R. D. PRIME-IPD SERIES Part 2. Retrieving, checking, and harmonizing data are underappreciated challenges in individual participant data meta-analyses. *Journal of Clinical Epidemiology* **136**, 221–223 (2021).

286. Wang, L. *et al.* Assessing robustness of hazard ratio estimates to outcome misclassification in longitudinal panel studies with application to Alzheimer’s disease. *PLOS ONE* **12**, e0190107 (2017).

287. Abo-Zaid, G. *et al.* Individual participant data meta-analyses should not ignore clustering. *Journal of Clinical Epidemiology* **66**, 865–873.e4 (2013).

288. McGuinness, L. A. & Sheppard, A. L. A descriptive analysis of the data availability statements accompanying medRxiv preprints and a comparison with their published counterparts. *MetaArXiv* (2020). doi:[10.31222/osf.io/p75xe](https://doi.org/10.31222/osf.io/p75xe)

289. Riboli, E. The EPIC Project: Rationale and study design. European Prospective Investigation into Cancer and Nutrition. *International Journal of Epidemiology* **26**, 6S–14 (1997).

290. Riboli, E. *et al.* European Prospective Investigation into Cancer and Nutrition (EPIC): Study populations and data collection. *Public Health Nutrition* **5**, 1113–1124 (2002).

291. Krawczyk, M. & Reuben, E. (Un)Available upon Request: Field Experiment on Researchers’ Willingness to Share Supplementary Materials. *Accountability in Research* **19**, 175–186 (2012).

292. Miyakawa, T. No raw data, no science: Another possible source of the reproducibility crisis. *Molecular Brain* **13**, 24 (2020).

293. Naudet, F. *et al.* Data sharing and reanalysis of randomized controlled trials in leading biomedical journals with a full data sharing policy: Survey of studies published in *The BMJ* and *PLOS Medicine*. *BMJ* k400 (2018). doi:[10.1136/bmj.k400](https://doi.org/10.1136/bmj.k400)

294. Jaspers, G. J. & Degraeuwe, P. L. A failed attempt to conduct an individual patient data meta-analysis. *Systematic Reviews* **3**, 97 (2014).

295. Higgins, J. P. T., White, I. R. & Anzures-Cabrera, J. Meta-analysis of skewed data: Combining results reported on log-transformed or raw scales. *Statistics in Medicine* **27**, 6072–6092 (2008).

296. Yusuf, S., Collins, R. & Peto, R. Why do we need some large, simple randomized trials? *Statistics in Medicine* **3**, 409–420 (1984).

297. Wilson, G. *et al.* Best Practices for Scientific Computing. *PLOS Biology* **12**, e1001745 (2014).

298. Wilson, G. *et al.* Good enough practices in scientific computing. *PLOS Computational Biology* **13**, e1005510 (2017).

299. Simillis, C. *et al.* Postoperative chemotherapy improves survival in patients with resected high-risk stage II colorectal cancer: Results of a systematic review and meta-analysis. *Colorectal Disease* **Published online 30th January**, (2020).

300. Tanneru, K. *et al.* Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia. *International Urology and Nephrology* (2020).

# Appendix

# By Chapter

## Chapter 2

### Publications beyond the scope of this thesis

**Peer reviewed**

* PRISMA main paper
* PRISMA E&E
* PRISMA 2020 software
* COVID Suicide Living Review
* Data extraction tools systematic review

**Under review/Preprints**

* MSc Paper on systematic reviews of this thesis topic

### Involvement of patients and the public

Patients were involved at several stages of this research. when designing the PhD programme of work, a Patient and Public Advisory Group (PPAG) provided feedback on the relevance of the question.

Additionally,

Lay summaries appear at the beginning of each chapter, reviewed by the Patient and Public Involvement panel. They provide a plain language summary

## Chapter 3

### Code for publication rate analysis

med\_res <-  
 # Use snapshot of published status from July 2021  
 medrxivr::mx\_search(  
 medrxivr::mx\_snapshot("ccedfb8a44304b9fba4e3ba518a8ce4ed2294770"),  
 query = "\*",  
 from\_date = "2019-07-01",  
 to\_date = "2019-08-01"  
 ) %>%  
 # Create indicator to show which records have been published  
 mutate(pub\_ind = ifelse(published == "NA", 0, 1)) %>%  
 # Group by indicator variable and count  
 group\_by(pub\_ind) %>%  
 count()

## Chapter 4

### Search strategy

Table 20: Overview of the full Medline search strategy.

| **#** | **Search term** | **Hits** |
| --- | --- | --- |
| **1** | dement\*.ti,ab. | 103404 |
| **2** | alzheimer\*.ti,ab. | 132832 |
| **3** | exp Dementia/ | 154234 |
| **4** | exp Alzheimer Disease/ | 87346 |
| **5** | Pick\* disease.ti,ab | 2794 |
| **6** | globular glial tauopathy.ti,ab | 24 |
| **7** | primary progressive aphasia.ti,ab | 1051 |
| **8** | logopaenic aphasia.ti,ab | 0 |
| **9** | posterior cortical atrophy.ti,ab | 381 |
| **10** | (age-associated) adj2 (memory decline).ti,ab | 11 |
| **11** | ((mild or slight) adj2 (cognitive or cognition) adj2 (disorder\* or defect\* or deficit\* or disabilit\* or dysfunction or impair\*)).ti,ab. | 14883 |
| **12** | ((cognit$ or memory or cerebr$ or mental$) adj3 (declin$ or impair$ or los$ or deteriorat$ or degenerat$ or complain$ or disturb$ or disorder$)).ti,ab. | 182141 |
| **13** | (MCI or aMCI or CIND or non-aMCI).ti,ab | 16893 |
| **14** | (cognitive impair\*).ti,ab | 56411 |
| **15** | Cognition Disorders/ | 62602 |
| **16** | Cognitive Dysfunction/ | 11999 |
| **17** | Mild Cognitive Impairment/ | 11999 |
| **18** | or/1-17 | 407352 |
| **19** | lipid\*.ti,ab. | 462968 |
| **20** | lipoprotein\*.ti,ab. | 140438 |
| **21** | cholesterol.ti,ab. | 227679 |
| **22** | hypercholesterol\*.ti,ab. | 33093 |
| **23** | hypocholesterol\*.ti,ab. | 3347 |
| **24** | triacylglycerol.ti,ab. | 11077 |
| **25** | lipemia\*.ti,ab. | 1836 |
| **26** | dyslipid?emia.ti,ab. | 29128 |
| **27** | hyperlipid?emia\*.ti,ab. | 25134 |
| **28** | hypolipid?emia.ti,ab. | 271 |
| **29** | HDL.ti,ab. | 61231 |
| **30** | LDL.ti,ab. | 71176 |
| **31** | VLDL.ti,ab. | 12485 |
| **32** | triglyceride\*.ti,ab. | 104904 |
| **33** | exp Dyslipidemias/ | 76480 |
| **34** | exp Cholesterol/ | 155339 |
| **35** | exp Lipoproteins/ | 141558 |
| **36** | or/19-35 | 777210 |
| **37** | statin\*.ti,ab. | 39998 |
| **38** | atorvastatin.ti,ab. | 7994 |
| **39** | cerivastatin.ti,ab | 646 |
| **40** | fluvastatin.ti,ab. | 1795 |
| **41** | pravastatin.ti,ab. | 3940 |
| **42** | rosuvastatin.ti,ab. | 3175 |
| **43** | simvastatin.ti,ab. | 8933 |
| **44** | pitavastatin.ti,ab | 816 |
| **45** | lovastatin.ti,ab. | 3667 |
| **46** | fibrat\*.ti,ab. | 3135 |
| **47** | ("fibric acid" adj3 derivat\*).ti,ab. | 341 |
| **48** | bezafibrate.ti,ab | 1523 |
| **49** | fenofibrate.ti,ab | 3109 |
| **50** | gemfibrozil.ti,ab | 1802 |
| **51** | clofenapate.ti,ab | 39 |
| **52** | clofibrate.ti,ab | 3035 |
| **53** | ciprofibrate.ti,ab | 481 |
| **54** | (bile adj3 sequest\*).ti,ab. | 816 |
| **55** | colestyramine.ti,ab | 60 |
| **56** | colestipol hydrochloride.ti,ab | 52 |
| **57** | colesevelam hydrochloride.ti,ab | 71 |
| **58** | nicotinic acid\*.ti,ab. | 5854 |
| **59** | inositol nicotinate.ti,ab | 30 |
| **60** | niacin.ti,ab | 4631 |
| **61** | ezetimibe.ti,ab. | 2766 |
| **62** | acipimox.ti,ab | 292 |
| **63** | evolocumab.ti,ab | 394 |
| **64** | alirocumab.ti,ab | 350 |
| **65** | lomitapide.ti,ab | 150 |
| **66** | (omega-3-acid adj2 ethyl ester\*).ti,ab | 85 |
| **67** | meglutol.ti,ab | 2 |
| **68** | Meglutol/ | 134 |
| **69** | exp Anticholesteremic Agents/ | 71609 |
| **70** | exp Fibric Acids/ | 9523 |
| **71** | exp Ezetimibe/ | 1954 |
| **72** | exp Nicotinic Acids/ | 36409 |
| **73** | or/37-72 | 138108 |
| **74** | 18 and 36 | 19659 |
| **75** | 18 and 73 | 2287 |
| **76** | 74 or 75 | 21029 |
| **77** | Animals/ not (Animals/ and Humans/) | 4552498 |
| **78** | 76 not 77 | 18226 |
| **79** | epidemiologic studies/ or case-control studies/ or cross-sectional studies/ or cohort studies/ or follow-up studies/ or longitudinal studies/ or prospective studies/ or retrospective studies/ | 2299133 |
| **80** | ((epidemiologic or prospective or retrospective or cross-sectional or case control\* or cohort or longitudinal or followup or follow-up) adj3 (study or studies)).ti,ab,kf. | 1043484 |
| **81** | (case control\* or cross-sectional or cohort? or follow-up or followup or longitudinal or prospective or retrospective or observational or population).ti. | 656500 |
| **82** | (cohort? adj2 (analys\* or compar\* or data or study or studies)).ab. | 184866 |
| **83** | (population adj2 (based or data\* or study or studies or register? or survey? or surveillance)).ab. | 200506 |
| **84** | or/79-83 | 2933516 |
| **85** | controlled clinical trial.pt. | 93095 |
| **86** | randomized controlled trial.pt. | 483099 |
| **87** | clinical trials as topic/ | 187183 |
| **88** | (randomi#ed or randomi#ation or randomi#ing).ti,ab,kf. | 585795 |
| **89** | (RCT or "at random" or (random\* adj3 (administ\* or allocat\* or assign\* or class\* or cluster or crossover or cross-over or control\* or determine\* or divide\* or division or distribut\* or expose\* or fashion or number\* or place\* or pragmatic or quasi or recruit\* or split or subsitut\* or treat\*))).ti,ab,kf. | 512675 |
| **90** | placebo.ab,ti,kf. | 203773 |
| **91** | trial.ti. | 199586 |
| **92** | (control\* adj3 group\*).ab. | 498141 |
| **93** | (control\* and (trial or study or group\*) and (waitlist\* or wait\* list\* or ((treatment or care) adj2 usual))).ti,ab,kf. | 19035 |
| **94** | ((single or double or triple or treble) adj2 (blind\* or mask\* or dummy)).ti,ab,kf. | 165010 |
| **95** | double-blind method/ or random allocation/ or single-blind method/ | 266392 |
| **96** | or/85-95 | 1616814 |
| **97** | 84 or 96 | 4175140 |
| **98** | MENDELIAN RANDOMIZATION ANALYSIS/ | 736 |
| **99** | Mendelian randomi\*.ti,ab,kf. | 1647 |
| **100** | 98 or 99 | 1738 |
| **101** | RANDOMIZED CONTROLLED TRIALS AS TOPIC/ | 124147 |
| **102** | (RCT? or (randomi#ed adj2 (control\* or intervention\* or experiment\* or trial\* or study or studies))).ti,ab,kf. | 405207 |
| **103** | ((random\* or comparative or intervention? or treatment?) adj3 (efficacy or effect\*)).ti,ab,kf. | 435773 |
| **104** | (clinical adj (intervention? or trial?)).ti,ab,kf. | 346211 |
| **105** | CLINICAL TRIALS AS TOPIC/ or CONTROLLED CLINICAL TRIALS AS TOPIC/ | 192430 |
| **106** | TREATMENT EFFECT/ | 904484 |
| **107** | or/101-106 | 1894420 |
| **108** | 100 AND 107 | 313 |
| **109** | instrument\* variab\*.ti,ab,kf. | 2380 |
| **110** | ((causal\* or causative) adj3 (associat\* or infer\* or implicat\* or effect\* or predict\* or factor? or risk? or relat\*)).ti,ab,kf. | 54710 |
| **111** | ((gene\* adj2 (associat\* or risk? or varia\* or determinant?)) or risk variant?).ti,ab,kf. | 234808 |
| **112** | (disease\* adj3 (expos\* or associat\* or etiolog\* or pathogenesis or risk?)).ti,ab,kf. | 304605 |
| **113** | risk factor?.mp. | 1045594 |
| **114** | exp CAUSALITY/ | 782487 |
| **115** | "confounding factors (epidemiology)"/ | 9873 |
| **116** | (confound\* or nonconfound\* or non-confound\*).ti,ab,kf. | 113902 |
| **117** | (statistics or epidemiolog\* or ((genetic\* or molecular) and medicine)).jw. | 205082 |
| **118** | or/109 -117 | 1768577 |
| **119** | 108 and 118 | 273 |
| **120** | 98 and 101 | 27 |
| **121** | 119 or 120 | 277 |
| **122** | 97 or 121 | 4175143 |
| **123** | 78 and 122 | 6045 |

### Web of Science Databases Searched

Table 21: Summary of Web of Science databases searched.

|  |  |  |
| --- | --- | --- |
| Database | Abbreviation | Years |
| Science Citation Index Expanded | SCI-EXPANDED | 1900-present |
| Social Sciences Citation Index | SSCI | 1956-present |
| Arts & Humanities Citation Index | A&HCI | 1975-present |
| Conference Proceedings Citation Index - Science | CPCI-S | 1990-present |
| Conference Proceedings Citation Index - Social Science & Humanities | CPCI-SSH | 1990-present |
| Emerging Sources Citation Index | ESCI | 2015-present |

### Code to search preprints

library(medrxivr)  
  
mx\_data <- mx\_api\_content(to\_date = "2019-09-01")  
  
bx\_data <- mx\_api\_content(server = "biorxiv",  
 to\_date = "2019-09-01")  
  
topic1 <- c(mx\_caps("statin"),  
 mx\_caps("ldl"),  
 mx\_caps("hdl"),  
 mx\_caps("TG"),  
 mx\_caps("triglycer"),  
 paste0("\\b",mx\_caps("TC"),"\\b"),  
 mx\_caps("ezetim"),  
 mx\_caps("fibrate"),  
 mx\_caps("bile acid"),  
 mx\_caps("lipoprotein"),  
 mx\_caps("lipid"),  
 mx\_caps("cholesterol"))  
  
topic2 <- c(mx\_caps("dementia"),  
 mx\_caps("alzheim"),  
 mx\_caps("MCI"),  
 mx\_caps("mild cognitive"))  
  
query <- list(  
 topic1,  
 topic2  
)  
  
bx\_results <- mx\_search(bx\_data, query)  
  
  
mx\_results <- mx\_search(mx\_data, query)

Note

### Calculating Gwet’s AC1


Gwet’s AC1 is defined as:


In reference to a two-by-two table with cells A, B, C and D, it is calculated using the following:


where is the chance agreement between raters, given as , where

### MR risk of bias tool

### Forest plots for lipid fractions










Table 22: Tool used to assess risk of bias in Mendelian randomisation studies, adapted from that developed by Mamluk et al.[146](#ref-mamluk2020)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Bias domain | Question | High | Moderate | Low |
| Weak instrument bias | Strength of association between instrument and exposure F statistic < 10 in the same sample (< 10 indicating a weak instrument) | F<10 | F= missing or F~10 | F>>10 |
| Genetic confounding bias | Reported test on association between confounders and IV (testing the assumption that the instrument is associated with your outcome only via your exposure) | Yes AND there is an obvious association | Not presented or |  |
| Yes presented AND there is some degree of association | Presented and no obvious association |  |  |  |
| ‘Other’ Confounding bias | Included confounders in the IV analysis | Yes |  | No |
| Additional direct effects between IV and outcome (exclusion restriction assumption) | Presence of pleiotropy for genetic IVs | Genetic IVs with no knowledge of mechanism for G-lipid association (e.g. GWAS hit, could be acting through any pathway…) | Biologically plausible lipid-specific mechanism of association for G-lipid (e.g. lipid metabolising genetic variants) | Same as moderate AND checks that there is no other known effect of genetic variants on outcome or its risk-factors |
| Bias due to selection of participants | Homogenous population or similar ancestry |  |  |  |
| If no: Stratified by ethnicity or adjusted for population stratification (yes/no) | Non-homogenous population (e.g. black and white together, etc.) | Population described as homogenous (e.g. whites only) BUT not corrected for ancestry informative markers like principal components derived from GWAS | Population described as homogenous (e.g. whites only) AND corrected for ancestry informative markers like principal components derived from GWAS |  |

## Chapter 5

### Amendments to protocol

### Code lists

## Chapter 6

### Email and documents sent to potental collaborators

### Section 2

## Chapter 8

### Catalogue of failures

Short section detailing the things I tried to do but which did not work.

# Other Appendix

## Software used to create this thesis

This thesis was written in RMarkdown. Several R packages were used as part of this project.[**R-base?**](#ref-R-base),[**R-bookdown?**](#ref-R-bookdown),[**R-dagitty?**](#ref-R-dagitty),[**R-data.table?**](#ref-R-data.table),[**R-DiagrammeR?**](#ref-R-DiagrammeR),[**R-dplyr?**](#ref-R-dplyr),[**R-flextable?**](#ref-R-flextable),[**R-ggdag?**](#ref-R-ggdag),[**R-ggplot2?**](#ref-R-ggplot2),[**R-kableExtra?**](#ref-R-kableExtra),[**R-knitr?**](#ref-R-knitr),[**R-koRpus?**](#ref-R-koRpus),[**R-koRpus.lang.en?**](#ref-R-koRpus.lang.en),[**R-magrittr?**](#ref-R-magrittr),[**R-Matrix?**](#ref-R-Matrix),[**R-medrxivr?**](#ref-R-medrxivr),[**R-metafor?**](#ref-R-metafor),[**R-networkD3?**](#ref-R-networkD3),[**R-patchwork?**](#ref-R-patchwork),[**R-readxl?**](#ref-R-readxl),[**R-robvis?**](#ref-R-robvis),[**R-sf?**](#ref-R-sf),[**R-sylly?**](#ref-R-sylly),[**bookdown2016?**](#ref-bookdown2016),[**dagitty2016?**](#ref-dagitty2016),[**ggplot22016?**](#ref-ggplot22016),[**knitr2015?**](#ref-knitr2015),[**knitr2014?**](#ref-knitr2014),[**koRpus2018?**](#ref-koRpus2018),[**koRpus.lang.en2019?**](#ref-koRpus.lang.en2019),[**medrxivr2020?**](#ref-medrxivr2020),[**metafor2010?**](#ref-metafor2010),[**robvis2020?**](#ref-robvis2020),[**sf2018?**](#ref-sf2018),[**sylly2018?**](#ref-sylly2018) All projects in these thesis attempt to conform to minimal best practices for research computing.[297](#ref-wilson2014),[298](#ref-wilson2017)

## Producing risk-of-bias visualisations with robvis

### Introduction

Risk of bias assessment - evaluation of the internal validity of studies included in a systematic review - often forms a key part of the evidence synthesis process, particularly in the health sciences.[**cochranechpt7?**](#ref-cochranechpt7) A well-developed family of tools is widely used, which have in common the characteristic that they evaluate specific domains of bias rather being constructed as a checklist or a quantitative score.[**cochranechpt7?**](#ref-cochranechpt7) These tools include the RoB 2 tool for randomized trials,[**sterne2019rob?**](#ref-sterne2019rob) the ROBINS-I tool for non-randomized studies of interventions,[139](#ref-sterne2016) the QUADAS 2 tool for test accuracy and the ROBIS tool for systematic reviews.[**whiting2011quadas?**](#ref-whiting2011quadas) Within each bias domains a judgement is reached about the strength of the study in that regard: for example, the first domain in the Cochrane RoB 2 tool deals with bias arising from the randomization process.[**sterne2019rob?**](#ref-sterne2019rob) Accessible graphics summarizing the results of these domain-based risk-of-bias assessments are included in reports of systematic reviews. A convenient plot in many reviews is a “traffic light” plot, which tabulates the judgement for each study in each domain. For larger numbers of studies, when such a table become unmanageable, a popular alternative is a weighted bar plot, which show the proportion of information with each judgement for each domain.[**higgins2008assessing?**](#ref-higgins2008assessing)

Researchers can face a number of barriers in creating these plots. While some evidence synthesis platforms, such as Cochrane’s Review Manager,[**cochrane2014review?**](#ref-cochrane2014review) are able to produce these visualizations, not all researchers use these systems to conduct their systematic reviews, and copying the risk-of-bias data into these systems simply to produce the plots is inefficient and error prone. Likewise, creating the figures by hand, through software such as MS PowerPoint or Adobe Illustrator, may lead to unintentional errors and require the plots to be redrawn during an update to the review. Additionally, while the field of evidence synthesis software has grown rapidly in recent years,[**marshall2015systematic?**](#ref-marshall2015systematic) this growth has not been equally distributed across the different aspects of the systematic review process. For example, a recent review found several software offerings aimed specifically at the abstract screening stage of the review process,[**harrison2020software?**](#ref-harrison2020software) but no similar time- and error-reducing tool has been proposed for visualizing the results of risk-of-bias assessments.

Fortunately, tools such as R, RStudio and Shiny (an R package for building interactive web apps) have made it easier than ever to produce such a tool.[**rref?**](#ref-rref),[**rstudioref?**](#ref-rstudioref),[**shinyref?**](#ref-shinyref) Here, we present robvis (Risk Of Bias VISualiation),[**mcguinness2019a?**](#ref-mcguinness2019a) an R package and Shiny web-app that allows users to create publication-ready risk-of-bias plots quickly and easily. Originally created for use with the major risk-of-bias assessment tools used in health research, the tool allows users to visualize the results from any domain-based risk-of-bias assessment or quality appraisal tool.

The tool is open-source and available to use free of charge. Users can download a stable version of the R package from CRAN (<https://cran.r-project.org/package=robvis>); or access and contribute to the development version via GitHub (<https://github.com/mcguinlu/robvis>).

### Development

Development of robvis began in April 2019 at the Evidence Synthesis Hackathon (ESH), an event which brings together interested researchers, practitioners and coders to discuss and develop new open-source evidence synthesis technologies. Test versions of both the R package and the web app were made available in early June 2019, with attendees of the ESH and members of the Bristol Appraisal and Review of Research (BARR) group at the University of Bristol being invited to test the tool and provide feedback. This feedback, along with other feature suggestions from the wider evidence synthesis community captured via GitHub issues, was incorporated and the first release version of the package was uploaded to CRAN in November 2019. The tool has been well received and is beginning to be cited in the evidence synthesis literature.[299](#ref-simillis2020),[300](#ref-tanneru2020),[**gibb2019consistent?**](#ref-gibb2019consistent),[**habadi2019prevalence?**](#ref-habadi2019prevalence),[**veloso2020effectiveness?**](#ref-veloso2020effectiveness)

### Installation

A stable version of robvis is hosted on the Comprehensive R Archive Network (CRAN) and can be installed using:

install.packages("robvis")

As development of robvis is ongoing, new features are often available in the development version some time before they appear in the stable CRAN version. The most recent development version can be install from GitHub using:

devtools::install\_github("mcguinlu/robvis")

### Usage

robvis contains two main functions. The first, rob\_traffic\_light(), creates a traffic light plot by tabulating each study by each domain, providing a more detailed view of the results of the risk-of-bias assessment. The second, rob\_summary(), creates a weighted bar plot showing the proportion of information with each judgement for each domain in the assessment tool specified.

A worked example using these functions is outlined below, showing the ease with which risk-of-bias plots can be created using robvis. A detailed description of the additional options that can be used with each function is presented in Table 23

Using the example data set (data\_rob2) which is built into the package and is presented in Table ?? for reference, the traffic light plot shown in Figure 34 is created using:

rob\_traffic\_light(data = data\_rob2,  
 tool = "ROB2",  
 psize = 15)




Figure 34: Example risk of bias traffic light plot created using robvis

Similary, using the same data set, the summary barplot shown in Figure 35 is created using:

rob\_summary(data = data\_rob2,  
 tool = "ROB2",   
 overall = TRUE)




Figure 35: Example risk of bias summary plot created using robvis and the example ROB2 dataset

A list of arguments available to the two functions in robvis are shown in Table 23

Table 23: Description of the arguments available in the two main robvis functions. ‘X’ indicates that the option is available for the respective function.

|  |  |  |  |
| --- | --- | --- | --- |
| Argument | rob\_traffic\_light() | rob\_summary() | Description |
| data | X | X | Defines the dataframe containing the summary (domain) level risk-of-bias assessments. See the text and Table 1 for the format expected by robvis |
| tool | X | X | Defines the risk of bias assessment tool used. The RoB2 (tool="ROB2"), ROBINS-I (tool="ROBINS-I"), and QUADAS-2 (tool="QUADAS-2") assessments tools are currently supported. Other tools can be visualised using the generic template (tool = "Generic") |
| colour | X | X | Defines the colour scheme for the plot. The default is colour = "cochrane" which uses the “Cochrane” (red, yellow, green) colours, while a preset option for a colour-blind friendly palette is also available (colour = "colourblind"). Alternatively, users can specify their own colour scheme e.g. colour = c("#f442c8", "#bef441", "#000000") |
| overall |  | X | Defines whether to include an additional bar showing the distibution of overall risk of bias judgements in the summary barplot figure. Default is overall = FALSE. |
| weighted |  | X | Defines whether weights should be used to produce the summary barplot figure. Default is weighted = TRUE, in line with current Cochrane Collaboration guidance. |
| psize | X |  | Defines the size of the points in the traffic light plot. Default is psize = 20. |

### Reception and Future Plans

As of December 2021, robvis has been downloaded more than 14500 times. It has been well received but the systematic review community, and has been cited frequently in the published literature. A paper describing the tool was published in a special issue of Research Synthesis Methods focusing on data visualisation methods. A chapter on the tool has been incorporated in to the “Doing Meta-Analysis in R” online textbook.[**mathias\_harrer\_2019\_2551803?**](#ref-mathias_harrer_2019_2551803)

While robvis is a stable package, a range of additional functionality could be added. At present, the number of tools with a specific template included in robvis is limited - adding additional templates is a priority. For example, a template for ROBIS, a tool for assessing risk of bias in systematic reviews, is in developement.[**whiting2016robis?**](#ref-whiting2016robis) Additionally, the tool does not yet allow for the production of paired forest plots, where the risk-of-bias judgement is presented alongside each specific result included in the meta-analysis.[**cochranechpt7?**](#ref-cochranechpt7) This was initially considered to be beyond the scope of the tool, as it involves the visualization of something other than risk-of-bias assessments. However, following user-driven demand, this functionality is in development and will be available in the near future. Finally, we would like to add similar functionality to that provided by the metafor::reporter() function, which generates a brief paragraph of text describing the results of a meta-analysis. The future robvis::reporter() function would provide a boilerplate description of the assessment tool used and the key domains at risk of bias.

## Creating

## Copies of papers arising from this thesis